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Preeclampsia (PE) is a severe placenta-related pregnancy disorder, that complicates 
around 5-8% of pregnancies.1 PE can have detrimental consequences during pregnancy 
for the mother, as it increases the risk of for example stroke, liver rupture, and lung 
edema. It also contributes significantly to perinatal morbidity, as approximately 12% of 
PE cases is complicated by fetal growth restriction, and around 20% results in preterm 
birth.2 Besides these short term consequences, PE is also associated with health risks 
later in life for both mother and child. Women who have suffered from PE have a 2-4 
times higher risk of developing cardiovascular diseases.3, 4 Furthermore, prematurity and 
low birth weight increase the risk of cardiopulmonary and neurological impairment in 
children.5, 6
Nowadays PE is defined as de novo hypertension after the 20th week of gestation, 
along with evidence of maternal organ damage and/or fetal growth restriction.7 
However, as early as 400 BC, Hippocrates already wrote that ‘a headache accompanied 
by heaviness and convulsions during pregnancy is considered bad’.8 In that time it 
was thought that all female diseases resulted from an imbalance in body fluids, and 
therefore treatments existed of dietary changes, purging and blood-letting.9 In the 17th 
century, the word ‘eclampsia’ arose and the disease was systematically described for the 
first time. In an attempt to prevent convulsions, phlebotomies during pregnancy were 
recommended.10 In the 19th century, the disease was called ‘toxemia’, as it was thought 
that it resulted from the inability to eliminate an increase in waste products.11 Treatment 
still mainly existed of bleeding and purging, in order to eliminate the excess of toxic 
elements. It was not until the 20th century that the pathophysiology of PE was linked 
to the abnormal placentation in early pregnancy.12 Although still not fully elucidated, 
it is now known that increased placental vascular resistance leads to an imbalance in 
pro - and antiangiogenic factors, causing generalized endothelial dysfunction.13, 14 The 
latter is characterized by disturbances in different vascular pathways, e.g. decreased 
activity of the nitric oxide pathway and increased activity of the endothelin system.15, 16 
Furthermore, there is an imbalance in the immune system response, with a shift towards 
pro-inflammatory conditions.17, 18
To date, still no cure is available for PE, except for delivery of the placenta. Patients 
are often stabilized with antihypertensive drugs, such as methyldopa and/or calcium 
antagonists, and magnesium sulfate to prevent further complications and prolong 
pregnancy as long as possible. Targeting the vascular endothelial dysfunction in PE is a 
promising strategy in developing new therapeutic options.
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The ex vivo placental perfusion system
For the research described in this thesis we used dual-sided ex vivo placental perfusion 
of isolated cotyledons, an established experimental model to study the transfer of drugs 
across the human placenta, their subsequent effects and placental metabolism. It is the 
only reliable method to predict in vivo fetal exposure to maternally administered com-
pounds without imposing risks on mother or child.19, 20 The model was first described in 
1967 by Panigel et al.21 and later modified by Schneider et al. in 1972.22 The model used 
for the studies in this thesis has been adapted from the model described by Schalkwijk 
et al.23 It consists of a plastic perfusion chamber and two peristaltic roller pumps. Heat-
ing devices and a water bath keep the temperature in the setup at 37 °C. Maternal and 
fetal perfusion media are aerated continuously with 95% O2 – 5% CO2. After arrival at the 
lab directly after birth, an intact cotyledon is selected and the corresponding chorionic 
artery and vein pair is cannulated to establish the fetal circulation. Subsequently, the 
cotyledon is cut from the rest of the placenta and placed inside the perfusion chamber. 
Maternal circulation is created by placing four blunt cannulas in the intervillous space 
and outflow from the intervillous space is collected in a reservoir. Changes in fetopla-
cental pressure and pH are recorded using acquisition software. A schematic overview 
of our placental perfusion model is shown in Figure 1.
Aims AND ouTliNe of The Thesis
In this thesis new treatment strategies for PE are discussed, targeting the placental 
vascular dysfunction that plays a key role in the pathogenesis of this disease. By using 
ex vivo techniques, such as perfusion of the isolated cotyledon and wire-myography, the 









figure 1. Schematic overview of the placental perfusion model in our lab.
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1The aims of this thesis are:
1. To understand placental vascular reactivity in health and disease
2. To evaluate possible new treatment options for PE, using ex vivo placental perfusion
chapter 2 provides an extensive overview of the vascular reactivity profile of the human 
placenta. It summarizes the most important pathways and factors that are involved in 
the regulation of (placental) vascular function during healthy pregnancy and changes 
associated with PE. Furthermore, potential treatment strategies interfering with these 
changes are discussed. chapters 3-6 focus on experimental therapeutic strategies 
targeting the vascular dysfunction seen in PE. In chapter 3 we study the transfer and 
effect of the phosphodiesterase-5 inhibitor sildenafil in placentas from healthy and PE 
pregnancies. In chapter 4 we try to elucidate the vasodilator mechanism of pentoxifyl-
line by studying its effect in porcine coronary arteries and human chorionic plate arter-
ies. chapter 5 discusses the possibility of using endothelin receptor antagonists for PE 
treatment. It includes an overview of all cases reported in literature of women who were 
exposed to these drugs during pregnancy. Following this, in chapter 6 we examine the 
transfer and effects of the endothelin receptor antagonists macitentan, sitaxentan and 
ambrisentan in the human placenta. chapter 7 explores the associations between first-
trimester in vivo placental vascular parameters and ex vivo placental vascular function at 
term. chapter 8 provides a general discussion and suggestions for future research, and 
in chapter 9 this thesis is summarized.
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AbsTRAcT
Adequate development of the placenta is essential for optimal pregnancy outcome. Pre-
eclampsia (PE) is increasingly recognized to be a consequence of placental dysfunction 
and can cause serious maternal and fetal complications during pregnancy. Furthermore, 
PE increases the risk of neonatal problems and has been shown to be a risk factor for 
cardiovascular disease of the mother later in life. Currently, there is no adequate treat-
ment for PE, mainly because its multifactorial pathophysiology remains incompletely 
understood. It originates in early pregnancy with abnormal placentation and involves a 
cascade of dysregulated systems in the placental vasculature. To investigate therapeutic 
strategies it is essential to understand the regulation of vascular reactivity and remodel-
ing of blood vessels in the placenta. Techniques using human tissue such as the ex vivo 
placental perfusion model provide insight in the vasoactive profile of the placenta, and 
are essential to study the effects of drugs on the fetal vasculature. This review highlights 
the different pathways that are involved in the vascular regulation of the human pla-
centa, changes that occur during PE and the importance of focusing on restoring these 




The placenta is an essential regulatory organ that provides the fetus with nutrients and 
oxygen, determines the passage of pharmacological and toxic agents, and regulates the 
endocrine and immune systems.1 Optimal placental function is crucial for fetal health 
and subsequent neonatal outcome. Insufficient development of the placenta is increas-
ingly recognized to underlie serious pregnancy complications such as preeclampsia (PE) 
and fetal growth restriction (FGR), thereby contributing to both maternal and perinatal 
morbidity and mortality.2-4
PE is a multi-system disorder, clinically characterized by de novo onset hypertension 
and proteinuria after 20 weeks of gestation, which complicates approximately 3-8% of 
pregnancies.3 Two forms of PE can be distinguished: early onset PE, manifesting before 
the 34th week of gestation, and late onset PE, manifesting after the 34th week of gesta-
tion.5 PE can have serious maternal consequences, such as kidney failure, liver disease, 
cerebral hemorrhage and lung edema, but can also result in FGR and/or premature 
birth. Evidence is accumulating that placenta-related pregnancy complications increase 
the risk of maternal and neonatal health problems in later life. For example, women who 
have suffered from PE have a higher chance of developing cardiovascular diseases,6, 7 and 
children born prematurely or with low birth weight have an increased risk of impaired 
cardiopulmonary and neurological development.8-10 Currently, there is no appropriate 
therapy available for PE. Treatment is aimed at prolonging pregnancy by symptom relief 
and prevention of further complications, but the only cure is delivery. However, this is 
often harmful for the preterm fetus, and therefore development of novel treatment op-
tions to safely prolong pregnancy is very important.
Although the exact etiology of PE remains unknown, a large body of evidence indi-
cates that it originates in the first weeks of pregnancy and is the result of abnormal 
placentation. Initially, impaired trophoblast invasion leads to aberrant remodeling of 
the spiral arteries, resulting in higher placental vascular resistance and hypo-perfusion, 
with oxidative stress related to ischemia-reperfusion damage and increased placental 
production of anti-angiogenic factors. The combination of these factors induces gener-
alized vascular dysfunction, thereby contributing to the hypertension and proteinuria 
occurring in PE patients.11-13 Since early- and late onset PE show distinct histopatho-
logical differences,5 separate pathogenic pathways have been suggested, proposing 
that late onset PE might be a predominant maternal syndrome, rather than a placental 
disorder.14, 15
Many vasoactive pathways have been proposed to be altered in PE, although data 
on the human placental vasculature are largely inconclusive. To investigate therapeutic 
strategies it is essential to understand the regulation of vascular tone and remodeling 
of blood vessels in the healthy placenta, and changes in PE. Research using the ex vivo 
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placental perfusion system or wire-myography, two models to study human tissue, may 
provide insight into vasoactive characteristics of the placenta. Ex vivo dual-sided placen-
tal perfusion is an experimental model to study vascular reactivity of the fetal side of the 
placenta in a single cotyledon, and using wire-myography similar experiments can be 
performed in isolated vessel segments.
The purpose of this review is to summarize the vascular reactivity profile of the fetal 
side of the human placenta, by describing its most important pathways and factors, 
being vascular endothelial growth factor (VEGF), the endothelin (ET) system, the renin-
angiotensin system (RAS), prostaglandins, nitric oxide (NO) and NO-dependent vaso-
dilators, serotonin and tryptophan (Trp), and calcitonin gene-related peptide (CGRP). 
Relevant studies were identified by making use of a systematic search in literature on 
20 April 2018. We highlight changes that occur during, and/or contribute to the patho-
physiology of PE, and discuss possible treatment strategies based on interfering with 
the regulation of placental vascular tone.
DeVeloPmeNT of The feToPlAceNTAl VAsculATuRe
Adequate development of the placental vasculature is essential for normal growth and 
development of the fetus during pregnancy.1 Many pregnancy complications are associ-
ated with disturbed placentation, such as PE, FGR, preterm birth and spontaneous abor-
tion.16 At term, the placenta consists of cotyledons, i.e., villous trees that are supplied 
by arteries branching off the umbilical circulation. These are surrounded by intervillous 
space filled with maternal blood coming from spiral arteries, to enable the exchange of 
oxygen and nutrients between mother and fetus.1
During embryonic implantation, the outer layer of the blastocyst, the trophectoderm, 
invades deep into the uterine wall. The trophectoderm differentiates into multiple 
types of trophoblast cells, including cytotrophoblast cells and, when these cells fuse, 
syncytiotrophoblast cells.17 The process of differentiation is closely regulated by mul-
tiple growth factors, hormones and environmental factors such as oxygen tension.18 The 
syncytiotrophoblast layer covers the cytotrophoblast and lines the villous trees, making 
direct contact with the maternal circulation and thereby playing an important role in the 
supply of oxygen and nutrients from mother to fetus, and waste products and carbon 
dioxide from fetus to mother. Furthermore, these cells are involved in pregnancy-related 
hormone production.17 In early gestation, when there is no direct exchange of oxygen 
and nutrients between the fetal and maternal circulations, the embryo is provided with 
nutrients via diffusion from the decidua.19 At this stage, cytotrophoblast plugs occlude 
the spiral arteries, allowing diffusion but preventing perfusion of the intervillous space, 
this way keeping a low oxygen environment.20 Around 10 weeks of gestation, extravillous 
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cytotrophoblast cells invade around the spiral arteries, initiating their remodeling and 
unplugging. This remodeling encompasses a 5- to 10-fold increase in terminal lumen 
diameter and structural changes of the vessel wall, such as demuscularization, creat-
ing a low resistance circulation.12, 18 Because of these changes, the perfusion capacity 
is increased and the blood velocity into the intervillous space is reduced to protect the 
vulnerable villous tree and to optimize exchange of oxygen and waste products.12 After 
the vascular network has been formed in early pregnancy, capillary growth continues 
until delivery, mediated by various growth factors. From mid-gestation onwards, there 
is an exponential growth in vascular volume of placental vessels to accommodate the 
needs of the growing fetus.1 Unlike most other blood vessels, vessels of the fetoplacen-
tal circulation are not innervated. Local vascular tone and fetal cardiac output are the 
main determinants of the blood flow through these vessels, regulated by circulating and 
locally produced hormones and vasoactive compounds, such as estrogen, prostaglan-
dins, ET-1 and NO.21 The most important pathways that are involved in the regulation of 
placental vascular tone and changes occurring in PE, as will be discussed in this review, 
are summarized in Table 1. Drugs targeting these systems and their potential relevance 
in the treatment of PE are described in Table 2.
VAsculAR eNDoTheliAl GRowTh fAcToR
The VEGF pathway plays a pivotal role in the formation and development of blood 
vessels during growth of the human placenta.22 The VEGF system has not only been 
implicated in the promotion of angiogenesis, but is also crucial to maintain vascular 
endothelial function. VEGF induces the release of NO and prostacyclin (PGI2) from endo-
thelial cells, indicating its potential in the regulation of vascular tone (Figure 1).23, 24 VEGF 
acts in a paracrine manner on endothelial cells, and its expression has been localized 
to villous trophoblast cells, maternal and fetal macrophages, decidual cells and the 
fetal membranes of the placenta.23, 25 Its biological actions are elicited upon binding to 
tyrosine kinase receptors (VEGFRs), of which VEGFR-1 and VEGFR-2 are considered the 
main functional receptors in the placenta. VEGFR-2 plays a major role in angiogenesis 
through promoting endothelial cell proliferation and vascular formation. Its location is 
restricted to fetal endothelial cells and syncytiotrophoblasts.26 VEGFR-1 is expressed in 
fetal and umbilical vein endothelial cells, decidual cells and (extra)villous trophoblast 
cells.27 While the function of VEGFR-1 is not entirely understood, it is thought that it 
regulates angiogenesis either positively or negatively through mechanisms involving 
VEGF-trapping and homo- or heterodimerization with VEGFR-2.28-30 Placental growth 
factor (PlGF), which is homologous to VEGF, is considered equally important in the 
regulation of placental angiogenesis, through its interaction with VEGFR-1.23 In addition, 
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soluble Fms-like tyrosine kinase (sFlt-1), a soluble form of VEGFR-1 generated through 
alternative splicing, binds with high affinity to its natural ligands VEGF and PlGF, thereby 
preventing interaction with their receptors (Figure 1).23 It is produced and released into 
the maternal circulation by villous trophoblast cells of the placenta.31 Interestingly, sFlt-1 
levels found in the venous perfusate of the maternal side in the perfused cotyledon 
of healthy human placentas closely reflect in vivo serum values, indicating that sFlt-1 
is predominantly secreted by the placenta.27 Moreover, Saleh et al. observed a rapid 
postpartum decline by >99% in circulating sFlt-1 levels of women with suspected or 
confirmed PE, further suggesting the placenta is the major source of sFlt-1 secretion.32
In healthy pregnancy, VEGF is highly expressed by placental tissue during the first 
trimester13 and is thought to act as a chemoattractant promoting trophoblast invasion.23 























figure 1. VEGF and ET-1 system in the human placenta and therapeutic strategies targeting this pathway. 
During PE there is an increase in sFlt-1 and ET-1, whereas VEGF and PlGF are decreased. Abbreviations: 
bigET-1 = big-endothelin-1; BM = basal membrane; ECE-1 = endothelin converting enzyme-1; ERA = endo-
thelin receptor antagonist; ET-1 = endothelin-1; ETAR = endothelin type A receptor; ETBR = endothelin type 
B receptor; NO = nitric oxide; PGI2 = prostacyclin; PlGF = placental growth factor; preproET-1 = preproen-
dothelin-1; sFlt-1 = soluble Fms-like tyrosine kinase-1; VEGF = vascular endothelial growth factor; VEGFR = 
vascular endothelial growth factor receptor; VSMC = vascular smooth muscle cell.
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during the third trimester, reflecting an antiangiogenic shift toward the end of pregnan-
cy.13 Excess sFlt-1 produced by preeclamptic villous tissue attenuates fetoplacental an-
giogenesis in vitro,33 implicating that the physiological rise in sFlt-1 levels during healthy 
pregnancy is essential for adequate control of placental angiogenesis. Studies examining 
the release of VEGF in the ex vivo perfused cotyledon of term placentas are consistent 
with the former findings, showing a bilateral release of total VEGF, predominantly in the 
maternal circulation, with a high ratio of sFlt-1 to free VEGF, resulting in near complete 
VEGF binding. Interestingly, free VEGF levels were only detected on the fetal side. This 
finding may not be too surprising, as sFlt-1 levels are marginally secreted on this side, so 
that free VEGF will not be sequestered.27 In the fetoplacental vasculature, VEGF acts as a 
potent vasodilator via the interaction with VEGFR-2. Ex vivo administration of free VEGF 
to the fetal side of the perfused cotyledon after pre-constriction with U46619 caused a 
dose-dependent vasodilation in the fetal circulation, which was partially attenuated by 
NO synthase inhibition.27 Similar observations were made in isolated human chorionic 
plate arteries; VEGF evoked a concentration-dependent vasodilator response in the fetal 
circulation following pre-constriction with phenylephrine.24 Importantly, the concentra-
tions that elicit a vasodilator response in the fetoplacental vasculature are within the 
physiological range of fetal serum levels of VEGF. With regard to PlGF, no changes in fetal 
perfusion pressure were observed in the fetoplacental vasculature, while it significantly 
provoked vasodilation in isolated human chorionic plate arteries.24, 27 These apparent 
opposite findings suggest that large arteries contribute relatively little to total resistance 
of the placental vasculature.
In recent years, excessive placental production of sFlt-1 has been implicated to be 
involved in the pathogenesis of PE. Multiple studies have reported elevated sFlt-1 levels 
in the circulation along with decreased free VEGF and free PlGF levels in women with 
PE,34, 35 while PE placentas displayed increased expression of sFlt-1 mRNA.36 In pregnant 
mice, sFlt-1 infusion or injection of an adenovirus encoding the sFlt-1 gene, elicits the 
hallmark features of PE, including hypertension, proteinuria and glomerular endothe-
liosis.36, 37 Furthermore, treatment of cancer patients with VEGF antagonists induces a 
PE-like syndrome, with hypertension and proteinuria.38 Consequently, reduced circulat-
ing levels of free VEGF and free PlGF promote the maternal syndrome of PE. Moreover, 
significant alterations of the VEGF system have been implicated in the fetoplacental vas-
culature during PE, which may actively contribute to increased blood flow resistance in 
the placental circulation.27, 39 The increase in placental sFlt-1 production may be triggered 
by several factors during PE, including inflammatory cytokines, angiotensin II type 1 
receptor auto-antibodies (AT1R-AA) and placental hypoxia, most likely involving hypoxia 
inducible factor-1a (HIF-1a) as a mediator.40, 41 Subsequently, sFlt-1 mediates hyperten-
sion through impairing endothelial NO production, which is normally upregulated by 
VEGF, thereby inducing endothelial dysfunction.42 This is accompanied by upregulated 
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ET-1 production,43 most likely as a consequence of impaired inhibition of ET-production 
by NO, and further reflecting endothelial dysfunction. Brownbill et al., making use of the 
ex vivo dual-sided placenta perfusion model, observed an enhanced vasodilator effect 
in the fetal circulation in response to exogenous VEGF administration in PE placentas as 
compared with healthy controls.39 However, this response was only seen at high VEGF 
doses, which fall outside the physiological range of fetal serum concentrations. More-
over, diminished fetal serum concentrations of free VEGF were reported, in accordance 
with higher fetal sFlt-1 levels during PE, probably contributing to a reduced vasodilator 
response of the fetoplacental vasculature in vivo. Where the higher fetal sFlt-1 levels 
arise from is largely unknown, although one could hypothesize that the trophoblasts 
either secrete more sFlt-1 into the fetal circulation, or that the excessive maternal sFlt-1 
levels are, at least in part, transported to the fetal side. Notably, an important role for 
VEGF localized to decidual tissue of the placenta has been identified. Fan et al. reported 
that endometrial-specific VEGF overexpression in mice significantly induced sFlt-1 
release.44 Combined with the increased decidual expression of VEGF mRNA in human 
PE placentas, this observation may indicate that VEGF regulates sFlt-1 release in the 
placenta at the maternal-fetal interface.44
Several studies have focused on improving the angiogenic imbalance in PE, for 
instance, through the extracorporeal removal of sFlt-1 using dextrane sulphate apher-
esis.45 This resulted in significant alleviation of PE symptoms.45 Furthermore, treatment 
with recombinant VEGF both in vitro and in vivo partially reduced the antiangiogenic 
consequences of excess sFlt-1 in an animal study.46 With regard to the fetoplacental vas-
culature, administration of recombinant VEGF might aid in reducing placental vascular 
resistance during PE. However, concern has been raised regarding potential harm to the 
fetus by VEGF that passes the placental barrier. The recent development of VEGF fused 
to elastin-like polypeptide, a biopolymer carrier that does not cross the placental barrier, 
could overcome this problem.46 Similarly, administration of PlGF in a PE rat model has 
shown promising results in reducing hypertension and proteinuria,47 while there are 
no studies assessing the vasoreactive effects of PlGF in the fetoplacental vasculature 
during PE. Another potential target for improving the VEGF pathway may be through 
the vasodilator hormone relaxin, a local upregulator of VEGF, that could potentially 
improve fetoplacental blood flow during PE.31 The safety profile of relaxin is currently 
being investigated for the treatment of women with PE.31
Inhibition of sFlt-1 secretion in the placenta itself forms an ideal approach towards 
restoring the angiogenic imbalance and improving placental blood flow. Moreover, 
given that sFlt-1 induces a rise in ET-1, such treatment would be able to target the ET-1 
system. Some may argue that this method is not desirable, since sFlt-1 appears to be 
required to maintain placental health.45 Several research groups have focused on inhib-
iting the release of sFlt-1 upstream. For instance, heme-oxygenase-1 (HO-1) attenuated 
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sFlt-1 induced hypertension in vivo.48 Onda et al. observed decreased sFlt-1 secretion 
from placental explants treated with proton pump inhibitors (PPI), which are known to 
upregulate HO-1.49 In keeping with this data, our group has found lower sFlt-1 and ET-1 
levels in women with (suspected) PE that were on PPI treatment.50 Recently, Cluver et al. 
conducted a randomized controlled trial involving 119 women with PE, and found no 
difference in median sFlt-1 levels between women treated with PPI and women treated 
with placebo.51 These conflicting findings demand future studies to establish the role 
of PPI treatment on sFlt-1 in women with PE. Statins also inhibit sFlt-1 secretion in pla-
cental explants through the stimulation of HO-1.52 While the safety profile of the latter 
is still under investigation, PPIs have been proven safe during pregnancy.51, 53 Ouabain, a 
cardiac glycoside, downregulates placental sFlt-1 production in vitro through inhibition 
of the HIF-1a pathway, while similar effects were observed with metformin, possibly by 
blockade of the mitochondrial electron transport chain.54, 55 Several other agents may be 
under evaluation for their potential sFlt-1 inhibiting properties, however the safety of 
their use during human pregnancy remains a main point of concern.
In summary, PE is characterized by increased circulating levels of sFlt-1, and decreased 
levels of VEGF and PlGF, causing an anti-angiogenic imbalance. Restoring this imbalance 
showed promising results in animal studies, and clinical trials are now awaited.
eNDoTheliN
Over the last 3 decades, a dominant role for the ET system has emerged in the modula-
tion of vascular tone in many organ tissues, including the human placenta. ETs belong to 
a family of three 21-amino acid peptides (ET-1, ET-2, ET-3), with ET-1 being the predomi-
nant vascular isoform and currently one of the most potent vasoconstrictors known.56 
ET-1 is secreted by endothelial cells and trophoblast cells towards the basolateral side of 
these cells, indicating its role as a paracrine or autocrine peptide.57, 58
Derived from its precursor peptide known as preproendothelin-1 (preproET-1), big-
endothelin-1 (bigET-1) is cleaved by endothelin converting enzymes (ECEs) and other 
enzymes, including matrix metalloproteinases (MMP) and chymase, into biologically 
active ET-1.59 Once synthesized, ET-1 modulates vascular tone through two cell surface 
G-protein-coupled receptors; ET type A (ETA) receptors located on the vascular smooth 
muscle cell (VSMC) and ET type B (ETB) receptors located on endothelial cells and VSMCs 
(Figure 1). Whereas ETA receptors and ETB receptors on VSMCs both induce vasocon-
striction, ETB receptors on endothelial cells account for the vasodilator effects of ET-1 
through the release of NO and prostaglandins, and additionally provide the means for 
clearing ET-1 from the circulation.59, 60 Receptor localization studies have localized ETA 
receptors in the veins and arteries of the chorionic plate, while ETB receptors were identi-
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fied in decidual cells, veins in stem villi, and blood vessels in distal regions of the villous 
tree.61 ET-binding sites have also been localized in trophoblastic tissue.62 Stimuli for ET-1 
release include ET-1 itself, hypoxia, inflammatory cytokines, along with other vasoactive 
substances such as Ang II.59
The functional role of the ET system in healthy pregnant women is not fully under-
stood. ET-1 has been demonstrated to exert mitogenic effects, promoting first trimester 
trophoblast proliferation and invasion in vitro.63 In addition, expression studies have 
shown an increased ratio of ETB to ETA receptors in the human placenta of healthy 
pregnant women compared to other vessel beds, which may account for the enhanced 
local vasodilatory state during pregnancy.64 While maternal serum levels of ET-1 remain 
similar to those of non-pregnant women during gestation, a substantial rise is detected 
during labor.65, 66 Increased uterine expression of ETA and ETB receptors was also observed 
during parturition, implicating ET-1 is involved in the initiation of uterine contractions.67 
High concentrations of ET-1 were also found in amniotic fluid and the fetal circulation 
including the umbilical vessels, being almost three-fold higher in the umbilical vein 
when compared to maternal serum levels during labor.68 Furthermore, ET-1 was found to 
be a potent vasoconstrictor of human umbilical vessels.69 Subsequently, earlier studies 
hypothesized that ET-1 is an important regulator of placental vascular tone. Wilkes et al. 
were the first to report a dose-dependent increase in perfusion pressure caused by ET-1 
in the ex vivo perfusion model,70 implying vasoconstriction. Furthermore, a long-lasting, 
strong concentration-dependent vasoconstrictor response to ET-1 was observed in iso-
lated chorionic plate vessels, stem villous and umbilical vessels, albeit to a higher degree 
in veins than in arteries.71, 72 However, blockade of the ETA receptor in placental veins 
resulted in little inhibitory effect on ET-1 mediated contractions, implying a high abun-
dance of constrictor ETB receptors in placental veins.73 Hence, differences in receptor 
distribution could account for the increased ET-1 sensitivity in placental veins, and may 
contribute to different vasopressor responses within the placenta. In placental arteries, 
the contractile response to ET-1 was significantly abolished by blocking ETA and to a 
lesser degree ETB receptors, indicating both subtypes mediate contractions in response 
to ET-1. Administration of the NO-donor nitroglycerin, counteracted these contractions 
for the most part, confirming that NO is able to neutralize the effects of ET-1 during 
physiological conditions.68, 74 The concentration at which ET-1 provokes a vasocontractile 
response in these experimental models is higher than its in vivo plasma levels.68, 70, 71 Thus, 
consistent with a predominantly abluminal release of ET-1, local production of ET-1 in 
the placenta determines the vasopressor responses to this peptide. The potency of ET-1 
is maintained throughout the fetoplacental vascular tree,71 unlike those of serotonin and 
thromboxane A2 (TxA2), which decline dramatically when reaching stem villous arteries, 
making ET-1 an important substance in maintaining placental vascular resistance.71, 75
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A role for ETs has been proposed in cardiovascular disease including hypertension.76 
Moreover, activation of the ET system has been implicated as a key final pathway in 
the pathogenesis of PE. Indeed, most studies have reported elevated plasma ET-1 
levels in women with PE as compared to normotensive pregnant women, while some 
studies even demonstrate a positive correlation with disease severity.66, 77-79 Benoit et al. 
investigated the vasoconstrictive function of ET-1 in PE placentas by exposing healthy 
isolated chorionic plate arteries to conditioned medium prepared from PE placentas. In 
their study, enhanced vasoconstriction was shown in response to this medium, which 
was in part inhibited by an ETA receptor blocker, while no effect was seen when blocking 
the ETB receptor.80 The latter finding suggests that an altered response to ET-1 is not 
the major contributor to the elevated vasoconstriction observed in PE. In keeping with 
these findings, both in the ex vivo placental perfusion model and in isolated placental 
arteries, no differences were observed in vascular response to ET-1 between healthy and 
PE placentas.81, 82 Nevertheless, elevated levels of ET-1 in the placenta may still account 
for increased placental vascular resistance in vivo and could further play a part in the 
maternal endothelial dysfunction observed in PE. Indeed, as discussed earlier, women 
with PE display elevated circulating concentrations of ET-1. Similarly, increased ET-1 
mRNA expression has been observed in placental tissue83, 84 of PE pregnancies. Thus, 
the main question that needs to be answered is: what causes this uniform rise in ET-1 
in women with PE? One prevailing theory is that elevated placental ET-1 production 
is released into the maternal circulation and triggers the manifestations of PE. The 
augmented release of this vasoactive peptide could be triggered by placenta-derived 
factors resulting from placental ischemia. In preclinical studies, pregnant mice infused 
with tumor necrosis factor-α (TNF-α) or AT1R-AA display significantly increased expres-
sion of preproET-1 in the placenta, and in the case of TNF-α, also in the maternal aorta.60 
In addition, the sFlt-1 concentration is positively correlated with a rise in ET-1 plasma 
levels.43 Intriguingly, administration of an ETA receptor antagonist in sFlt-1-infused mice 
significantly abolished hypertension.37 Hence, it is possible that placental sFlt-1 directly 
induces local ET-1 production. Experimental animal studies were not able to confirm this 
theory, as exogenous administration of sFlt-1 in pregnant mice only induced preproET-1 
mRNA levels in the kidney but not in the placenta.37 The observation that treatment 
with VEGF inhibitors in cancer patients or rats induces a PE-like syndrome with a rise in 
ET-1,38 further indicates that the ET-1 elevation in the maternal circulation is a direct con-
sequence of VEGF inactivation by sFlt-1.59 Taken together, it is plausible to assume that 
the elevated sFlt-1 levels rather than local ET-1 production in the placenta are the main 
source of the increased circulating ET-1 levels in PE. Since ET-1 triggers oxidative stress 
in placental tissue,85 a vicious cycle may arise, where ET-1 production in the placenta 
contributes to the release of placenta-derived factors including sFlt-1 into the maternal 
circulation.
chapter 2  |  Placental vascular reactivity in health and disease
30
This hypothesis, which suggests that placental ET-1 overproduction may contribute to 
enhanced release of sFlt-1 into the maternal circulation, was recently investigated by Li 
et al., making use of mice with a modified ET-1 gene that causes high ET-1 production.86 
Their study demonstrates that maternal overproduction of ET-1 in pregnant mice is 
responsible for the development of full spectrum PE-like symptoms. However, placental 
overproduction of ET-1 was significantly associated with high plasma sFlt-1 levels in 
the maternal circulation, and contributed to elevated blood pressure. These findings 
confirm the concept that local ET-1 production in the placenta could contribute to PE 
through increasing sFlt-1 release in the maternal circulation. In turn, as discussed, sFlt-1 
binds to VEGF, thereby inducing endothelial dysfunction and increasing plasma ET-1 
production. Additionally, the decreased circulating volume and decreased placental 
perfusion59 in PE women might further elevate placental ET-1 levels. Alterations in the 
expression or localization of ET-1 receptors in the placenta may also enhance placental 
vascular resistance in PE. Rutherford et al., using affinity binding assays, observed no 
difference in either density or affinity of the ET-1 receptors in PE placentas.61 Faxen et 
al. reported reduced ETA receptor mRNA expression in PE placentas, while in another 
study this was only observed in late-onset PE. Downregulation of these receptors due 
to elevated ET-1 levels may underlie these findings.87, 88 On the other hand, studies 
investigating ETB receptor expression reported both increased and decreased mRNA 
levels in PE placentas.88, 89 Altogether, the evidence regarding changes in placental ET 
receptor expression during PE remains ambiguous. Lastly, it has been hypothesized that 
MMPs, enzymes that can cleave bigET-1 into ET-1, are significantly increased in women 
with PE.60 An elevated expression of MMP-2 in placental tissue, which has been reported 
recently, could account for increased ET-1 production in the placenta.90 Also, increased 
ECE levels in serum of women with PE has been observed,91 although its expression level 
in PE placentas has not yet been determined.
Endothelin receptor antagonists (ERAs) are clinically implemented for the treatment 
of cardiovascular diseases such as pulmonary hypertension, renal failure and cancer.60 
Concerning their actions in the treatment of the maternal syndrome of PE, most of 
our understanding comes from experimental animal models of PE. Particularly in the 
reduced uterine perfusion pressure (RUPP) model or sFlt-1-induced hypertension in rats, 
selective blockade of the ETA receptor resulted in attenuated hypertension.37, 92 In spite 
of these reports, ERAs are contraindicated in pregnancy, as genetic ETA knockout models 
or treatment with ETA receptor antagonists have led to fetal malformations or death in 
rodents.93 Thaete et al. determined the levels of a selective ETA receptor antagonist in 
fetal plasma of pregnant rats following long-term maternal exposure, and observed 
that only 2% of plasma levels reached the fetus.94 Despite these findings, it is currently 
unknown whether ERAs cross the placental barrier in humans. Given the low molecular 
weight and lipophilic characteristics of these drugs, (partial) placental transfer seems 
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probable, since it is long known that lipophilic drugs with a molecular weight below 600 
in general rapidly cross the placental barrier.95 However, specific knowledge on ERAs in 
the human placenta is imperative to determine their usefulness in reducing placental 
vascular resistance in PE, because if ERAs are indeed to pass the placental barrier in 
humans, their potential teratogenic effects would possibly compromise their use in 
pregnancy. Linking ERAs to elastin-like peptides that do not cross this barrier, could 
provide an alternative approach to target the ET-1 pathway in the maternal circulation 
without affecting the fetus.60 In addition, as observed by Thaete et al.,94 administration 
of ERAs during late pregnancy, after completion of fetal organogenesis, might be harm-
less. Which ET-receptor subtype should be blocked requires further investigation, as few 
studies have investigated the role of ERAs in PE placental vessels. In healthy placental 
arteries, ETA receptor antagonism and to a lesser degree ETB receptor antagonism both 
diminished the vasoconstrictor response of ET-1.68 Obviously, changes in receptor ex-
pression may influence the response to ERAs during PE.
In conclusion, the ET system plays seems to play an important role in the pathogenesis 
of PE. Compared to healthy pregnancy, increased circulating levels of ET-1 are found in 
PE. To target this system, future studies making use of the ex vivo human placental perfu-
sion model should first determine the passage of ERAs through the human placental 
barrier. In addition, alternative mechanisms to target the ET system such as inhibiting 
ET-1 release, inactivating ET-1 in the circulation or suppressing endothelial ET-1 synthe-
sis either directly (e.g with small interfering RNA) or indirectly (through inhibition of 
sFlt-1) should be further explored in future studies.
ReNiN-ANGioTeNsiN sysTem
The RAS contributes to the long-term regulation of arterial pressure via its effects on 
vascular tone and sodium homeostasis. Angiotensinogen, the precursor to all angio-
tensins, is converted via renin into Ang I. Ang I is not biologically active and is cleaved 
primarily by angiotensin-converting enzyme (ACE) to form Ang II, the main effector 
peptide of the RAS. Of note, Ang II can also be generated via chymase which is produced 
by villous syncytiotrophoblasts, although evidence that this occurs in vivo is lacking.96 
Once formed, Ang II can stimulate both the angiotensin II type 1 receptor (AT1R) and the 
angiotensin II type 2 receptor (AT2R) (Figure 2). Although the affinity of Ang II is ~15-fold 
greater for the AT2R than the AT1R,97 the AT1R is the dominant receptor expressed fol-
lowing fetal life.98 Activation of the AT1R elicits the classical actions of the RAS including 
aldosterone release, sodium retention, vasoconstriction and pro-inflammatory effects. 
Conversely, activation of the AT2R induces natriuresis, vasodilation and anti-inflammato-
ry effects (Figure 2). The discovery of novel angiotensin fragments and receptors has led 
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to the identification of depressor RAS pathways, which encompasses the AT2R and the 
angiotensin-converting enzyme 2 (ACE2)/Ang 1-7/Mas receptor axis, that counteract 
the classical actions of AT1R stimulation.98
The maternal RAS undergoes major changes during pregnancy. All of the components 
of the RAS are increased in uncomplicated pregnancies, except for ACE.99 During early 
gestation, the ovaries and maternal decidua contribute to an increase in extra-renal re-
nin release.100 In addition, the high estrogen level maintained by the placenta promotes 
hepatic angiotensinogen synthesis. Consequently, circulating Ang II and aldosterone 
levels are increased during pregnancy.101 Yet, despite the increase in circulating Ang 
II, pregnant women and gravid animals are less sensitive to the pressor effects of Ang 
II.102, 103 In a landmark study by Gant et al. from 1973, it was demonstrated that normo-
tensive pregnant women require twice the dose of Ang II to elicit a 20 mmHg increase 
in diastolic arterial pressure as compared to non-pregnant women.104 This refractoriness 
to Ang II has been attributed to increases in progesterone and PGI2 which can decrease 
sensitivity to Ang II-induced vasoconstriction,105 but may also be, at least in part, medi-
ated by an upregulation of the depressor RAS pathways. For example, it has been dem-
onstrated that during normotensive pregnancies circulating ACE2 is upregulated,103, 106 
plasma Ang 1-7 increases by 20-fold103 and that the AT2R/AT1R balance rises.103 Similarly, 
in murine studies, genetic and/or pharmacological AT2R107-110 or ACE2111 deficiency leads 
to pregnancy induced hypertension, supporting a key role for the depressor RAS path-
ways in the normal cardiovascular adaptations to pregnancy.














figure 2. The RAS in human pregnancy and therapeutic strategies targeting this pathway. During PE there 
is a decrease in renin, Ang I, Ang II and Ang 1-7, whereas circulating levels of AT1R-AA are increased. Abbre-
viations: ACE = angiotensin converting enzyme; ACEi = ACE inhibitor; Agt = angiotensinogen; Ang = angio-
tensin; ARB = angiotensin II type 1 receptor blocker; AT1R = angiotensin II type 1 receptor; AT2R angiotensin 
II type 2 receptor; AT1R-AA; angiotensin II type 1 auto-antibodies; MasR = Mas receptor.
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Compared to the characteristic refractoriness to Ang II observed during normal preg-
nancy, PE is characterized by increased sensitivity to Ang II and altered expression of RAS 
components.102, 104, 112, 113 Circulating renin, Ang I, Ang II and aldosterone levels are lower 
in women with PE as compared to women with uncomplicated pregnancies.99, 114 More-
over, the pregnancy-induced increase in plasma Ang 1-7 in women with uncomplicated 
pregnancies is not observed during PE.99 Although little is known about AT2R expres-
sion during PE, women with a history of PE have a lower AT2R/AT1R ratio than women 
who had uncomplicated pregnancies,115 suggesting that AT2R expression is decreased 
during PE. Conversely, during PE, the presence of AT1R-AA116 and the increase in AT1R-
bradykinin receptor (B2) heterodimers117, 118 potentiate the pro-hypertensive effects of 
the AT1R. Moreover, in PE women, AT1R-AA titer is proportional to sFlt-1, suggesting that 
AT1R-AA may stimulate additional pathways (for example ET-1 and anti-angiogenetic 
factors (sFlt-1 and soluble endoglin (sEng)) in addition to directly activating the AT1R.119
Within the placenta, all of the components necessary for a functional RAS are 
expressed on both the maternal and fetal sides.120-128 The AT1R is the predominant AT 
receptor expressed throughout the placenta.120 Within the placental villi, it has been 
demonstrated that AT1R are localized in and around the blood vessels.120 Consequently, 
Ang II induces a potent dose-dependent vasoconstrictor effect within the fetoplacental 
circulation,129-131 with isolated chorionic plate vessels being more sensitive to Ang II than 
segments from umbilical132, 133 and uterine131 arteries. Similarly, in animals, the infusion 
of Ang II markedly increases fetal-placental pressure.134, 135 Using the dually perfused ex 
vivo human placenta model, Glance et al. demonstrated that administration of Ang II to 
the maternal circulation induces a dose-related increase in fetal perfusion pressure.130 
Conversely, administration of Ang II to the fetal circulation does not induce an increase 
in maternal perfusion pressure,130 indicating one-way direction (maternal to fetal) of 
Ang II. This suggests that high circulating maternal Ang II concentration could result 
in elevated fetoplacental Ang II concentration and enhanced pressor responsiveness 
to Ang II. Moreover, sensitivity of the fetoplacental vasculature to Ang II may also be 
dependent on thromboxanes and/or prostaglandins since selective cyclooxygenase 
(COX)-1 inhibition with low dose acetylsalicylic acid (via infusion into the intervillous 
space)136 or dual COX-1 and COX-2 inhibition with meclofenamate137 attenuates Ang 
II-induced vasoconstriction. Interestingly, refractoriness to Ang II-induced vasoconstric-
tion is even greater in the fetoplacental circulation than the maternal systemic circula-
tion during late gestation.138 Furthermore, tachyphylaxis to Ang II has been reported in 
the fetoplacental circulation of term placentas from uncomplicated pregnancies.139 This 
reduced sensitivity to Ang II may serve to protect the fetoplacental circulation from the 
normally occurring increases in maternal Ang II concentration.
In contrast to uncomplicated pregnancies, angiotensinogen, Ang II and AT1R are sig-
nificantly higher in chorionic villous tissue from nulliparous third trimester PE pregnan-
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cies.140 While these authors did not observe any differences in placental ACE, ACE2, or 
Ang 1-7 levels between PE and uncomplicated pregnancies, there is evidence that ACE 
expression and activity141 and chymase96 are upregulated in PE placentas, which would 
result in an increase in placental Ang II generation. In agreement with these studies, 
when isolated chorionic plate arteries from uncomplicated pregnancies are perfused 
with placental conditioned media from PE placentas, vasoconstriction (equal to 50% 
of the response to KCl 100) is blunted by 40% by chymase inhibition and 20% by ACE 
inhibition.80 Moreover, AT1R blockade with losartan attenuated the contractile response 
to PE-conditioned media by 30%, while AT2R blockade with PD123319 only reduced 
the contractile response by 16%.80 Collectively these data suggest that elevated Ang 
II acting via the AT1R may favor vasoconstriction in placental chorionic villi during PE, 
which may contribute to impaired fetal blood flow and poor fetal outcomes. However, 
to date, studies using isolated chorionic vessels or the dually perfused ex vivo placental 
perfusion model to investigate Ang II sensitivity in PE placentas have reported that the 
pressor response to Ang II is decreased133, 142 or unchanged143 as compared to placentas 
from uncomplicated pregnancies. The reason for the discrepancy between these studies 
is unclear, but may relate to the use of magnesium sulfate (MgSO4) or the combined use 
of cesarean and vaginally delivered placentas. Previous studies have demonstrated that 
MgSO4, which is used clinically to prevent eclampsia, attenuates the sensitivity of the 
fetal-placental vasculature to Ang II.143, 144 Differential expression of RAS components in 
PE and uncomplicated placentas has not been observed in vaginally delivered placen-
tas,145 suggesting that the expression of the RAS is altered in placentas during labor.
Drugs that inhibit the RAS (ACE inhibitors (ACEi) and AT1R blockers (ARBs)), which are a 
mainstay for the treatment of hypertension, are contraindicated during pregnancy due 
to the high risk of teratogenic effects. In preclinical studies, ACEi use was associated 
with increased risk of intrauterine death and still births.146, 147 In women, ACEi during 
second and third trimesters of pregnancy has been shown to have adverse effects on 
the fetus,148 including FGR, respiratory, renal and circulatory abnormalities, and patent 
ductus arteriosus.149-151 Similar fetal abnormalities are seen with maternal ARB treat-
ment during the second and third trimesters of pregnancy.152 An alternative approach 
to antagonize the effects of AT1R activation during PE might be to antagonize AT1R-AA 
with the help of a high affinity 7-amino acid sequence (‘n7AAc’). Cunningham et al., 
have recently demonstrated that in the reduced uterine perfusion pressure model of 
PE, AT1R-AA blockade with this inhibitory peptide prevents PE symptoms, including the 
normalization of arterial pressure and reduces sFlt-1, preproET-1, pro-inflammatory and 
generation of reactive oxygen species.153 However, there is still doubt whether AT1R-AA 
truly activate AT1R in vivo,154 and thus it cannot be excluded that inhibiting AT1R-AA has 
effects that are unrelated to the RAS.
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Taken together, in pregnancies complicated by PE the RAS is altered, featuring an 
increased sensitivity to Ang II and suppressed maternal plasma levels of most RAS 
components. Yet, the levels of angiotensinogen and Ang II in the placenta are increased. 
Unfortunately, drugs that directly inhibit the RAS are contraindicated in pregnancy. New 
approaches, such as AT1R-AA antagonism, could be of therapeutic value in the future, 
once it has been established what exactly such treatment interferes with.
PRosTAGlANDiNs
Two of the most important prostaglandins in pregnancy are TxA2 and PGI2. They both 
originate from the common precursor prostaglandin H2 (PGH2), which is formed by con-
version of arachidonic acid under the influence of COX-1 and/or COX-2.155 To form TxA2 
and PGI2, which act as each other’s natural antagonist, PGH2 is converted by thrombox-
ane synthase or prostacyclin synthase respectively (Figure 3). PGI2 is a vasodilator, and a 
very potent inhibitor of platelet aggregation.156 Furthermore, in pregnancy PGI2 inhibits 
uterine contractility.157 In contrast, TxA2 is a potent vasoconstrictor, which additionally 
induces platelet aggregation and stimulates uterine contractility.156, 157 The placenta has 
been shown to produce both TxA2 and PGI2, as well as prostaglandins E2 and F2α, which 
both exert vasoconstrictor effects in the fetoplacental vasculature (Figure 3).131, 158-161 
TxA2 might also mediate the constrictor effects of ET-1, 5-hydroxytryptamine (5-HT) and 
Ang II.162
Compared to the non-pregnant state, serum concentrations of PGI2 metabolites are 
increased during normal pregnancy, with a peak in the first trimester.163 In PE, the produc-
tion of PGI2 in the placenta and umbilical vessels is reduced,164, 165 while the levels of PGI2 
and its metabolites are also diminished in plasma, urine and amniotic fluid.163, 166, 167 This 
indicates a possible role for decreased PGI2 activity in the pathogenesis of PE. Remark-
ably, the response of the ex vivo perfused PE placenta to PGI2 is diminished compared 
to healthy controls.142 As one of the first, Walsh et al. found that there is an imbalance 
between TxA2 and PGI2 in the PE placenta, with a three-fold increase in TxA2 production, 
and a 50% reduction in PGI2 release.168 This TxA2/PGI2 imbalance causes a shift towards 
vasoconstriction, possibly leading to hypertension and reduced uterine flow. A factor 
that possibly contributes to the TxA2/PGI2 imbalance in PE is an elevation in circulating 
levels of lipid peroxides.169 Lipid peroxides stimulate TxA2 production, and simultane-
ously inhibit PGI2.170 Wang et al. showed that placental perfusion with peroxides indeed 
leads to a rise in the TxA2/PGI2 ratio.171 Trophoblast cells are the main source of this 
increased TxA2 synthesis, and accordingly, they display increased expression of COX-1 in 
PE,172, 173 which may further amplify the elevation of the TxA2 plasma levels are elevated 
in severe PE versus normal pregnancy.174
chapter 2  |  Placental vascular reactivity in health and disease
36
Of all prostaglandins, TxA2 exerts the most powerful vasoconstrictive effect in the 
placenta, as shown by many ex vivo studies.131, 175 Administration of the TxA2 agonist 
U46619 in the isolated perfused cotyledon or chorionic plate arteries elicits a potent 
dose-dependent response.176-182 However, the response differs greatly among different 
vessel types, in contrast to other prostaglandins (e.g. E2 and F2α) that are also known to 
constrict fetoplacental vasculature through binding different receptors.75, 131 Broegger 
et al. found a positive correlation between vessel sensitivity to the TxA2 agonist U46619 
and the inner vessel diameter,75 suggesting differences in receptor numbers and/or dis-
tribution along placental vasculature, however this still needs to be confirmed through 
quantification methods. These findings critically question the general opinion that TxA2 
is one of the most important regulators of placental vascular tone, since the smallest 
vessels are presumed to be the most contributory to resistance.183 In PE placentas, 
the release of TxA2 in response to 5-HT exposure during ex vivo placental perfusion is 
increased.184 However, the vasoconstrictive response to U46619 is significantly attenu-















figure 3. The prostaglandin pathway in the human placenta and therapeutic strategies targeting this path-
way. During PE circulating levels of TxA2 and PGF2α are increased, while PGI2 levels are decreased, resulting 
in an imbalance. Abbreviations: B2R = bradykinin receptor; BK = bradykinin; PGE2 = prostaglandin E2; PGE2R 
= PGE2 receptor; PGF2α = prostaglandin F2α; PGF2R = PGF2α receptor; PGH2 = prostaglandin H2; PGI2 = pros-




Targeting the TxA2/PGI2 imbalance as a preventive strategy for PE has been performed 
for a long time by studying the effects of low-dose acetylsalicylic acid. Low-dose 
acetylsalicylic acid selectively inhibits the synthesis of TxA2, without interfering with 
the production of PGI2.185 This is thought to be the due to compartmentalization of 
the production sites of TxA2 and PGI2 in the placenta, as TxA2 is primarily produced by 
trophoblast cells near the maternal circulation and PGI2 by endothelial cells near the 
fetal circulation.185 Studies on the efficacy of low-dose acetylsalicylic acid have shown 
contradictory results. Some of these differences could be explained by timing of treat-
ment initiation or patient selection. A systematic review and meta-analysis including 
10 randomized controlled trials comparing first trimester low-dose acetylsalicylic acid 
versus placebo or no treatment in women at risk for PE found a significant reduction in 
the overall risk ratio (RR 0.35; 95% CI 0.13-0.94) of developing early onset PE.186 However, 
early identification of women who are at high risk for PE remains very difficult, and when 
started after 16 weeks of gestation the beneficial effects of acetylsalicylic acid seem no 
longer evident.187, 188 Acetylsalicylic acid use is regarded safe throughout pregnancy, as 
no associations with adverse fetal outcome (e.g. congenital abnormalities, intraven-
tricular hemorrhage, premature closure of the ductus arteriosus) or maternal outcome 
(e.g. postpartum hemorrhage, placental abruption) have been found.189, 190 Although an 
increased risk of vaginal bleeding has been reported, this was not associated with an 
increased risk of pregnancy loss.189 Another interesting method could be to selectively 
target COX-2. Sones et al. showed upregulation of COX-2 in a PE mouse model. Treating 
these mice with a single dose of the selective COX-2 inhibitor celecoxib during decidual-
ization prevented maternal hypertension and normalized placental- and fetal growth.191 
However, the effects on PE in human pregnancy remain to be investigated. Moreover, 
although short term exposure to celecoxib in the third trimester showed no increase 
in maternal or neonatal complications,192 the risks of long-term exposure during preg-
nancy are not yet known.
In conclusion, there is a distinct imbalance between TxA2 and PGI2 in PE, causing a 
preponderance towards the vasoconstrictive function of the prostaglandin axis. Until 
now, targeting this axis has been only proven useful in the prevention of PE in high-risk 
patients.
NiTRic oxiDe
NO, previously identified as endothelium-derived relaxing factor,193 plays a key-role in 
vasodilation. It is synthesized by a family of nitric oxide synthases (NOS), most impor-
tantly endothelial NOS (eNOS) and inducible NOS (iNOS), that are present in various cell 
types including endothelial cells and fetal trophoblasts. These NOS enzymes cause ca-
chapter 2  |  Placental vascular reactivity in health and disease
38
talysis of L-arginine, resulting in production of NO, after stimulation by different factors 
(e.g. endothelial shear stress, estrogen, bradykinin, acetylcholine). By activating soluble 
guanylate cyclase (sGC), NO causes an increase in intracellular free cyclic guanosine 
3’,5’-monophosphate (cGMP), leading to vasodilation through closure of Ca2+ channels 
(Figure 4).194-196
In normal pregnancy, circulating levels of NO are increased,197 as well as the blood 
plasma levels of hormones and growth factors that stimulate NO release, like estrogen, 
VEGF and PlGF.198, 199 Apart from blood pressure regulation, NO also influences cytotro-
phoblast invasion and spiral artery remodeling in early gestation.200 It has been shown 
in ex vivo placental perfusion experiments that inhibition of the NO pathway causes an 
increased response to the TxA2 agonist U46619,201 indicating that there is NO release in 
response to vasoconstriction, possibly due to increased shear stress.
The role of the NO pathway in PE has been extensively discussed in literature, and the 
mechanisms contributing to its dysfunction seem multifactorial.194, 195 In animal models, 
systemic inhibition of NO synthesis leads to development of a PE-like syndrome, with 
maternal hypertension and proteinuria, as well as fetal growth restriction.202, 203 Further-
more, studies using rat models with RUPP, causing PE symptoms, showed a decrease in 
NO synthesis and/or release from endothelial cells.204 Altogether, these studies suggest 
that indeed loss of NO can contribute to development of PE. In women with PE, circulat-
ing NO metabolites have been found to be significantly decreased versus healthy preg-
nant women.197, 205-207 Similarly, lower circulating levels of the NO-dependent vasodila-
tors estrogen, VEGF and PlGF have been reported.36, 208, 209 In addition, plasma levels of 
asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, are elevated in PE 
patients,210 further contributing to impaired eNOS activity. Protein expression of eNOS 
seems unchanged in placental tissue of PE pregnancies,206, 211 although eNOS mRNA ex-
pression has been reported to be increased, possibly as a compensatory mechanism.212 
Oxidants, such as reactive oxygen species (ROS), are produced during oxidative stress 
and are known to scavenge NO, resulting in the formation of peroxynitrite (Figure 4). It 
is thought that in PE there is an increase in ROS, explaining, at least partly, the reduced 
bioavailability of NO despite increased eNOS expression.196 Indeed, peroxynitrite has 
been shown to be increased in vessels of women with PE.213 Accordingly, Bisseling et al. 
found that the antioxidant N-acetylcysteine improved the NO-mediated effects in the 
fetoplacental circulation during ex vivo placental perfusion in healthy and PE placentas 
to a similar extent.196 However, in a randomized controlled trial where women with 
severe early onset PE received either N-acetylcysteine or placebo, no improvement of 
maternal disease and no differences in neonatal outcome were observed.214 Other ex 
vivo placental perfusion studies showed that administering N(ω)-nitro-L-arginine methyl 
ester (L-NAME), a NOS inhibitor, induced a significant increase in the baseline perfusion 
pressure of healthy placentas.196, 215, 216 However, in PE placentas this pressure increase 
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is much less pronounced, suggesting that NO-mediated vasodilation is decreased in 
PE.196, 216 Another intriguing possibility is that placental eNOS is uncoupled in PE, and 
produces superoxide rather than NO. However, to our knowledge, this has not been 
investigated to date.
Many clinical trials have evaluated whether drugs that affect the NO pathway, like NO 
donors (e.g. organic nitrates and S-nitrosothiols) and NO precursors (e.g. L-arginine) are 
capable of restoring the NO-pathway in PE. Although they caused a significant decrease 
in blood pressure, there were no effects on maternal or fetal outcome.217-221 Therefore, 
evidence for their effectiveness is limited, and they are additionally known to quickly 
develop drug tolerance and to have significant side-effects.222 Indeed, the vasodilator 
response to various NO-donors is attenuated in PE placentas.142 Studies investigating 
the reactivity of isolated chorionic plate arteries showed similar results. In this set-up, 
NO-donors result in potent vasodilation of pre-constricted healthy placental arter-
























figure 4. The NO-pathway and NO-dependent vasodilators in the human placenta and therapeutic strate-
gies targeting this pathway. During PE there is a decrease of NO and ACh, while levels of ROS, peroxynitrite, 
ADMA and histamine are increased. Abbreviations: ACh = acetylcholine; ADMA = asymmetric dimethylar-
ginine; B2R = bradykinin receptor; BK = bradykinin; cGMP = cyclic guanosine 3’,5’-monophosphate; eNOS 
= endothelial nitric oxide synthase; GMP = guanosine 3’,5’-monophosphate; H1R = histamine type 1 recep-
tor; H2R = histamine type 2 receptor; mAChR = muscarinic acetylcholine receptor; NO = nitric oxide; PDE5 
= phosphodiesterase-5; ROS = radical oxygen species; sGC = soluble guanylate cyclase; VSMC = vascular 
smooth muscle cell.
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efficacy of NO-donors could be due to increased scavenging of NO and/or disruptions 
more downstream in the NO-pathway. Interestingly, not much is known about directly 
modulating sGC, through either activators (e.g. YC-1) or stimulators (e.g. riociguat), in 
the placenta. These compounds potentiate the effects of the NO-pathway in an NO-
independent way.226, 227 Brownfoot et al. showed that YC-1 inhibits placental production 
of sFlt-1 and sEng, and that it reduces endothelial dysfunction in preeclamptic tissue.228 
Until now, no (pre)clinical trials with sGC-modulators in PE have been published, but it 
could be a novel therapeutic target. Another way to potentiate the action of the NO-
pathway, is to inhibit the degradation of the active cGMP into the inactive GMP by phos-
phodiesterases. A drug that is currently under investigation is the phosphodiesterase-5 
(PDE5) inhibitor sildenafil. In PE animal models, sildenafil improved fetal outcome and 
additionally diminished maternal symptoms.229, 230 Ex vivo studies showed a significant 
vasodilator response of chorionic plate arteries to sildenafil.231, 232 However, this has not 
been studied in placentas from PE pregnancies. Samangaya et al. performed a small 
randomized controlled trial of sildenafil versus placebo in women with PE, but found 
no improvement in duration of pregnancy or neonatal outcome.233 Currently, a large 
multicenter randomized controlled trial is further evaluating the effects of sildenafil on 
pregnancy outcome in extreme FGR due to placental insufficiency.234 Unfortunately, the 
first cohort of this study, from the United Kingdom, reported that sildenafil did not pro-
long pregnancy and did not improve fetal outcome.235 Furthermore, the Dutch cohort 
has recently been halted since sildenafil did not show beneficial effects and there was an 
increase of neonatal complications in the treated group.236
To summarize, NO-mediated vasodilation is impaired in PE compared to normal 
pregnancy, possibly due to a decrease in NO synthesis and/or release, increased NOS 
inhibition, or increased NO scavenging by ROS. Although many drugs targeting this 
pathway have been evaluated in PE, none of them improved fetal outcome. Possibly 
direct stimulation and/or activation of sGC could provide a favorable treatment option.
NiTRic oxiDe-DePeNDeNT VAsoDilAToRs
bradykinin
Bradykinin (BK) is known to be a powerful stimulator of the release of both NO and 
PGI2 (Figure 4), inducing vasodilation and increasing vascular permeability through 
binding of the G-protein-coupled B2 receptors. In contrast, binding the B1 receptor, that 
is mostly expressed in the central nervous system in response to injury, induces typical 
signs of inflammation.237
In the placenta, the B2 receptor has been documented in decidua, placental and ex-
travillous trophoblasts and in the fetal endothelium.238 Although generally considered 
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to be a vasodilator, BK is also known to induce vasoconstriction in placental vessels, 
probably through the stimulation of TxA2 production (Figure 3).239 However, most ex 
vivo studies were unable to show responses of chorionic plate arteries to BK, possibly 
because it is rapidly metabolized in placental tissue.177, 179, 225 After a single passage of 
the fetoplacental circulation, BK loses 98% of its biological activity,240 indicating effective 
clearance of BK in placental vasculature. The most important enzyme responsible for 
BK degradation is ACE,241 and indeed the effect of BK on placental vessels is potenti-
ated in the presence of an ACEi.242 BK stimulates cell migration and plays an important 
role in trophoblast invasion through the B2 receptors.238 Consistent with the alterations 
in PE, there is a significant reduction of the B2 receptor gene- and protein expression, 
compared to healthy placentas.243, 244 Possibly, this contributes to impaired trophoblast 
invasion. However, the precise role of BK in PE remains unknown and therapeutically 
targeting this system would be difficult, as for example ACEi are severely fetotoxic and, 
as outlined in section 5, also impact the RAS.148
Acetylcholine
Even though the placenta is a non-neuronal and non-innervated tissue, acetylcholine 
(ACh), as well as its synthesizing hormone choline acetyltransferase, are present in 
large concentrations in the human placenta.245 ACh is continuously synthesized in the 
syncytiotrophoblast cells from where it is released into both the maternal and fetal 
circulations, as shown by ex vivo placental perfusion studies. However, it does not seem 
to have an effect on fetoplacental vascular tone.246 ACh exerts its action through 2 types 
of cholinergic receptors: the muscarinic (mAChR) and nicotinic receptors (nAChR), both 
of which are expressed in the human placenta.247, 248 It has been suggested that ACh 
plays an important role in the trans-placental passage of amino acids, and in placental 
hormone release.249 Furthermore, it is involved in the development of placental vessels 
and syncytiotrophoblasts.250
In the PE placenta, ACh synthesis and output are decreased,251, 252 as is the density of 
mAChR.253 In contrast, the expression of nAChR is increased.254 Interestingly, binding of 
nicotine to nAChR stimulates the production of growth factors, such as VEGF, leading 
to increased angiogenesis.255 In line with this, smoking during pregnancy seems to be 
protective against PE,256, 257 although it is well known that smoking increases the risk of 
many other adverse pregnancy outcomes. To investigate the therapeutic potential of 
nAChR agonists in PE, Mimura et al. tested the effect of nicotine on damaged endothelial 
cells. They found that nicotine significantly increased PlGF levels and counteracted the 
endothelial dysfunction caused by increased sFlt-1 levels, suggesting a possible thera-
peutic target for restoring the anti-angiogenic imbalance as seen in PE.258
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histamine
Histamine is an angiogenic and vasoactive mediator, that is derived from mast cells.259 
It plays an important role in allergic and inflammatory processes, and is also involved in 
pregnancy.260 Histamine exerts its biological actions through binding to four receptors, 
two of which are involved in vascular reactivity: H1 and H2. Binding to the H1 receptor 
causes contraction of smooth muscle cell, whereas activation of the H2 receptor stimu-
lates vasodilation (Figure 4).260
In first trimester, maternal serum levels of histamine are highest, decreasing with 
progressing gestation.261 Histamine has been shown to promote trophoblast invasion.262 
During placental development, hypoxia is an important trigger for mast cell activation, 
stimulating angiogenesis through production of HIF-1α and VEGF. HIF-1α activity 
leads to increased synthesis of histamine within mast cells, and their degranulation.263 
Isolated vessel studies show that in human placental arteries and veins, histamine 
predominantly causes vasoconstriction,264-266 an effect that is attenuated by adding a 
H1 receptor blocker.264 However, a vasodilator effect on placental arteries through the 
H2 receptor has also been recorded.267 Both effects indicate that histamine is involved 
in regulation of placental vascular tone. Histamine is predominantly metabolized by 
diamine oxidase (DAO), an enzyme that is highly expressed in, and produced by the 
placenta.268 An increase in circulating DAO levels during advancing gestation causes 
a decrease of circulating histamine levels. In animal studies, histamine injection and/
or DAO inhibition had fatal consequences, indicating a protective role for DAO against 
reaching harmful histamine levels.269, 270 Also in human pregnancy, reduced activity of 
DAO has been linked to unfavorable outcome.268
In pregnancies complicated by PE, placental tissue concentrations of histamine and 
mast cells are significantly higher as compared to normal pregnancy.271, 272 Furthermore, 
higher mast cell density and a lower vascular/extravascular index of histamine have 
been identified, indicating a change in mast cell distribution, as well as in circulating 
histamine concentration.272 On the contrary, isolated placental arteries of PE placentas 
show a decreased responsiveness to histamine ex vivo indicating reduced placental 
sensitivity for histamine.266 Whether blockade of the H1 receptor, or stimulation of the 
H2 receptor could offer treatment potential for PE has not yet been investigated.
seRoToNiN AND TRyPToPhAN
Tryptophan (Trp) is an essential amino acid and, in addition to its requirement in protein 
synthesis, is the precursor to several vasoactive metabolites. Two main Trp metabolizing 
pathways are present in the placenta, being the serotonin pathway initiated by conver-
sion of Trp by tryptophan hydroxylase (TPH) and the kynurenine pathway, initiated by 
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conversion of Trp by either tryptophan 2,3-dioxygenase (TDO), indolamine 2,3-dioxy-
genase-1 (IDO1), or indolamine 2,3-dioxygenase-2 (IDO2).273
serotonin
Serotonin, also known as 5-HT, is mainly known for its functions in the central nervous 
system. Furthermore, it regulates blood vessel tone and blood pressure. For these 
functions outside the central nervous system 5-HT might originate from platelets.274 Ad-
ditionally, locally produced serotonin might aid in regulation of placental blood vessel 
tone. Serotonin is a metabolite of Trp, and the responsible enzyme, Trp hydroxylase, is 
expressed in the placenta.275 In blood vessels 5-HT can exert different effects, ranging 
from constriction to dilation, depending on the receptor(s) it binds to.276 Watts et al. 
concluded that 5-HT is able to induce vasoconstriction in virtually every isolated blood 
vessel, mediated predominantly by 5-HT2A (Figure 5), and partly by 5-HT1B/1D recep-
tors.276 Results from wire-myography experiments reveal that segments from umbilical 
and chorionic plate arteries and veins show a strong dose dependent vasoconstrictive 
response to 5-HT, dependent on 5-HT2 and not 5-HT1 or 5-HT3 receptors.131, 177, 277-280
Although placental arteries and veins respond similarly to 5-HT, sensitivity to 5-HT 
decreases with vessel size.71, 132 Like with prostaglandins, this could indicate differences 
in receptor density and/or distribution. Given the wide variety of constrictor and dilator 
5-HT receptor,276 it is not surprising that in perfused vessel segments 5-HT often elicits a 
biphasic pressure response, with a pressure decrease preceding vasoconstriction.281 In 
ex vivo placental perfusion experiments infusion with 5-HT results in a dose-dependent 
elevation in perfusion pressure.82, 162, 216, 282-284 However, these rises in pressure vary greatly 
between experiments and often decline slowly.
Responses to 5-HT are largely dependent on calcium (Ca2+). Hence, both the extra-
cellular Ca2+ concentration and Ca2+ antagonists affect the 5-HT response in chorionic 
arteries and veins.279 Other factors involved in the 5-HT response are prostaglandins, 
more specifically TxA2. This prostanoid was detectable in the perfusate of ex vivo 
perfused placentas after 5-HT induced vasoconstriction, supporting the concept that 
placental vessels are able to produce TxA2 locally (Figure 5). Moreover, both the COX-
inhibitor acetylsalicylic acid and the TxA2 antagonist GR32191 significantly attenuate 
the vasoconstriction in response to 5-HT.162 Not only TxA2, but also prostaglandin F2ɑ 
potentiates the 5-HT response in chorionic veins in both wire-myography and vessel 
segment perfusion experiments.278 These results show that prostaglandins potentially 
regulate vascular resistance by modifying the 5-HT response.
Blood levels of 5-HT change during pregnancy and are affected by PE. Whereas the 
platelet 5-HT concentration increases during both healthy and PE pregnancies, the free 
5-HT concentration is elevated during PE pregnancies only, in both the maternal and 
fetal circulation.285-287 Moreover, this free 5-HT plasma concentration directly correlates 
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with systolic and diastolic blood pressure in women suff ering from severe PE.287 Ex vivo 
placental perfusion experiments showed unaltered or increased vascular resistance in 
response to 5-HT in PE as compared to healthy placentas.82, 184 Conversely, in isolated 
umbilical vessels and placental veins from PE placentas, the sensitivity to 5-HT did not 
increase throughout the third trimester like in healthy placentas, with a reduced 5-HT 
vasoconstrictor response as compared to healthy placental veins as a result.266, 288
Research on therapeutic possibilities of interfering with the 5-HT pathway has mainly 
focused on the role and safety of antidepressants such as selective serotonin reuptake 
inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), and tricyclic 
antidepressants. Studies have not been conclusive, possibly because PE has been de-
fi ned in various ways, and eff ects of antidepressants might depend on the timing of 
exposure during pregnancy.289 Platelets of PE patients have a higher transport rate of 
5-HT compared to healthy pregnant women.290 Importantly, since a large prospective 
population-based study has shown that depression per se results in an increased risk 
of developing PE in women suff ering from depression, independently of treatment,291 
eff ects of antidepressants on PE should be convincingly distinguished from the eff ect of 
the depression itself. Indeed, women who took antidepressant medications, but with-
out depression, tended to display an increase in the risk of PE.292 It could be reasoned 
that inhibition of the responsible serotonin transporter by SSRI could contribute to a re-
duced platelet 5-HT delivery in the periphery, and prevention of undesired vasoconstric-
tion. The use of another drug, the 5-HT2 receptor antagonist ketanserin, was aborted in 
a double-blind randomized trial due to persistent hypertension in severe early-onset 














figure 5. 5-HT and tryptophan in human pregnancy and therapeutic strategies targeting this pathway. 
During PE there is a decrease of IDO1, while circulating levels of TxA2, PGF2α and 5-HT are increased. Abbre-
viations: 5-HT = 5-hydroxytryptamine; 5-HT2R = 5-HT type 2 receptor; IDO = indolamine 2,3-dioxygenase; 
IFN-γ = interferon-γ; PGF2α = prostaglandin F2α; PGF2R = PGF2 receptor; TNF-α = tumor necrosis factor-α; 
TPH1 = tryptophan hydroxylase-1; Trp = tryptophan; TxA2 = thromboxane A2; TxA2R = TxA2 receptor.
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ketanserin, 73.3% experienced persistent hypertension, which was treated successfully 
with the rescue medication nicardipine.293 Besides the disappointing effects on blood 
pressure reduction, the use of ketanserin could also not aid in the prevention of further 
complications or pregnancy prolongation.293
In conclusion, whereas 5-HT induced vasoconstriction is equal or potentially even 
increased in the microvasculature of PE placentas, larger vessels seem to be less sensi-
tive to 5-HT compared to those in healthy pregnancy. This difference between the larger 
and smaller vessels might be due to the presence or absence of different 5-HT receptors, 
that can have opposing effects. Nonetheless, the combined increased plasma levels and 
increased microvascular sensitivity to 5-HT can have a detrimental effect on vascular 
resistance in vivo and thus complicate placental blood flow and cause progressive wors-
ening of PE.
Tryptophan
Trp conversion occurs for 95% via the kynurenine pathway into kynurenine and other 
metabolites (Figure 5). These metabolites have functions in inflammation and regulation 
of vascular tone.295 The first and rate-limiting step of the pathway is the conversion of 
Trp to N-formylkynurenine, by either TDO, IDO1, or IDO2. While TDO is mainly expressed 
in the liver, IDO1 is highly expressed in the placenta during pregnancy. Its expression 
increases with the duration of pregnancy, and in closer proximity of the fetal-maternal 
interface.296 Despite several conflicting reports, cell types in which IDO1 seems to be 
present include trophoblasts and decidual immune- and stromal cells.297 In placental 
tissue, the microvascular endothelial cells together with the ends of maternal spiral 
arteries are the main locations of IDO1 expression.298, 299 The high IDO1 expression is 
generally believed to be essential for maintenance of fetal-maternal tolerance.297, 300 
However, studies in animals have shown that Trp metabolism via IDO1 might be involved 
in regulation of vascular tone as well.301 Knowledge on the effects of Trp in the human 
placental vasculature is very limited. A recent study showed that Trp can induce vascular 
relaxation in isolated vessel segments of the chorionic plate arteries. IDO1 seems to play 
a critical role in this process, since its inhibition attenuates the vascular relaxation in the 
presence of Trp. However, for isolated chorionic plate arteries to relax in response to Trp, 
it was necessary to stimulate them overnight with TNF-ɑ and interferon (IFN)-γ,302 which 
might be due to the fact that chorionic plate arteries do not express IDO1 under nor-
mal circumstances298 and therefore, it needs to be upregulated by these inflammatory 
cytokines first before an effect can be seen. The ex vivo perfused cotyledon responded 
to Trp with a decrease in fetal perfusion pressure, even without pre-constriction of the 
placental vasculature,302 suggesting that IDO1 metabolites contribute to regulation of 
placental microvascular resistance vessels. Since microvascular endothelial cells of the 
placenta were reported to express IDO1 under normal physiological conditions, it is 
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likely that these cells contribute to the vascular relaxation in response to Trp.298 IDO1 is 
also present in vascular endothelial cells of the decidua basalis,298 and thus it could be 
speculated that endothelial IDO1 has a vasodilatory effect in the maternal decidua. Trp 
is an endothelium dependent vasodilator, and the metabolite kynurenine is proposed 
to contribute to this vasodilator response (Figure 5).301, 303 However, there might also 
be other metabolites with vasodilator effects besides kynurenine. Although these exact 
metabolites and mechanisms that contribute to vasodilation remain to be identified, the 
metabolism of Trp by IDO1 plays an important role in the regulation of vascular tone in 
placental microvasculature.
Altered Trp metabolism through the IDO1 pathway may be involved in the develop-
ment and/or progression of PE and FGR. In these conditions, expression and activity of 
IDO1 is reduced.299, 302, 304, 305 Yet, after overnight stimulation of chorionic arteries of PE 
and FGR placentas with TNF-α and IFN-γ, Trp still induced vascular relaxation.302 How-
ever, these results should be interpreted with caution, since experiment numbers were 
very low and the added doses of Trp substantially exceeded physiological levels. Ex vivo 
perfusion experiments measuring the response of PE placentas to Trp in the presence 
and absence of IDO1 inhibitors are required to establish whether indeed IDO1 plays a 
critical role in PE.
If reduced Trp metabolism due to low IDO1 expression is causal for increasing pla-
cental vascular resistance, finding ways to increase Trp metabolism by IDO1 could be a 
potential target for treatment of the reduced placental blood flow in PE and FGR. How-
ever, it should be noted that, in contrast to PE, which is associated with reduced IDO1 
activity, many other diseases are associated with increased Trp metabolism, and IDO1 
inhibitors are now being tested in clinical trials as anticancer therapy. Extreme caution is 
warranted for use of these inhibitors during pregnancy and in women at child bearing 
age, as they might have detrimental effects on pregnancy progression.
Altogether, the metabolism of Trp by IDO1 seems to be crucial for a healthy pregnancy 
progression. The reported functions of Trp metabolism in regulation of vascular tone, 
together with the fact that IDO1 is mainly expressed in microvascular endothelial cells, 
imply a role for IDO1 in regulation of vascular tone in the placenta. Finally, given the 
fact that 95% of Trp is metabolized through the kynurenine pathway, it is possible that 
even a small reduction of IDO1 in PE may substantially increase the amount of Trp that is 





CGRP is a neuropeptide, widely distributed in the central and peripheral nervous system, 
that has a potent vasodilator effect on vascular tone. CGRP acts through binding of the G 
protein-coupled calcitonin receptor-like receptor (CRLR), in the presence of the receptor 
activity modifying protein-1 (RAMP1).306
In the human placenta, both CRLR and RAMP1 are abundantly expressed in the vas-
cular endothelium and underlying smooth muscle cells of the umbilical, chorionic and 
stem villous vessels, as well as in the villous trophoblast.307 Stevenson et al. showed a 
significant increase in maternal plasma CGRP levels throughout normal pregnancy, with 
a rapid drop after delivery, indicating the placenta as a source of CGRP production.308 
Furthermore, it has been shown that there is a weight- and gestational age-dependent 
increase in neonatal plasma CGRP levels.309 This suggests a role for CGRP in vascular 
adaptation in pregnancy and fetal growth and development. It has also been suggested 
that CGRP is involved in maintaining uterine relaxation during pregnancy.310 Isolated 
chorionic plate arteries show a dose-dependent relaxation response to CGRP, an effect 
that is attenuated in the presence of a CGRP receptor antagonist, further indicating that 
CGRP plays a role in the control of fetoplacental vascular tone.307, 311 In placental arteries 
of pregnancies complicated by PE or FGR the vasodilator effect of CGRP is significantly 
reduced.311-313 In line with this finding, Dong et al. showed that mRNA expression of CRLR 
and RAMP1 in placental vessels of PE pregnancies is reduced, which was accompanied 
by a decrease in CRLR and RAMP1 protein expression and CGRP binding sites in vascular 
and trophoblast tissue of PE placentas.313 Furthermore, maternal serum levels of CGRP 
are significantly lower in women with PE compared to uncomplicated pregnancies.314 
This evidence supports a potential role of compromised CGRP-mediated vasodilation in 
the pathogenesis of PE. In animal models of PE, administration of CGRP reduced mater-
nal hypertension and pup mortality in rats.315 In agreement with this finding, infusion 
of a CGRP receptor antagonist induced maternal hypertension and caused a significant 
decrease in pup weight.316
Unfortunately, knowledge on the underlying mechanisms of CGRP on fetoplacental 
development is still lacking and direct targeting of the CGRP-pathway remains com-
plicated. CGRP itself can only be administered parenterally, has a very short half-life 
and is costly. Rutaecarpine, a traditional Chinese drug that potentiates the release of 
endogenous CGRP, could be a therapeutic option. However, its effect in pregnancy 
is unknown.317 Also, an αCGRP analogue with a longer half-life has been described in 
murine studies, investigating its application in cardiovascular disease, where it showed 
antihypertensive effects.318
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coNclusioN AND PeRsPecTiVes
Since the blood vessels of the fetoplacental vasculature lack autonomous innervation, 
circulating and locally produced hormones are essential in regulating vascular tone. As 
has been shown in this review, mechanisms behind this regulation are very intricate, as 
they involve many pathways, and are influenced by numerous factors. Adequate devel-
opment of the placenta is essential for an optimal course of pregnancy and subsequent 
maternal, fetal and neonatal outcome. The pathophysiology of placental diseases such 
as PE seems multi-factorial and complex, including a cascade of dysregulated systems. 
Finding new treatment options that safely prolong pregnancy is essential for reducing 
the risk of fetal, neonatal and maternal complications. This review has highlighted the 
importance of focusing on restoring the dysfunctional vascular regulatory systems 
when studying treatment strategies for PE. Techniques using human tissue, such as the 
ex vivo placental perfusion model and wire-myography, are indispensable in unravel-
ing the vasoactive profile of the human placenta, to help understand the pathological 
changes occurring during PE.
Future research should focus on both efficacy and safety, by performing well designed 
dose-finding studies before starting clinical trials. Targeting the ET-axis by blocking the 
ET-1 mediated effects or restoring the sFlt-1/PlGF imbalance currently seems to have the 
greatest therapeutic potential. Here a first step might be to determine trans-placental 
passage of ERAs and to quantify their effects on sFlt-1 release in the ex vivo perfusion 
model. Another promising treatment option would be increasing NO-mediated vaso-
dilation through sGC stimulators or activators. Although such drugs showed beneficial 
effects on placental tissue, results of clinical trials are still not available. When consider-
ing new drugs for treatment, the first step should be to determine their trans-placental 
transfer and effect on the fetal vasculature, for which the ex vivo placental perfusion 
model is a very reliable method. Parallel studies with isolated arteries may help to 
obtain a more detailed mechanistic insight. With this, differences in pathophysiology 
between early- and late onset PE and the changes in pharmacokinetics that occur dur-
ing pregnancy should be kept in mind. Furthermore, individual differences in pathway 
disturbance may call for a more personalized therapeutic approach.
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AbsTRAcT
Background: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a 
promising treatment for preeclampsia (PE). However, a sildenafil trial was recently halted 
due to lack of effect and increased neonatal morbidity.
Methods: Ex vivo dual-sided perfusion of an isolated cotyledon and wire-myography on 
chorionic plate arteries were performed to study the effects of sildenafil and the non-
selective PDE inhibitor vinpocetine on the response to the NO donor sodium nitroprus-
side (SNP) under healthy and PE conditions. Ex vivo perfusion was also used to study 
placental transfer of sildenafil in 6 healthy and 2 PE placentas. Furthermore, placental 
mRNA and protein levels of eNOS, iNOS, PDE5 and PDE1 were quantified.
Findings: Sildenafil and vinpocetine significantly enhanced SNP responses in chorionic 
plate arteries of healthy, but not PE placentas. Only sildenafil acutely decreased baseline 
tension in arteries of both healthy and PE placentas. At steady state, the foetal-to-mater-
nal transfer ratio of sildenafil was 0.37±0.03 in healthy placentas versus 0.66 and 0.47 in 
the 2 PE placentas. mRNA and protein levels of PDE5, eNOS and iNOS were comparable 
in both groups, while PDE1 levels were lower in PE.
Interpretation: The absence of sildenafil-induced NO potentiation in arteries of PE pla-
centas, combined with the non-PDE-mediated effects of sildenafil and the lack of PDE5 
upregulation in PE, argue against sildenafil as the preferred drug of use in PE. Moreover, 





Suboptimal development of the placenta results in serious pregnancy complications 
such as preeclampsia (PE) and foetal growth restriction (FGR), that contribute signifi-
cantly to perinatal and maternal morbidity and mortality.1,2 Besides increasing the risk of 
adverse events during pregnancy, placenta-related diseases have lifelong consequences 
for the health of both mother and child. For example, PE increases the maternal risk of 
developing cardiovascular disease3,4 and can cause persistent vascular dysfunction in 
the systemic and pulmonary circulation of the offspring,5 whereas preterm birth and 
low birthweight greatly increase the risk of cardiopulmonary morbidity and neurode-
velopmental impairment later in life.6,7 Currently, PE treatment is aimed at symptom 
relief and prevention of further complications in an attempt to prolong pregnancy until 
term. Many antihypertensive agents have been studied over the years, but they at most 
temporarily stabilise the clinical manifestations of PE, without directly targeting placen-
tal hypoperfusion.8,9 The only cure is termination of pregnancy to deliver the placenta, 
which often leads to preterm birth of the foetus. Therefore, developing new treatment 
options to treat PE and safely prolong pregnancy is of great importance.
Although the aetiology of PE remains largely unknown, it finds its origin in early 
pregnancy with suboptimal placentation, characterised by increased placental vascular 
resistance and hypoperfusion, leading to systemic endothelial dysfunction.10-12 One 
of the key features of this endothelial dysfunction is a decreased activity of the nitric 
oxide (NO) pathway.13-15 NO acts as an important vasodilator, synthesised by a family 
of nitric oxide synthases (NOS), predominantly endothelial NOS (eNOS) and inducible 
NOS (iNOS). NOS enzymes are present in various cell types including endothelial cells 
and foetal trophoblasts, and stimulation of these enzymes (e.g., by endothelial shear 
stress or oestrogen) results in the production of NO through catalysis of L-arginine. By 
activating soluble guanylate cyclase (sGC), NO induces an increase in production of 
cyclic guanosine 3’,5’-monophosphate (cGMP), leading to vasodilation through closure 
of Ca2+ channels.13,14
Besides regulation of vascular tone, NO also plays an important role in cytotrophoblast 
invasion of the receptive endometrium and subsequent spiral artery remodelling dur-
ing early pregnancy.16 Throughout normal pregnancy there is an increase in maternal 
plasma levels of NO,17 as well as NO-stimulating factors such as vascular endothelial 
growth factor and placental growth factor.18,19 However, in women with PE these plasma 
levels are significantly lower.17,20,21 Sildenafil, as a phosphodiesterase-5 (PDE5) inhibitor, 
enhances vasodilation mediated by the NO pathway, by inhibiting degradation of ac-
tive cGMP into inactive GMP by PDE5. Sildenafil is currently approved for the treatment 
of erectile dysfunction and pulmonary hypertension.22 In PE animal models, sildenafil 
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improved foetal outcome and diminished maternal symptoms by increasing blood flow 
to the uterus.23,24
Because of its potential to improve placental hypoperfusion by increasing systemic 
vasodilation, sildenafil has been considered for the treatment of PE and FGR over the 
last years. However, an international consortium of large multi-centre randomised 
controlled trials (the STRIDER study), investigating the effect of sildenafil compared 
to placebo on pregnancy outcome in extreme FGR due to placental insufficiency,25,26 
was recently halted due to lack of beneficial effects in the first two cohorts27,28 and an 
increase in neonatal morbidity and mortality in the treatment group of one cohort.28,29 
These results emphasise the importance of taking into account the possible effects that 
maternal medication use can have on the foetus. When considering drugs for treatment 
in human pregnancy, it is essential to know the trans-placental transfer and effects on 
the placental vasculature. Hence, besides transfer, study of the placenta can give insight 
into vascular effects of sildenafil in the foetus. Dual ex vivo perfusion of a single placental 
cotyledon is the only reliable experimental method to study drug transfer across the 
human placental barrier to date.30 With this model Russo et al. recently showed that 
sildenafil crosses the placenta of healthy term pregnancies,31 however to our knowledge 
this has never been performed in PE placentas. The aim of our study is to evaluate the 
effects of sildenafil on NO-mediated vasodilation in the foetoplacental vasculature, to 
evaluate placental transfer in healthy and PE placentas, and to study placental expres-
sion levels of components of the NO pathway under healthy and PE conditions. This 
could help to provide a possible explanation for the negative findings obtained with 
sildenafil in the above-mentioned clinical trials. Understanding these negative findings 
will be helpful for the development of future therapies.
meThoDs
Patients and setting
The study received exemption for approval from the local institutional Medical Ethics 
Committee according to the Dutch medical Research with Human Subjects Law (MEC-
2016-418 and MEC-2017-418), and all patients gave written consent prior to donating 
their placenta. Randomly selected placentas of uncomplicated singleton pregnancies 
and of patients with early onset PE (diagnosis before 34+0 weeks of gestation) were 
collected immediately after delivery at Erasmus University Medical Center, Rotterdam, 
The Netherlands. Because it is generally believed that late onset PE (from 34+0 weeks of 
gestation onwards) has a different pathophysiological mechanism than early onset PE, 
being more a maternal rather than a placental syndrome,32 and also showing clear his-
topathological differences in the placenta,33 late onset PE was excluded from the current 
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study. Further exclusion criteria were retained placenta, viral infections (HIV, hepatitis B, 
Zika), the presence of foetal congenital abnormalities on ultrasound, participation in the 
STRIDER study and for the healthy controls any form of diabetes. Baseline characteristics 
such as maternal age, medical history, obstetrical history, use of medication, blood pres-
sure, mode of delivery, gestational age at delivery, foetal sex, foetal weight, placental 
weight and pregnancy complications were obtained from the digital medical files.
wire-myography experiments
Second order branches of chorionic plate arteries were identified, carefully dissected 
and stored overnight in cold, oxygenated Krebs-Henseleit buffer. The next morning 
the vessels were cut into segments of 2 mm and mounted in 6-mL organ baths (Dan-
ish Myograph Technology, Aarhus, Denmark), filled with Krebs-Henseleit buffer at 37°C 
and gassed with 95% O2 – 5% CO2. Tension was normalised to 90% of the estimated 
diameter at 100 mmHg effective transmural pressure. Maximum contractile responses 
were determined using 100 mmol/L potassium chloride (KCl). After washout of the KCl, 
precontraction was elicited using the thromboxane A2 agonist U46619 (10 nmol/L) 
resulting in 75-100% of the contraction induced by 100 mmol/L KCl. Subsequently, a 
concentration-response curve (CRC) was constructed for SNP (0·001 – 100 μmol/L). To 
study the effect of PDE inhibition on NO-mediated vasodilation, vessel segments were 
either pre-incubated for 30 minutes with sildenafil (1 μmol/L), the non-selective PDE 
inhibitor vinpocetine (10 μmol/L) or without additives as control.
Placental perfusion setup
The perfusion model used in our study has been adapted from the model previously 
described by Schalkwijk et al.34 It exists of a perfusion chamber, two peristaltic roller 
pumps, heating devices and a water bath (37°C). The maternal and foetal perfusion me-
dia consisted of Krebs-Henseleit buffer (in mmol/L: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 
1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3), supplemented with heparin 5000 IU (0.5 
mL/L) and aerated with 95% O2 - 5% CO2. After selecting an intact cotyledon, the foetal 
circulation was established by cannulating the chorionic artery and corresponding 
vein. Flow rate was carefully increased to 3 or 6 mL/min, depending on the experiment. 
When this was successful, the cotyledon was cut from the placenta and placed inside the 
perfusion chamber. Maternal circulation (flow rate 12 mL/min) was created by placing 
four blunt cannulas in the intervillous space through remnants of the spiral arterioles. 
Venous outflow was collected in a reservoir underneath the cotyledon and run back 
to the maternal reservoir. A placental washout period of approximately 45 minutes 
was performed before starting an experiment. Changes in pressure were continuously 
measured by pressure transducers and recorded throughout the experiment using ac-
quisition software (Biopac, Goleta, CA, USA).
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Placental vasoreactivity
To study the effect of sildenafil on the foetal vascular bed of the placenta, NO-mediated 
vasodilation was tested in the absence or presence of sildenafil. When a stable baseline 
pressure had been reached after the washout period, sildenafil (500 ng/mL) was added 
to the foetal medium in half of the placentas that were randomly selected. After approxi-
mately 15 minutes 1 mmol/L serotonin (5-HT) was administered to the foetal circulation 
to preconstrict the vasculature. Subsequently, the NO donor sodium nitroprusside (SNP) 
was used to induce vasodilation (1 mmol/L). Changes in placental vascular resistance 
were used to assess the magnitude of the vasodilator response.
Placental transfer of sildenafil
To study placental transfer, sildenafil was administered to the maternal circulation at 
start of the experiment in a concentration of 500 ng/mL, the maximal tolerated concen-
tration in humans.35 System adherence of sildenafil was tested by adding the drug to the 
perfusion system in the absence of a placenta. At t=0, antipyrine (100 mg/L) was added 
to the maternal buffer as a positive control of passive diffusion across the placental 
barrier and to prove adequate overlap between maternal and foetal circulations, and 
the macromolecule FITC-dextran (40 kDa, 36 mg/L) was added to the foetal buffer as a 
marker of integrity of the capillary bed. Samples of the maternal and foetal buffer were 
taken at seven set time points, and immediately stored at -80 °C.
Quality control
The placenta was excluded from further analysis when fluid leakage from the foetal 
circulation exceeded 3 mL/h, the foetal-to-maternal (F/M) ratio of antipyrine was <0.75 
at t=180, or the maternal-to-foetal (M/F) ratio of FITC-dextran was >0.03 at t=180.36
Analysis of antipyrine and fiTc-dextran
Antipyrine concentration was analysed by first deproteinising the samples with per-
chloric acid 6%. After this, a mixture of 0·2 mg/mL NaNO2 and 0.6% H2SO4 was added 
in a 1:1 ratio to form nitroantipyrine. Using ultraviolet–visible spectroscopy (Shimadzu 
UV-1800), absorption at 350 nm was measured. For analysis of FITC-dextran, fluores-
cence was measured using a Multiwell Plate Reader (Victor X4 Perkin Elmer, excitation/
emission 485/519 respectively).
lc-ms analysis of sildenafil
The concentration of sildenafil in placental perfusate was measured with a FDA validated 
liquid chromatography-mass spectrometry method (LC-MS), using Thermo TQS Vantage 
LC-MS/MS for the analysis. Column 2.1x100 mm Waters Acquity CSH C18 1.7 µm. The 
mobile phase A consisted of 2 mM ammonium acetate in 0.1% formic acid in water. 
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The mobile phase B consisted of 2 mM ammonium acetate in 0.1% formic acid in LC-MS 
methanol. Flow rate was 0.5 mL/min. The mobile phase composition changed linearly 
during analysis in a percentage mobile phase A (from 80% to 0) and B (from 2% to 100%). 
Total analysis time was four minutes. The injected volume was 10 µl. Internal standard 
was vardenafil. The method was validated according to FDA guidelines between 2-1000 
µg/L for sildenafil and 2-500 µg/L for desmethylsildenafil.37
qPcR
Within 20 min after delivery of the placenta pieces of tissue were dissected from both 
the foetal and maternal side of the placenta and snap frozen in liquid nitrogen. For RNA 
extraction, small pieces of tissue were homogenised in RLT lysis buffer (Qiagen, Venlo, 
The Netherlands) with β-mercaptoethanol. After proteinase K treatment (Invitrogen, 
Breda, The Netherlands) for ten minutes at 55 °C, total RNA was extracted using the 
RNeasy Fibrous Tissue Mini Kit (Qiagen). RNA was eluted in RNase free water, and con-
centration and purity were assessed on a NanoDrop1000 Spectrophotometer (Thermo 
Fisher Scientific, Bleiswijk, The Netherlands). Complimentary DNA (cDNA) was synthe-
sised from 0.5 µg RNA template with the SensiFast cDNA Synthesis Kit (Bioline, London, 
UK) according to the manufacturer’s instructions. This cDNA was used for quantitative 
PCR (qPCR) using the SYBR Green qPCR Kit (Bioline, London, UK) and specific primer 
pairs on a CFX-96 light cycler (Bio-Rad, Hercules, CA, USA). qPCR was performed with 
the following conditions: initial denaturation at 95 °C for eight min and 30 s, followed 
by 40 cycles comprising 15 s at 95 °C, and 60 s at 60 °C. Target genes were normalised 
against the reference genes β-actin and Peptidylprolyl Isomerase A (PPIA) and relative 
gene expression was calculated by the ΔΔCt method. A melt curve was run for each 
gene to confirm amplification of a single PCR product. The specific primer pairs are listed 
in Table S1.
western blot analysis
Snap frozen pieces of placental tissue were homogenised in RIPA buffer (150 mM NaCl, 
1% Triton X-100, 0.5% Sodium Deoxycolate, 0.1% SDS, 50 mM Tris PH 8.0) with protease 
and phosphatase inhibitors. After incubation on ice for 20 min, samples were centrifuged 
at 4 °C, 13000 rpm for three min. Supernatant was collected of each sample, and total 
protein concentration was determined with the Pierce® BCA Protein Assay Kit (Thermo 
Fisher Scientific). Per sample 50 μg of total protein was loaded onto a 4-15% mini-protean 
TGX gel (Bio-Rad). Samples were resolved at 80 V for 20 min followed by 110 V for 60 min 
(PDE5a) or 120 min (eNOS). Transfer of proteins to the membrane was done on ice for 
one h at 110 V. Subsequently, after blocking in TBS + 5% BSA for one h, the membranes 
were incubated with anti-PDE5A 1:1000 (Abcam Cat# ab64179, RRID:AB_1566572, 1 
mg/ml), anti-eNOS 1:500 (BD Biosciences Cat# 610296, RRID:AB_397690, 250 µg/ml), 
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or anti-iNOS 1:1000 (Abcam Cat# ab182640, 1 mg/ml), and anti-β-actin 1:1000 (Abcam 
Cat# ab8229, RRID:AB_306374) for 1.5 h at room temperature. Hereafter, the membranes 
were incubated with 1:15000 diluted fluorescently-labelled secondary antibody for one 
h. Bands were visualized by the Odyssey® Infrared Imaging System, and analysed in Im-
age Studio Lite (LI-COR Biosciences). The density of each band was normalised to β-actin 
and displayed as arbitrary unit (AU) value.
statistical analysis
A power analysis was performed based on our previous experience with wire-myography 
experiments.38 Based on the same standard deviation, at an α level of 0.05 and with 
statistical power at 80%, a derived minimum sample size of 6 per group was determined. 
Because of skewed distributions, non-parametric tests were applied. Statistical analysis 
was performed with SPSS (version 21, SPSS Chicago, IL, USA) and GraphPad Prism (ver-
sion 5, 2007, La Jolla, CA, USA) on Windows. Statistical analysis between groups was 
performed using either a Mann-Whitney U test or Wilcoxon matched pairs test for two 
groups, and a Kruskal-Wallis test or a Friedman test for repeated measures with a Dunn’s 
post-hoc test for three groups where appropriate. Log10-transformed SNP values at 
which the half-maximal response occurred (pEC50) were individually estimated with 
sigmoid curve fitting software (GraphPad Prism 5). Data are displayed as median (inter-
quartile range) or mean±SEM unless stated otherwise. A p-value <0·05 was considered 
to be statistically significant.
ResulTs
wire-myography experiments
Chorionic plate arteries of 12 healthy and six PE placentas were dissected and mounted 
into Mulvany wire-myographs. Clinical characteristics can be found in Table S2. For ana-
lysing the CRC of SNP, five healthy and one PE placentas were excluded because of severe 
spontaneous vasomotion, making it impossible to analyse SNP effects. Sildenafil acutely 
decreased baseline tension vs. control in vessel segments of both healthy (p=0.01) and 
PE placentas (p=0.05) during the incubation period (Figure 1a). Such effects were not 
seen for vinpocetine. SNP fully relaxed U46619-preconstricted vessels in all conditions, 
and both sildenafil and vinpocetine enhanced (p=0.02) the SNP response in healthy ves-
sel segments (Figures 1b and 1c and Table 1). No such potentiation was seen in vessel 




















































































figure 1. Wire-myography experiments. Panel a, decrease of baseline tension in response to PDE inhibi-
tors. Panels b and c, effect of PDE inhibition with sildenafil or vinpocetine on SNP-mediated relaxation of 
chorionic plate vessels of seven healthy (b) and five PE (c) placentas. Data (mean±SEM) are expressed as % 
of U46619 precontraction. *p<0.05; **p<0.01 (Friedman test for repeated measures).
Table 1. Effects of sildenafil and vinpocetine on isolated chorionic plate arteries obtained from healthy and 
early onset preeclamptic (PE) placentas.
pec50 emax
control sildenafil vinpocetine control sildenafil vinpocetine
Healthy 7.5 (7.9-7.3) 8.0 (8.3-7.6)* 8.0 (8.3-7.6)* 92 (86-110) 98 (87-112) 102 (97-111)
PE 7.6 (8.0-7.2) 7.6 (7.8-7.1) 7.5 (8.1-7.3) 85 (65-90) 97 (56-104) 90 (82-121)
Data are median (interquartile range). pEC50: -log10-transformed SNP concentrations at which the half-
maximal response occurred. Emax: maximal effect of SNP (% of U46619 precontraction). *p<0.05 vs. control 
(Friedman test for repeated measures).
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Placental vasoreactivity
A total of 26 (18 healthy and eight PE) placentas were included in the analysis. Clinical 
characteristics of these placentas can be found in Table S3. As expected, the gestational 
age and birth - and placental weight were lower in PE placentas, and they were associ-
ated with a higher maternal blood pressure. Baseline pressure at the start of the ex-
periment was significantly lower in placentas from PE pregnancies compared to healthy 
placentas (p=0.03) (Table 2). Moreover, the 5-HT-induced pressure increase was lower 
in the PE group (p=0.07). SNP reversed the 5-HT-induced pressure increases, although 
significantly less in PE placentas (p=0.02) compared to controls. Under no condition did 
sildenafil significantly improve the SNP response (Table 2).
Placental transfer of sildenafil
Of the received placentas, a total of six out of 12 healthy and two out of 11 PE placentas 
met the quality control criteria, and were included in the analysis. For healthy term 
placentas the success rate of ~50% is higher than the average reported in literature.36 To 
our knowledge there are no previous reports on success rate of perfusion experiments 
in preterm PE placentas.
Table 2. Placental vasoreactivity in healthy pregnancy and early onset preeclampsia (PE).
Parameter healthy (n=18) Pe (n=8)
Baseline pressure (mm Hg) 34 (28-36) 23 (17-31)*
5-HT-induced pressure increase (mm Hg) 60 (47-91) 47 (34-55)
control (n=9) sildenafil (n=9) control (n=4) sildenafil (n=4)
Response to SNP (% 5-HT precontraction) 105 (97-112) 110 (103-120) 74 (55-96)* 85 (62-114)
Data are median (interquartile range). *p<0.05 compared to healthy (Mann-Whitney U test).
All included placentas showed good overlap of the maternal and foetal circulations 
with a F/M ratio for antipyrine of >0.75 (Figure S1). Table 3 shows the clinical charac-
teristics of the included placentas. All women underwent elective caesarean section, 
because of previous caesarean section (four), previous shoulder dystocia (one) and 
intracranial hematoma that contra-indicated vaginal delivery (one). Both PE patients un-
derwent caesarean section because of maternal illness and foetal distress. As expected, 
the placentas from PE pregnancies were born at an earlier gestational age (~32 weeks) 
and associated with a higher maternal blood pressure and a lower birth - and placental 
weight. The six healthy placentas were perfused at a foetal flow rate of 3 or 6 mL/min 
(n=3 for each). Since there were no significant differences in transfer ratios of antipyrine 
and sildenafil between the two flow rates (Figure S2), the results have been combined.
Figure 2a shows the placental transfer of sildenafil in healthy placentas. The transfer 
rate of sildenafil was highest in the first hour, and after ~90 min an equilibrium between 
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1 2 3 4 5 6 1 2
Maternal age (y) 36 31 24 36 38 39 30 26
Parity 1 1 1 1 3 1 0 0
Caucasian ethnicity yes no yes no no yes no yes
Body mass index (kg/m2) 24.6 27.3 27.8 20.8 29 24.7 28.5 23.1
Smoking no no no no no no no no
Highest DBP (mm Hg) 75 86 80 80 75 80 120 109
Gestational age (weeks) 39.0 38.0 38.5 38.6 39.1 39.0 32.0 31.4
Mode of delivery CS CS CS CS CS CS CS CS
Foetal Sex M M M M F F M M
Birth weight (g) 4325 3475 3420 4010 3815 2940 1150 1460
Birth weight (centile) 96 76 55 89 83 16 0 6
Placental weight (g) 784 550 581 659 825 618 348 339
DBP = diastolic blood pressure; CS = caesarean section; M = male; F = female.
















































figure 2. Placental transfer of sildenafil in healthy 
and PE placentas. Panels a and b, concentration 
of sildenafil in the maternal (closed symbols) and 
the foetal circulation (open symbols) in six healthy 
(a) and two PE (b) placentas. Data are mean±SEM. 
Panel c, F/M ratio of sildenafil in individual healthy 
(grey circles) and PE placentas (black squares).
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the maternal and foetal circulations had been reached. After 180 min of perfusion the 
F/M ratio of sildenafil was 0.37±0.03. In the two PE placentas the placental transfer of 
sildenafil followed a similar pattern (Figure 2b), and the F/M ratios in these two placen-
tas were the highest of all placentas studied (0.66 and 0.47, Figure 2c). At the end of the 
experiment, under steady state conditions, in healthy placentas 43±3% and 16±1% of 
the total amount of added sildenafil were recovered in the maternal and foetal compart-
ments, respectively, while in PE conditions these percentages amounted to 36±8% and 
20±1%. This implies that, under healthy conditions, after three hours of perfusion 59% 
of the total starting amount of sildenafil could be retrieved in the perfusion buffers. 
After running the system without a placenta, a comparable 52% (mean of two measure-
ments) was retrieved at the end of the experiments, indicating that the loss of sildenafil 
is largely caused by tube adherence.
mRNA and protein expression
Snap frozen samples of 12 healthy and seven PE placentas were used to determine mRNA 











































































figure 3. mRNA expression. qPCR analysis of placental biopsies from the maternal (black bars) and foetal 
side (white bars) of 12 healthy and seven PE placentas. Data (mean±SEM) are expressed as fold change 
versus the maternal side biopsies of healthy controls. Panels a-d represent data for eNOS, iNOS, PDE5A and 
PDE1A. *p<0.05; **p<0.01 (Mann-Whitney U test or Wilcoxon matched pairs test).
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acteristics can be found in Table S4. Of all measured PDEs, PDE5A displayed the highest 
expression (Figure S3). For PDE5A and eNOS, expression on the maternal side was higher 
than on the foetal side in healthy and PE placentas (Figure 3). PDE1A expression was 
higher on the foetal side than maternal side in both conditions, although significance 
was reached in healthy placentas only (Figure 3). For iNOS, expression on the foetal side 
was higher than on the maternal side in PE placentas only (Figure 3). However, it should 
be noted that iNOS expression was extremely low and highly variable, and was also 
not detectable at protein level. No statistically significant differences between patient 
groups were observed, with the exception of PDE1A, which was lower on the foetal side 
of PE vs. healthy placentas. In agreement with the gene expression data, protein expres-
sion of PDE5A and eNOS did not differ between patient groups (Figure S4 and S5).
DiscussioN
This study shows that sildenafil decreased baseline pressure in isolated chorionic plate 
arteries from both healthy and PE placentas. Yet, it enhanced the relaxant effects of the 
NO donor SNP only in chorionic plate vessels obtained from healthy placentas, and not 
in vessels from PE placentas, nor when applied at the foetal side in the cotyledon setup. 
A similar enhancement was observed for the non-selective PDE inhibitor vinpocetine 
in chorionic plate vessels obtained from healthy placentas, although this drug did not 
decrease baseline pressure. Placental transfer of sildenafil was highest in the two PE 
placentas. Finally, while PDE5 expression was higher at the maternal side of the placenta 
versus the foetal side, its expression was not changed in PE, nor was the expression of 
other PDEs.
Sildenafil has been proposed to enhance NO availability in FGR and PE, and may thus 
improve endothelial function and placental perfusion.39 Exactly this effect was observed 
when studying NO-induced responses in isolated chorionic plate arteries obtained from 
healthy placentas: sildenafil facilitated the response to SNP. The fact that this was not 
observed when adding SNP on top of sildenafil to the foetal circulation of the intact 
cotyledon setup implies that this effect is limited to a selected subset of placental ves-
sels. Also, it might well be that other pathways than NO are important in regulation of 
vascular tone in the whole cotyledon setup.15 The non-selective PDE inhibitor vinpo-
cetine similarly potentiated SNP-induced vasorelaxation in healthy isolated chorionic 
plate arteries. Yet, no such potentiating effects were observed with either sildenafil or 
vinpocetine in isolated chorionic plate arteries from PE placentas, suggesting that the 
potential beneficial effects of PDE inhibition are absent in this condition. In contrast, 
in ageing vessels, with upregulated PDE levels, sildenafil and vinpocetine did enhance 
SNP responses,40 thereby reversing the disturbed endothelial function in this condition. 
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In agreement with the lack of effect of sildenafil in PE arteries, we did not detect PDE 
upregulation, maternally or foetally, at the mRNA or protein level in PE placentas. These 
data indicate that PDE upregulation is unlikely to underlie the disturbed endothelial 
function that has been reported in PE. We could even argue that the lost potentiating ef-
fect of sildenafil in PE suggests a reduced significance of the NO pathway in vasodilation 
in these arteries. We stress that in the present study we specifically evaluated NO respon-
siveness, based on the assumption that the beneficial effect of sildenafil would relate to 
its capacity to block PDE5 and hence should be seen in the form of NO potentiation. We 
did not quantify endothelial dysfunction – this would have required the application of 
an endothelium-dependent vasodilator. Furthermore, we studied foetoplacental vessels 
rather than spiral arteries, although it is the latter that determine placental perfusion. 
Unfortunately, acquiring spiral arteries would have required a myometrial biopsy, which 
was not possible in our hospital. However, even though the development of placental 
insufficiency starts with aberrant remodelling of the maternal spiral arteries,10,11 subse-
quent changes in the foetoplacental vasculature have been described,41,42 emphasising 
the relevance to study these vessels. Needless to say, it cannot be said with certainty 
that the current findings also apply to the maternal spiral arteries.
Sildenafil decreased baseline pressure in isolated chorionic plate arteries, both from 
healthy and PE placentas. This resembles the vasodilator effect of sildenafil reported by 
Walton et al. in the preconstricted cotyledon setup.43 Such a decrease was not observed 
for the non-selective PDE inhibitor vinpocetine, nor for the highly selective PDE5 in-
hibitor tadalafil (by Walton et al.43), despite its much greater potency versus sildenafil. 
Yet, sildenafil and vinpocetine identically potentiated SNP in healthy chorionic plate 
arteries. Taken together, these data strongly suggest that the acute sildenafil-induced 
foetal dilation is unrelated to PDE5 inhibition. It may rather represent a non-specific 
effect of sildenafil. To what degree this still represents interference with PDEs other 
than PDE5A remains to be investigated. Our data support the presence of PDE5A as the 
most abundant PDE in placental tissue, and additionally show expression of PDE10A, 
PDE4A and PDE1A at lower levels. Only foetal PDE1A was altered in PE placentas, being 
actually lower, i.e., opposing the concept of upregulated PDEs in PE. Importantly, our 
data do support PE-related vascular changes, since baseline pressure was lower in PE 
cotyledons, and 5-HT-induced constriction was reduced.
Ex vivo cotyledon perfusion is a safe method to predict placental transfer of drugs in 
vivo, avoiding foetal exposure.30 In healthy human placentas, Russo et al. demonstrated 
earlier that sildenafil passes the placental barrier, although they observed much higher 
F/M ratios (0.90 vs. 0.37 here).31 Applying two different sildenafil concentrations, Russo 
et al. obtained levels in the foetal compartment corresponding with approximately 13-
14% of the total added amount of sildenafil,31 which is identical to what was observed 
in the current study (16%). Yet, in their setup maternal steady-state levels were as high 
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as those in the foetal compartment, while in our setup, maternal levels amounted to 
43% of the total added amount of sildenafil. To explain the disappearance of sildenafil 
(~40% in our setup versus ~70% in the Russo paper), one has to assume that the drug 
is either metabolised, adheres to tubing, and/or accumulates in tissue. Both Russo et 
al. and the present study observed that ~45% of sildenafil adhered to tubing. Russo 
et al. did not observe metabolism, and given the fact that the sum of the percentage 
adhered to tubing plus the percentages of intact sildenafil in maternal and foetal com-
partments in our setup equalled the total added amount, our data also do not support 
metabolism, nor significant accumulation of sildenafil in tissue. Conversely, Russo et al. 
observed significant tissue accumulation, absolute tissue levels being identical at the 
two applied sildenafil concentrations, despite the fact that these concentrations differed 
10-fold. This implies that their tissue levels were up to 30-fold higher than those in the 
maternal compartment. In the present study, tissue levels (per g tissue), at most cor-
responding with a few percent of the added amount of sildenafil, would have equalled 
the maternal levels (per mL). Hence, the much lower maternal levels in the Russo study 
appear to be entirely due to tissue accumulation of sildenafil, a phenomenon which was 
not observed in the current study. At this stage we are not aware of data supporting 
tissue accumulation of sildenafil.
To what degree albumin (present in the perfusion buffer in the study by Russo et 
al., but not in our study) determines tissue accumulation is unknown. Sildenafil binds 
plasma proteins for ~95%, which in vivo influences the concentrations in the maternal 
and foetal circulations. However, mimicking physiological protein concentrations in the 
ex vivo experimental set-up remains very difficult, since this does not only concern albu-
min, but also other drug-binding proteins like α1-acid glycoprotein and α-fetoprotein.30 
The concentrations of these proteins vary between maternal and foetal circulations, 
change with advancing gestational age, and might be altered by conditions like PE.44 
Importantly, the presence or absence of albumin should not affect the F/M ratio of the 
free drug concentration at steady state.30 Unfortunately, to our knowledge, no data on 
sildenafil concentrations in cord blood and maternal plasma of pregnant women are 
currently available in the literature, making it impossible to compare the observed ex 
vivo transfer ratio to the actual in vivo situation.
Of interest, the transfer ratio of sildenafil in the two preterm PE placentas were the 
highest of all perfused placentas, whilst the general assumption is that placental drug 
transport increases throughout gestation.45 Although preterm non-PE placentas would 
have been the appropriate control for the PE placentas, these data indicate that in PE 
conditions placental transfer of sildenafil could be enhanced at an early stage. Naturally, 
these results need to be interpreted with caution, since unfortunately the group size 
is very limited. This is due to the fact that it is very challenging to successfully perfuse 
preterm placentas, and especially PE placentas. Hence, extending the PE group, or 
chapter 3  |  Placental effects and transfer of sildenafil
84
including preterm healthy placentas to study the effect of gestational age on sildenafil 
transfer was not feasible. Notably, the mean measured concentration of sildenafil at t=0 
in the maternal circulation was higher in the healthy placentas compared to the PE ones. 
This seems to be due to measurement variability, as a similar variation is shown by Russo 
et al.31 However, we believe that the starting concentration is of no influence to the F/M 
ratio, since it has been shown that even a 10-fold difference in starting concentration 
produced similar ratios.31
Clinical studies reported inconclusive results with sildenafil in the treatment of PE. 
In a small observational clinical trial sildenafil improved foetal growth in ten women 
with pregnancies complicated by early FGR,46 although another study reported no 
effect on foetal outcome nor prolongation of pregnancy.47 Recently, the large multina-
tional randomised controlled STRIDER trials evaluating the effects of sildenafil versus 
placebo on pregnancy outcome in women with severe placental insufficiency were 
halted prematurely.25 Interim analysis showed no improvement on foetal outcome in 
two cohorts27,29 and there was an increased incidence of pulmonary hypertension of 
the new-born in the treatment group of the Dutch cohort.28,29 Given the fact that silde-
nafil passes the placenta, it might have had unwanted effects in the foetus, e.g. on lung 
development. One of the vascular changes that is associated with pulmonary hyper-
tension is a lower percentage of peripheral lung vessels, as frequently seen in foetuses 
with a congenital diaphragmatic hernia (CDH).48 Russo et al. (2016) showed in a rabbit 
model that, although sildenafil exposure during pregnancy significantly increased the 
percentage of peripheral lung vessels in offspring with CDH, it had the opposite effect 
in healthy foetuses without CDH, as it significantly reduced the percentage of peripheral 
lung vessels compared to placebo treated animals.48 Furthermore, although sildenafil 
treatment attenuated wall thickening of peripheral pulmonary vessels in CDH, it has 
been shown to increase muscularisation of the small pulmonary vessels in mice without 
CDH.49 Excessive muscularisation of the foetal pulmonary vasculature could lead to an 
increased lumen diameter, thereby increasing vascular resistance. Another possibility 
could be that, since sildenafil reduces pulmonary vascular resistance in the foetus,48 its 
placental transfer resulted in acute withdrawal problems after birth in a high-risk group 
already prone to develop pulmonary hypertension, as treatment was not continued in 
the neonates. To avoid any unwanted effects on the foetus, neonatal continuation of 
sildenafil treatment might have been an option. The use of the potent and highly selec-
tive PDE5A inhibitor tadalafil could also provide a better option than sildenafil, since it 
has a longer half-life and is less likely to pass the placenta.43 However, this needs to be 
further studied in placental transfer experiments, also given the lack of maturation of 
the CYP3A pathway in neonates that is crucial for tadalafil metabolism.50
In conclusion, in contrast to the general belief, we were unable to demonstrate selec-
tive PDE upregulation in PE, nor did sildenafil potentiate NO in PE placentas. It did so 
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in healthy placentas, and the absence of this potentiation in PE suggests that interfer-
ence at other levels than PDE5 might be required to improve endothelial dysfunction 
in this condition, e.g. with sGC activators or stimulators. Importantly, we confirmed the 
previously described direct vasodilation induced by sildenafil, and observed that this is 
unrelated to PDE5 inhibition. Furthermore, our data reveal the possibility that sildenafil 
could reach higher foetal levels during preterm PE treatment. To what degree increased 
placental transfer and/or PDE5-independent effects of sildenafil may have contributed 
to its deleterious consequences in the STRIDER trial remains to be determined. We stress 
that when considering a drug for treatment during pregnancy, its placental transfer, 
preferably per trimester of gestation, should be investigated first.
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figure s1. Placental transfer of antipyrine. Panel A, maternal and foetal concentrations. Panel B, F/M ratio, 
with the cutoff point of 0.75 (dashed red line).














































































figure s3. mRNA expression of different PDEs on the maternal side (a) and foetal side (b) of healthy (black 
bars) and PE (white bars) placentas.



























figure s4. Protein expression of PDE5A based on Western blot analysis at the maternal (a) and foetal (b) 








figure s5. Representative Western blot of PDE5 protein expression.
Table s1. qPCR primer sequences.









Table s2. Clinical characteristics of the placental vasoreactivity study in healthy pregnancy and PE.
characteristic healthy (n=18) Pe (n=8)
Maternal age (y) 33 (29.8-37.3) 30.5 (25.5-31.8)*
Parity 1 (1-1.25) 0 (0-0.75)*
Caucasian ethnicity (n) 12/18 5/8
Body mass index (kg/m2) 22.4 (20.3-27.5) 26.4 (22.6-30.9)
Smoking (n) 2/18 0/8
Highest DBP (mm Hg) 78 (72-81) 106 (96-110)*
Protein/creatinine ratio (g/mol) nm 401 (157-908)
Gestational age (weeks) 39 (39-39.2) 30.3 (26.5-31.5)*
Caesarean section (n) 14/18 7/8
Male infants (n) 10/18 4/8
Birth weight (g) 3318 (3101-3558) 1215 (656-1549)*
Placental weight (g) 614 (499-721) 321 (176-357)*
Data are presented as median (interquartile range). DBP = diastolic blood pressure; nm = not measured. 
*p<0.05.
Table s3. Clinical characteristics of the organ bath study in chorionic plate arteries obtained from healthy 
and PE placentas.
characteristic healthy (n=7) Pe (n=5)
Maternal age (y) 35 (33-38) 30 (25.5-31.5)*
Parity 1 (1-2) 0 (0-0)*
Caucasian ethnicity (n) 4/7 3/5
Body mass index (kg/m2) 24.9 (22.9-31.6) 27.8 (21.5-34.5)
Smoking (n) 2/7 0/5
Highest DBP (mm Hg) 80 (70-82) 109 (101-115)*
Protein/creatinine ratio (g/mol) nm 351 (117-809)
Gestational age (weeks) 38.6 (38.5-39) 30.4 (28.8-31.7)*
Caesarean section (n) 7/7 5/5
Male infants (n) 1/7 4/5
Birth weight (g) 3355 (2985-3555) 1170 (1115-1380)*
Birth weight (centile) 46 (16-74) 9 (3-44)
Placental weight (g) 625 (601-827) 339 (241-402)*
Data are presented as median (interquartile range). DBP = diastolic blood pressure; nm = not measured. 
*p<0.05.
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Table s4. Clinical characteristics of qPCR and Western blot analysis study in placentas obtained from 
healthy and PE pregnant women.
characteristic healthy (n=12) Pe (n=7)
Maternal age (y) 35.5 (29-38.8) 30 (25-33)
Parity 1.5 (1-2) 0 (0-1)*
Caucasian ethnicity (n) 7/12 4/7
Body mass index (kg/m2) 24.6 (22.4-33.7) 28.1 (22.8-33.2)
Smoking (n) 0/12 0/7
Highest DBP (mm Hg) 80 (73-82) 108 (95-115)*
Protein/creatinine ratio (g/mol) nm 202 (31-580)
Gestational age (weeks) 39 (38.5-39.2) 29.6 (28.4-31.6)*
Caesarean section (n) 12/12 6/7
Male infants (n) 7/12 3/7
Birth weight (g) 3673 (3384-3975) 1150 (910-1300)*
Birth weight (centile) 78 (63-91) 13 (9-50)*
Placental weight (g) 711 (639-804) 291 (235-348)*
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AbsTRAcT
Recently, the non-selective phosphodiesterase inhibitor pentoxifylline (PTX) has gained 
interest as a possible therapeutic that could target both the generalized endothelial dys-
function and the immune system imbalance in preeclampsia (PE). However not much is 
known about its effects on the placenta. Therefore, in this study the vascular effects of 
PTX were evaluated. PTX concentration-response curves after incubation with SQ22536 
or L-NAME were constructed in porcine coronary arteries and human chorionic plate 
arteries of both healthy and PE placentas. The effect of PTX-incubation on vasodilation 
through the cGMP - and cAMP pathways was studied in segments of the same vessels 
using the endothelium-independent NO donor sodium nitroprusside and the adenylyl 
cyclase activator forskolin, respectively. PTX exerted direct vasodilator effects on both 
porcine coronaries and human chorionic plate arteries, that could be blocked by L-
NAME, indicating that this effect is mainly NO/cGMP-mediated. This dilator effect was 
increased in arteries of PE placentas. PTX enhanced the vasodilator effects of sodium 
nitroprusside and forskolin in chorionic plate arteries derived from healthy, but not PE 
placentas. Since PTX induced direct vasodilation in chorionic plate arteries, and even 
to a greater extent in PE, it could be a beneficial treatment option to improve placental 




Preeclampsia (PE) is a serious placenta-related pregnancy disorder, affecting approximately 
5-8% of all pregnancies.1 It is characterized by hypertension with an onset after 20 weeks of 
gestation, accompanied by evidence of maternal organ damage (e.g. proteinuria, elevated 
liver enzymes, pulmonary - or cerebral edema) and/or fetal growth restriction.2 Early onset 
PE, i.e. diagnosis before the 34th week of gestation,3 is not only associated with an increased 
risk of maternal and fetal complications during pregnancy, but it can also lead to health 
problems later in life for both mother and child.1, 4, 5 Different pathophysiological mecha-
nisms have been proposed for early onset PE, all involving impaired placentation in early 
pregnancy, leading to increased vascular resistance, generalized endothelial dysfunction 
and endovascular inflammation. Previous studies showed that PE patients have increased 
plasma levels of pro-inflammatory cytokines, such as interleukin(IL)-6, interferon(IFN)-γ 
and tumor necrosis factor(TNF)-α. On the other hand, the anti-inflammatory cytokines IL-5 
and IL-10 seem to be suppressed.6, 7 Furthermore, increased concentrations of pro-inflam-
matory cytokines have been found in placental tissue of PE patients compared to healthy 
controls.8 This imbalance in the immune response attributes to the impaired placentation, 
endothelial damage and ischemic-reperfusion injury seen in PE.9-11 It would therefore 
be very interesting to target both the generalized endothelial dysfunction and the im-
mune system imbalance to treat early onset PE, for example by using the methylxanthine 
derivative pentoxifylline (PTX). PTX is a non-selective phosphodiesterase (PDE) inhibitor, 
that increases the intracellular concentration of cAMP.12 It has been shown to have anti-
inflammatory properties, scavenge oxygen radicals, improve endothelial function, induce 
vasodilation, increase erythrocyte flexibility and inhibit platelet aggregation.13, 14 Although 
currently only registered for intermittent claudication, PTX has been suggested as a pos-
sible preventive or therapeutic intervention for inflammatory placental diseases such as 
PE and preterm birth.15, 16 Previously, Speer et al. showed that PTX reduces inflammation 
in placental explants.12 Furthermore, it has been indicated that PTX has a beneficial effect 
on the fetoplacental circulation in patients with imminent preterm labor.16 However, the 
mechanisms behind these vascular effects are not well understood. Therefore, the aim of 
this study was to evaluate the vascular effects of PTX, using both porcine coronary arteries 
as well as human chorionic plate arteries of healthy and PE placentas.
meThoDs
Tissue collection
Placentas of women with uncomplicated singleton pregnancies who underwent an 
elective cesarean section were collected immediately after delivery at the Erasmus MC 
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University Medical Center, Rotterdam, the Netherlands. Also, placentas of women with 
early onset PE (diagnosis before the 34th week of gestation) were collected. The study 
was exempted from approval by the local institutional Medical Ethics Committee accord-
ing to the Dutch medical Research with Human Subjects Law (MEC-2016-418 and MEC-
2017-418), and all patients gave written consent to use of their placenta and data prior 
to the experiments. Additionally, porcine hearts were collected from the slaughterhouse.
wire-myography experiments with porcine coronary arteries
Coronary arteries were dissected from the hearts and stored overnight in cold, oxygen-
ated Krebs-Henseleit buffer (in mmol/l: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 8.3; pH 7.4). Vessel segments of 4 mm were suspended on stainless 
steel hooks in 15-ml organ baths, filled with Krebs-Henseleit buffer at 37°C and aerated with 
95% O2 – 5% CO2. After a period of equilibration, vessel segments, stretched to a stable force 
of about 15 mN, were exposed to 30 mmol/l KCl twice. Subsequently, maximum contractile 
responses were determined using 100 mmol/l KCl. After washout of the KCl, segments were 
pre-incubated for 30 min in the absence or presence of one of the following inhibitors: the 
adenylate cyclase inhibitor SQ22536 (100 µmol/l), the NOS-inhibitor L-NAME (100 µmol/l) 
or PTX (100 µmol/l). All vessel segments were then pre-constricted using the thromboxane 
A2 agonist U46619 (1 µmol/l). Segments that were pre-incubated with SQ22536 or L-NAME 
were used to construct concentration-response curves to PTX (1 nmol/l - 300 µmol/l), and 
segments that were pre-incubated with PTX were exposed to sodium nitroprusside (SNP, 1 
nmol/l - 100 µmol/l) or forskolin (1 nmol/l - 30 µmol/l). Vessel segments without any addi-
tives were used as a control for all concentration-response curves. Changes in tissue con-
tractile force were recorded with a Harvard isometric transducer (South Natick, MA, USA).
wire-myography experiments with human chorionic plate arteries
Segments of second order branches of chorionic plate arteries (2 mm in length) were 
mounted in 6-ml organ baths (Danish Myograph Technology, Aarhus, Denmark), filled 
with Krebs-Henseleit buffer at 37°C and aerated with 95% O2 – 5% CO2. Tension was 
normalized to 90% of the estimated diameter at 38 mmHg effective transmural pressure 
to mimic the physiological circumstances of placental vessels. Maximum contractile 
responses were determined using 100 mmol/l KCl. Experimental protocols were similar 
to those used for the porcine coronary arteries. After washout of KCl, all vessel segments 
were pre-constricted with U46619 (10 nmol/l). Concentration-response curves for PTX 
(1 nmol/l - 300 µmol/l) were performed in a subset of segments, that had been pre-
incubated for 30 min with either SQ22536 (100 µmol/l), L-NAME (100 µmol/l) or both. 
Again vessel segments without any additives were used as a control. Concentration-
response curves for SNP (1 nmol/l - 100 µmol/l) and forskolin (1 nmol/l - 30 µmol/l) were 




PTX (Trental®) was acquired from the hospital pharmacy of Erasmus MC, Rotterdam, the 
Netherlands. All other compounds came from Sigma-Aldrich, Schnelldorf, Germany.
Data analysis
Data are presented as mean±SEM. Vascular responses are expressed as a percentage 
of the contractile response to 100 mmol/l KCl or U46619. Log10-transformed values at 
which the half-maximal response (pEC50) occurred were individually estimated using 
sigmoid curve fitting software (GraphPad Prism 5, La Jolla, CA, USA). In case of normally 
distributed data, groups were analyzed using 1-way ANOVA with Bonferroni post-hoc 
evaluation. When 1-way ANOVA was significant, individual comparisons were made with 
Student’s t test. A p-value of <0.05 was considered statistically significant.
ResulTs
Porcine coronaries
Figure 1A shows the concentration-response curves to PTX in porcine coronary arteries. 
The maximum relaxation (Emax) induced by PTX was 68±5% of U46619 pre-constriction, 
with a pEC50 of -4.2±0.1. Incubation with L-NAME or SQ22536 reduced Emax to 30±9% 
and 55±7% respectively, however this was only significant for L-NAME (p=0.003, Table 
1). Incubation with either antagonist shifted the PTX curve to the left, evidenced by a 
decrease in pEC50 (p=0.05, Table 1). Incubation with PTX tended to shift the SNP (p=0.09) 
and forskolin (p=0.06) curves to the left, without altering Emax (Figures 1B and 1C and 
Table 1).























































figure 1. Results of the wire-myography experiments using porcine coronary arteries. Panel A shows the 
concentration-response curves to pentoxifylline (PTX) in control segments (circles) or after incubation with 
SQ22536 (triangles) or L-NAME (squares). Panel B shows the concentration-response curves to sodium ni-
troprusside (SNP) in control segments (closed circles) or after incubation with of 100 µmol/l PTX (open cir-
cles). Panel C shows the concentration-response curves to forskolin in control segments (closed squares) or 
after incubation with 100 µmol/l PTX (open squares). Data are mean±SEM (n=5-9). *p<0.01, 1-way ANOVA 
for repeated measures with Bonferroni post-hoc evaluation.
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human chorionic plate arteries
The concentration-response curves to PTX, SNP and forskolin in human chorionic plate 
arteries are shown in Figure 2. In chorionic plate arteries of healthy placentas, PTX in-
duced an Emax of 74±8% of U46619 pre-constriction, with a pEC50 of -4.4±0.1 (Table 2). 
Incubation with L-NAME, SQ22536, or both did not affect Emax (Table 2, Figure 2A), but 
L-NAME with or without SQ22536 did shift the PTX curve to the left (p=0.02 and p=0.04, 
respectively). Incubation with PTX potentiated both SNP and forskolin, evidenced by 
a decreased pEC50 (p=0.002 and p=0.008, respectively, Figure 2B and 2C, Table 2). In 
chorionic plate arteries of PE placentas, the Emax induced by PTX tended to be larger 
than in healthy placentas (p=0.07, Table 3). None of the antagonists altered the pEC50 of 
Table 1. Organ bath experiments with porcine coronaries.
incubation
cRc control sQ22536 l-NAme PTx
pEC50




PTX 68±5 55±8 30±9**
SNP 91±4 79±12
Forskolin 99±3 98±2
pEC50: log10-transformed concentrations at which the half-maximum response occurred. Emax: maximum 
effect expressed as % relaxation of U46619 constriction. *p<0.05 and **p<0.01 compared to control, 1-way 
ANOVA for repeated measures with Bonferroni post-hoc evaluation.
Table 2. Organ bath experiments with human chorionic plate arteries of healthy placentas.
incubation
cRc control sQ22536 l-NAme sQ22536 + l-NAme PTx
pEC50




PTX 74±8 64±10 59±9 53±10
SNP 90±6 90±4
Forskolin 88±8 113±10
pEC50: log10-transformed concentrations at which the half-maximum response occurred. Emax: maximum 




PTX in PE vessels (Figure 2D, Table 3). Furthermore, PTX did not alter the response to SNP 
and forskolin in PE arteries (Figure 2E and 2F, respectively).























































































































figure 2. Results of the wire-myography experiments using human chorionic plate arteries. The upper part 
of the figure (Panels A, B and C) represent the results of chorionic plate arteries of healthy placentas (solid 
lines, n=6-10) and the lower part (Panels D, E and F) the results of chorionic plate arteries of preeclamptic 
placentas (dashed lines, n=3-5). Panels A and D show the concentration-response curves to pentoxifylline 
(PTX) in control segments (circles) or after incubation with SQ22536 (triangles), L-NAME (squares) or both 
(diamonds). Panels B and E show the concentration-response curves to sodium nitroprusside (SNP) in con-
trol segments (closed triangles) or after incubation with of 100 µmol/l PTX (open triangles). Panels C and F 
show the concentration-response curves to forskolin in control segments (closed squares) or after incuba-
tion with 100 µmol/l PTX (open squares). Data are mean±SEM.
Table 3. Organ bath experiments with human chorionic plate arteries of preeclamptic placentas.
incubation
cRc control sQ22536 l-NAme sQ22536 + l-NAme PTx
pEC50




PTX 95±3 72±9 69±11 68±16
SNP 90±4 70±12
Forskolin 89±5 93±6
pEC50: log10-transformed concentrations at which the half-maximum response occurred. Emax: maximum 
effect expressed as % relaxation of U46619 constriction. *p<0.05 and **p<0.01 compared to control, Stu-
dent’s t test.
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DiscussioN
This study shows that PTX has direct vasodilator effects on both porcine coronaries 
and human chorionic plate arteries, and that these effects can be blocked by L-NAME. 
Besides directly inducing vasodilation, PTX also enhanced the vasodilator effects of the 
NO donor SNP and the adenylate cyclase activator forskolin in chorionic plate arteries 
derived from healthy, but not PE placentas.
In line with previously reported effects of PTX on for example rat mesenteric arteries 
and rabbit aorta,18, 19 PTX evoked concentration-dependent relaxation in the current 
study. Similar to the results of Hansen et al.19, who showed inhibition of the PTX re-
sponse by L-NAME in rat mesenteric vessels, we saw a blocking effect on PTX response 
by L-NAME in porcine coronary arteries and human chorionic plate arteries. The fact 
that incubation with the adenylate cyclase inhibitor SQ22536 did not result in similar 
blocking effects indicates that, at least in these vessels, the acute dilator PTX response 
is mainly cGMP-mediated. PTX did enhance the vasodilator effects of both SNP and 
forskolin in healthy chorionic plate arteries, confirming that it affects both cGMP and 
cAMP degradation. In contrast, no such potentiation was seen in the rabbit aorta,18 
emphasizing the difficulties of translating results from animal studies to humans.
PTX tended to induce stronger relaxant effects in PE arteries, yet was unable to poten-
tiate forskolin or SNP in these arteries. The latter is reminiscent of what was observed 
for the PDE inhibitors sildenafil and vinpocetine in PE arteries,17 and suggest that the 
larger relaxant effects of PTX are unrelated to PDE inhibition. Hence, PTX might still be 
a beneficial treatment option to improve placental perfusion, acting via a non-PDE-
dependent mechanism.
Besides its vasodilator properties, PTX has been shown to reduce inflammation. In 
placental explants with LPS-induced inflammation, PTX reduced expression and pro-
duction of the pro-inflammatory cytokines TNF-α, IFN-γ and IL-1β.12 It could therefore 
be speculated that PTX is a good candidate to treat placental inflammatory conditions 
in vivo. PTX is already studied as anti-inflammatory treatment in preterm born infants 
with suspected late-onset sepsis or necrotizing enterocolitis, with promising results.20, 21
Before starting a clinical trial in pregnancy, it is essential to gain knowledge on the 
placental transfer of PTX. No teratogenic effects of PTX have been described in animal 
studies, and clinical trials with PTX as treatment to prevent preterm labor did not report 
negative effects, although no long-term follow-up has been performed.16 Furthermore, 




Since it has vasodilator and anti-inflammatory properties, PTX is a very interesting drug 
that could target both the generalized endothelial dysfunction and the immune system 
imbalance seen in PE. As a next step we suggest to study placental transfer of PTX in 
both healthy and (preterm) preeclamptic placentas. Furthermore, we should expand our 
knowledge on the anti-inflammatory effects of PTX in the PE placenta, using placental 
explants and/or trophoblast cell culture. With this, possible differences between early 
– and late onset PE, with or without fetal growth restriction should be kept in mind. 
Furthermore, a pharmacokinetic model of PTX in pregnant women should be made 
before starting a clinical trial.
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AbsTRAcT
Preeclampsia (PE) is a pregnancy complication, featuring elevated blood pressure and 
proteinuria, with no appropriate treatment. Activation of the endothelin system has 
emerged as an important pathway in PE pathophysiology based on experimental PE 
models where endothelin receptor antagonists (ERAs) prevented or attenuated hyper-
tension and proteinuria. Hence, ERAs have been suggested as potential therapy for PE. 
However, developmental toxicity studies in animals have shown severe teratogenic 
effects of ERAs, particularly craniofacial malformations. Nonetheless, sporadic cases of 
pregnancy in women using ERAs to treat pulmonary hypertension have been described. 
In this review we give an overview of cases describing ERA use in pregnancy and criti-
cally address their possible teratogenic effects. A systematic search in literature yielded 
18 articles describing 39 cases with ERA exposure during human pregnancy. In most 
cases there was only exposure in the first trimester, but exposure later or throughout 
pregnancy was reported in 5 cases. Elective termination of pregnancy was performed 
in 12 pregnancies (31%), two ended in a spontaneous miscarriage (5%) and no fetal 
congenital abnormalities have been described in the remaining cases. These preliminary 
findings support the idea that ERA treatment for severe, early onset PE might be an 
option if applied later in pregnancy, when organogenesis is completed to avoid terato-
genic risks. However, third trimester toxicology studies are warranted to evaluate drug 
safety. Subsequently, it remains to be established whether ERA treatment is effective 
for alleviating maternal symptoms, as demonstrated in preclinical PE models, allowing 




Preeclampsia (PE), a syndrome featuring de novo hypertension accompanied by protein-
uria and/or evidence of maternal acute kidney injury, liver dysfunction, neurological fea-
tures, hemolysis or thrombocytopenia, and/or fetal growth restriction (FGR), is the most 
frequently encountered medical complication during pregnancy.1 Ultimately, PE may 
lead to severe complications, thereby increasing maternal, fetal and neonatal morbidity 
and mortality.2, 3 While randomized trials have tested interventions with different antihy-
pertensive agents including methyldopa and various calcium antagonists, these drugs 
only show a temporary effect on stabilization of the clinical manifestations of PE, but not 
on hard clinical outcomes such as mortality.4-6 To date, the only effective treatment of PE 
is delivery of the placenta and hence the baby, often severely premature. Consequently, 
novel treatment strategies to prevent or alleviate PE are urgently needed. Achieving an 
additional week of gestational age in premature infants enhances fetal maturity and 
hereby leads to a decrease in fetal mortality and enhances neonatal outcome.7 There is 
strong experimental evidence that activation of the endothelin (ET)-system plays a key 
role in the pathophysiology of PE.8 In addition, increased ET-1 levels have been reported 
in PE compared to healthy pregnancies.9 A possible therapeutic strategy could therefore 
be to target the activated ET-axis by using endothelin receptor antagonists (ERAs).8 
However, the latter approach remains controversial since developmental toxicity studies 
have shown serious teratogenic effects in offspring of animals treated with ERAs dur-
ing pregnancy. Nonetheless, it is important to note that this teratogenicity observed in 
animals does not necessarily translate to humans. The aim of this review is to provide 
a complete overview of ERA use in pregnancy, based on evidence from humans and 
animals, and to critically address their potential teratogenic effects.
eNDoTheliN-1 As The RooT cAuse of PReeclAmPsiA
Though not fully elucidated, evidence suggests that the activation of the ET-axis is 
strongly linked to the manifestations of PE.10, 11 The ET-system consists of a family of 
3 structurally closely related amino acid peptides (ET-1, ET-2 and ET-3). The main ET 
synthesized and secreted by endothelial cells is ET-1, this peptide is also synthesized 
and secreted by the syncytiotrophoblasts of the placenta.12 ET-1 exerts its effect by 
binding to the cell-membrane G-protein-coupled ET type A receptors (ETAR) and ET 
type B receptors (ETBR).13 Activation of ETAR and ETBR on vascular smooth muscle cells 
initiates prolonged vasoconstriction as well as cell proliferation. Conversely activation 
of the ETBR on endothelial cells mediates vasodilation by releasing nitric oxide (NO) and 
prostacyclin (Figure 1). ETBR activation may therefore counterbalance the ETAR-mediated 
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vasoconstrictive response.14, 15 In addition, the ETBR serves as a clearance receptor for 
endothelins.16
ET-1 in pregnancy is regulated by numerous factors as recently reviewed by Granger 
et al.8 The functional role of the ET-system in healthy pregnant women is not well 
known, it seems to promote first trimester trophoblast proliferation and invasion,17 and 
an increased ratio of ETBR to ETAR has been observed in human placental villi during 
their development (Figure 1).18 Furthermore, while maternal serum levels of ET-1 during 
healthy gestation remain similar to those of non-pregnant women, a substantial rise 
is detected during labor,19, 20 implicating ET-1 involvement in the initiation of uterine 
contractions.21 In addition, high concentrations of ET-1 in the amniotic fluid and in the 
fetal circulation are observed, being almost 3-fold higher in the umbilical vein when 
compared to maternal serum levels around labor.22
In animal models inducing placental ischemia, chronic elevation of soluble Fms-like 
tyrosine kinase-1 (sFlt-1), infusion of tumor necrosis factor-alpha (TNF-α) or agonistic 
autoantibodies to the angiotensin II type I receptor (AT1-AA), all induce a PE-like 
syndrome. In all these animals a significant increase in the expression of the precur-
sor peptide prepro-ET-1 is seen in the kidney, as well as in the maternal vasculature 
in the case of AT1-AA and in the case of TNF-α in both the maternal vasculature and 
the placenta.23-25 This enhanced prepro-ET-1 expression likely translates in higher ET-1 
levels, underlying the rise in blood pressure in PE, as this rise can be prevented by ERAs. 
Furthermore, in these animals the ETBR is downregulated in endothelial cells.26 Similarly, 
decreased ETBR expression in vascular endothelial cells has been found in pregnant 
women suffering from PE.27 Subsequently, a wide range of clinical studies in pregnant 
women has observed a 2- to 3-fold rise of circulating ET-1 in PE compared to normal 
pregnancies.9, 10, 28, 29 In addition, multiple regression analysis revealed that ET-1 is an 
independent determinant of urinary protein in PE and of the suppression of the renin-
angiotensin aldosterone system in this condition.10
Regarding ERA effects in the treatment of the maternal syndrome of PE, knowledge 
comes from experimental animal models of PE. For example, in the reduced uterine 
perfusion pressure model in rats, ETAR blockade reduced maternal blood pressure.30 
This is suggestive for an upregulation of the ET-1-ETAR pathway in this model, which 
when blocked allows counter regulatory factors (like NO) to lower blood pressure.8, 31 In 
rats infused with sFlt-1 and soluble endoglin, treatment with selective ETAR antagonists 
also significantly decreased hypertension, urinary protein-to-creatinine ratio, hemolysis 
and liver enzymes, and increased platelets (Table S1, online-only data supplement).32 
Moreover, compared to placebo, FR-139317, an ETAR antagonist (Table 1), potentially by 























figure 1. Role of endothelin in healthy pregnancies and preeclampsia-like syndrome. This fi gure shows the 
ET-1 levels in healthy pregnancy and non-pregnant women (in black) and the eff ects of a PE-like syndrome 
(in red). In blue the eff ects of increased ET-1 levels in the fetal circulation during healthy pregnancy are 
shown and in green the eff ects of ERAs on ET-1 levels.
Table 1. Diff erent endothelin receptor antagonists and their targeted receptor.
eRA Receptor blockade
A-127722 ETA









SB-209670 ETA / ETB
SB-217242 ETA / ETB
Sitaxentan ETA
TBC-3214 ETA
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Thaete et al. examined the effect of selective ETAR (A-127722 and FR-139317) and dual 
(A-182086) ERAs on fetal and placental growth in rats, with and without long-term NO 
synthase (NOS) inhibition with L-NAME. The dual ERA resulted in fetal and placental 
growth restriction, without attenuating the fetal and placental growth restriction 
caused by L-NAME infusion. In contrast, the selective ETAR antagonists improved fetal 
and placental growth during NOS inhibition, and were without adverse effects in the 
absence of NOS inhibition.34 These studies suggest that blocking ETAR-mediated ET-1 
signaling might be more beneficial in PE or FGR then dual ETAR/ETBR blockade. Selective 
ETBR blockade in the same PE animal model with L-NAME was lethal for all animals.35
Nonetheless, excitement about ERAs as a possible treatment for PE has been damp-
ened by severe teratogenic effects following maternal ERA administration as well as 
by ET-1, ET-3 and ETAR or ETBR gene disruption experiments during gestation in animal 
models, in particular serious craniofacial and cardiovascular malformations, pigmentary 
abnormalities and aganglionic megacolon.36 Because of this, clinical trials studying ERA 
treatment to alleviate or even to prevent PE are lacking.
eNDoTheliN-1 DuRiNG embRyoGeNesis
To explain the occurrence of teratogenic effects during ERA treatment, understanding 
the role of ET-1 during embryogenesis is crucial. During early embryonal development, 
the ET-pathway plays an important role in the induction and maintenance of neural 
crest cells,37 cells migrating to many different locations and differentiating into a wide 
variety of cell types including the craniofacial skeleton, cartilage, neurons and glia of the 
peripheral nervous system, connective tissue, neuroendocrine cells, and melanocytes.38 
The ET-axis is also involved in maintaining the high vascular resistance that is needed 
in the fetal lung development during pregnancy.39 In the lung ETAR is abundantly ex-
pressed during both the pre- and (early) postnatal periods, whereas the ETBR is mildly 
expressed during early lung development. The lung ETBR expression increases and stabi-
lizes in the last prenatal stages and after birth, preventing muscularization of pulmonary 
pre-capillaries by stimulating vasodilation and ET-1 clearance.40 Alteration of ET-1 or its 
receptors seems to affect normal embryonal development by impairing neural crest cell 
migration,36, 41 as has been demonstrated by studies using murine knockout models.42, 43 
Clouthier et al. showed that ETAR deficient mice have severe craniofacial defects, such 
as underdeveloped mandibles and abnormal middle ear structures. If left untreated, 
pups died shortly after birth because of asphyxia due to these structural defects. Fur-
thermore, there was a 100% cumulative penetrance of cardiovascular abnormalities, for 
example interruption of the aorta (44%), tubular hypoplasia (56%) and ventricular septal 
defect (92%).42 ET-1 deficient mice also display cardiovascular malformations including 
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ventricular septal defect, absent right subclavian artery and interruption of the aorta. 
Importantly, the frequency and severity of these abnormalities increased when they 
were additionally treated with BQ-123, a selective ETAR antagonist (Table S1). This sug-
gests that the lack of ETAR stimulation by ET-1 is compensated, at least in part, by other 
ET isoforms (e.g., ET-2, ET-3).43
It has also been suggested that ET-1 plays a key role in closure of the ductus arteriosus 
after birth, although evidence is conflicting. The ductus arteriosus is a shunt connecting 
the pulmonary artery and aortic arch in utero, this way most of the fetal blood bypasses 
the pulmonary circulation. At birth, blood oxygenation shifts from the placenta to the 
lungs, making the ductus arteriosus redundant and initiating its closure.44 Some stud-
ies have indicated that oxygen-triggered ET-1 release regulates closure of the ductus 
through binding to ETAR on vascular smooth muscle cells.45, 46 However, other experi-
mental studies have shown that although blocking the ETAR indeed counteracts the 
constricting effects of ET-1, the ductus still closes, both in vitro and in vivo.47, 48 Therefore, 
the exact effect of ETAR blockade on closure of the ductus arteriosus remains uncertain.
TeRAToGeNic effecTs of eNDoTheliN RecePToR ANTAGoNisTs
With regard to their teratogenic effects, either selective or dual ERA exposure during 
animal pregnancy has supplemented the findings of gene disruption studies, revealing 
the crucial role of ET-1 in embryonal development.
Treatment of wild type 129S6 mice with an ETAR antagonist (TBC-3214) on gestational 
day (GD) 8, 9 or 10 showed a significant increase in pups with craniofacial malformations 
compared to the control group (up to 100% depending on day of treatment). There were 
no differences in litter size, fetal weight or fetal mortality (Table S1).49
The toxicity of Sitaxentan on embryo-fetal development in Sprague-Dawley rats was 
evaluated by Cross et al.45 Sitaxentan is a highly selective ETAR antagonist (Table 1) that 
was withdrawn from therapeutic use in 2010 because of the risk of idiosyncratic liver 
injury. In this study, rats were divided into 3 groups of different treatment periods (GD 
0-6, 6-16 or 16-lactation), and each group was subdivided to test multiple dosages rang-
ing from 20-120 mg/kg/day. There were no differences in fetal weight and fetal mortality 
between treatment and vehicle groups. Treatment from GD 6-16 with a dosage of 80 
mg/kg/day or higher resulted in a significant increase of craniofacial and cardiovascu-
lar malformations (Table S1).50 Similarly, in another study Sprague-Dawley rats were 
treated with different dosages of another selective ETAR antagonist (L-753,037) on GD 
6-20. There were no differences in litter size and fetal mortality between treated and 
control groups. However, treatment with the dose of 40 mg/kg/day resulted in a signifi-
cant reduction in fetal weight, and dosages of 10 mg/kg/day or higher resulted in an 
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increased incidence of congenital abnormalities (Table S1).51 To further investigate the 
function of the ET-system in fetal development, Taniguchi et al. exposed pregnant rats 
to a selective ETAR antagonist during 5 different gestational periods (GD 7-20, 7-9, 9-11, 
11-13 or 7-8/11-20). Unfortunately, the ETAR antagonist dosage was not specified, nor 
did the authors report litter size or fetal weight. However, the authors did observe that 
most congenital malformations were seen in offspring of rats that were treated on GD 
7-20 or 9-11 (comparable to GD 13-64 and 17-22 in humans), with a 100% penetrance 
for craniofacial malformations. In the other treatment groups, no craniofacial malforma-
tions were seen (Table S1).52
Treinen et al. studied the effect of two dual ERAs (SB-217242 and SB-209670) on fetal 
development in Sprague-Dawley rats on GD 6-17. A significant decrease in litter size 
and fetal weight was observed at the highest dosages for each antagonist. Moreover, a 
dose-dependent increase in craniofacial and cardiovascular abnormalities was seen at 
doses of 50 mg/kg/day (SB-217242) and 10 mg/kg/day and higher (SB-209670). There 
was no difference in fetal mortality compared to control rats (Table S1).53
Lastly, the effect of different dosages of the dual ERAs SB-217242 and SB-209670 
(administered on GD 6-20) on fetal development of New Zealand White rabbits has 
been studied. The SB-217242 treatment group showed a reduction in litter size at 50 
mg/kg/day, while no effect was seen for treatment with SB-209670. For SB-217242, a 
dose-dependent increase in congenital abnormalities (predominantly craniofacial) was 
seen from 50 mg/kg/day, with 100% of fetuses being affected at 300 mg/kg/day. When 
rabbits were treated with SB-209670, an increase in congenital cardiovascular malfor-
mations was only seen at the highest dosage (Table S1).53
eNDoTheliN RecePToR ANTAGoNisTs iN humAN PReGNANcy
Currently, only the dual ERAs Macitentan, Ambrisentan and Bosentan are approved for 
clinical use for the treatment of pulmonary arterial hypertension (PAH) and digital ulcers 
due to systemic sclerosis not responsive to standard therapy. Beneficial effects of these 
drugs have also been shown in treatment of cancer and renal failure.54 While ERA use is 
absolutely contraindicated during pregnancy, there are sporadic cases of women who 
used ERAs during a certain period of their pregnancy. We conducted a systematic search 
of the literature (Figure S1, online-only data supplement) up to 18 February 2019 to 
create an overview of cases reporting the use of ERAs in pregnancy (Table 2).
Thirty-nine cases of ERA use in human pregnancy have been described in 18 ar-
ticles.55-72 The study characteristics are provided in Table 2. All women were suffering 
from PAH, and many of them received combination treatment with e.g. sildenafil or 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ERA Bosentan, while the ETAR selective blockers Sitaxentan and Ambrisentan were each 
used in one case; the remaining 11 cases did not specify the type of ERA. ERA treatment 
was stopped in most patients early in the first trimester. In only 4 cases that continued 
pregnancy, the ERA was used throughout the entire pregnancy,56, 70, 72 and in another 
case up to 28 weeks of gestation.64 In the case described by Cotrim et al., there was only 
short exposure during the third trimester, as treatment with Bosentan was started at 28 
weeks of gestation and the patient delivered one week later because of severe maternal 
deterioration related to PAH and premature rupture of membranes.57 Three case reports 
did not provide information about the period of treatment.65, 68 Only 8 case reports men-
tioned the ERA dosages that were used: 62.5-250 mg twice daily for Bosentan and 2.5 
mg daily for Ambrisentan, 57, 58, 65, 69, 70 which are standard dosages for PAH treatment.73 
Elective termination of pregnancy was performed in 12 women (31%), all because of 
maternal condition related to PAH.57, 59, 61, 68 Two patients had a spontaneous miscarriage 
(5%).62, 71 Eighteen women delivered via caesarean section, one had a vaginal delivery 
and for 6 patients the mode of delivery was not reported. Gestational age at delivery 
ranged from 25 weeks to term. Most women delivered prematurely on maternal indi-
cation (worsening of PAH). In all 5 women that delivered at term treatment has been 
stopped in the first trimester. No congenital abnormalities were reported (Table 2).
Despite being absolutely contraindicated during pregnancy, the substantial number 
of reported cases of the use of ERAs during pregnancy is remarkable. Exacerbation of PAH 
symptoms is likely to occur in pregnancy because of pronounced pregnancy-induced 
hemodynamic changes, especially the rise in plasma volume and cardiac output.74 
From the reported cases leading to live offspring (n=25) no congenital abnormalities 
were reported, compared to a prevalence of 4% in the general population.75 Also the 
percentage of miscarriages of 5% (2 of 39 reported cases) is lower than the percentage 
of 10-20% observed in the general population.76, 77 It should be remarked that medically 
indicated elective termination of pregnancy was performed in a high number (31%) of 
women with PAH using ERAs, so it cannot be excluded that the number of miscarriages 
and congenital abnormalities has been underestimated. In the very limited number of 
women (n=5) who were exposed to Bosentan in the third trimester of pregnancy no 
congenital abnormalities were observed.
eNDoTheliN RecePToR ANTAGoNisTs As TReATmeNT foR PReeclAmPsiA
Translating results from animal studies to humans remains difficult, especially since pla-
cental morphology differs greatly between species.78 A method that allows to compare 
the development of the human embryo with that of for example rats is the Carnegie 
staging. These 23 stages are based on the morphological development of the vertebrate 
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embryo and can be applied to all vertebrates, given that the embryonic development 
of almost all vertebrates, including humans, is identical. As shown in Figure 2, in most 
of the animal studies that report severe congenital abnormalities ERAs were adminis-
tered before the end of the Carnegie stages. In pregnant women, these drugs could 
be administrated later, e.g. at the end of the second trimester when organogenesis is 
complete and the symptoms of PE typically manifest. Our review of cases using Bosen-
tan as treatment for PAH in women with term and preterm neonates showed no major 
(congenital) adverse effects as a consequence of treatment. This supports the idea that 
administration of ERAs later in pregnancy, i.e. from a gestational age of 20 weeks, could 
be safe. One should keep in mind that earlier administration might be more optimal 
as it may interfere with the origin of placental insufficiency leading to PE. However, 
since activation of the ET-axis appears to be involved in the clinical symptoms requiring 
preterm delivery, administration of ERAs at a later stage might be sufficient to delay 
delivery, thereby improving neonatal outcome. Another point of concern could be that, 
although organogenesis has been completed in third trimester of pregnancy, fetal lung 
maturation has not. Since the ET-axis is involved in fetal lung development39 and ETAR 
are abundantly expressed in the fetal lungs during the pre- and (early) postnatal peri-
ods,40 ETAR blockade at a later stage of pregnancy might counteract the high pulmonary 
vascular resistance needed for adequate lung maturation. Here it is important to realize 
that neonates born to mothers with PE have increased serum ET-1 levels compared to 
controls,79 implying that ETAR blockade might actually normalize this situation. Further-
more, neonates with PAH are often treated with the ERA Bosentan,80, 81 after which no 
adverse effects of treatment on lung- and brain development have been described, 
although no long term follow-up studies are available.80
Knowledge about the placental transfer of ERAs is virtually non-existent. In rats, the 
fetal plasma level of the ERA ABT-546 was only 2% of the maternal plasma levels during 
maternal administration late in pregnancy, suggesting that only a minute fraction of 
the drug crosses the placenta.82 Importantly, this study showed no adverse effect of ERA 
treatment late in pregnancy on pup weight or survival.82 However, no third trimester 
toxicology studies have been performed, nor has any study assessed the transfer of 
ERAs in human placentas. With the ex vivo dual-sided placental perfusion model it is 
possible to obtain information about the transfer of different ERAs through the human 
placenta.83 Although it seems likely that there will be (at least partial) placental transfer, 
given the low molecular weight and lipophilic properties of these drugs,84 studying 
this will provide essential knowledge on placental pharmacokinetics. In addition, it can 
be examined whether the transfer is different in placentas derived from early onset PE 
pregnancies as compared to term or preterm uncomplicated pregnancies. Furthermore, 
methods preventing ERAs from passing the placental barrier (e.g. by linking them to 
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elastin-like peptides) can be tested using this model. This approach would allow target-
ing the maternal ET-system without aff ecting the fetus.8
An important question would be whether a selective ETA or a dual ERA would be most 
preferable. In diff erent animal models of PE an ETAR selective antagonist reverses symp-
toms without other adverse eff ects, supporting the use of an ETAR selective receptor 
antagonist. In addition, selective inhibition/deletion of the ETBR in animals is associated 
with distinct congenital abnormalities and death.35, 85 On the other hand, based on the 
limited evidence in human pregnancies indicating that the dual ERA Bosentan, when 
administered in the third trimester of pregnancy in women with PAH, is not associ-
ated with craniofacial abnormalities would perhaps favor the use of this dual receptor 
blocker, especially because it is already approved for clinical use. A further possibility 
might be the application of endothelin-converting enzyme-1 (ECE-1) inhibitors, since 
ECE-1 activity is also increased in women with PE.86 However, such drugs, by suppressing 
ET-1 formation, would mimic the eff ect of dual ERAs. Potential caveats are their selectiv-
ity and the possibility that ET-1 is also formed by non-ECE-1 enzymes, like chymase.87
figure 2. Developmental stages of pregnancy. This fi gure shows developmental stages of pregnancy in 
humans and rats, according to Carnegie staging as this can be applied to all vertebrates to compare the 
timing of development of diff erent organs in diff erent species. To reach the end of embryonic development 
(Carnegie stage 23) takes 17.5 days in rats and 58 days in humans. In pink highlighted, the period of ERA 
administration from day 1 – day 17.5, which is during all Carnegie stages in rat pregnancies as discussed 
in this paper. In green the time point when patients should be treated with ERAs is shown: 82 and 49 days 
after the Carnegie - and human embryonic stages respectively, much later when compared to the treat-
ment period in animal studies.
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Another important point of concern when considering ERAs for treatment of PE are 
their possible side effects. Some of the reported side effects are similar to PE symptoms, 
such as edema, headache, and elevated liver enzymes. When these PE symptoms occur 
during ERA treatment it will be very challenging to distinguish side effects from disease 
exacerbation. Another common side effect is anemia, and sometimes thrombocytopenia 
is seen. Therefore, plasma levels of hemoglobin, thrombocytes and liver enzymes should 
be closely monitored during treatment. Women with elevated liver enzymes, severe 
anemia or thrombocytopenia should not be started on ERA treatment. Furthermore, in 
case these side effects occur treatment might have to be discontinued in some cases.
cliNicAl imPlicATioNs AND PeRsPecTiVes
Given the increase in ET-1 during PE, targeting the ET-1 pathway in severe, early onset 
PE could potentially be a favorable new treatment strategy to improve maternal, fetal 
and neonatal outcomes when started after the completion of organogenesis. Espe-
cially since not all anti-hypertensive drugs can be used during pregnancy, due to either 
teratogenic effects or the lack of PE prevention. Recently, a randomized controlled trial 
studying the effects of sildenafil, a phosphodiesterase-5 inhibitor, versus placebo on 
pregnancy outcome in severe FGR has been halted, since sildenafil did not show benefi-
cial effects and there were more neonatal complications in the treatment group in one 
of the cohorts.88 Although no teratogenic effects of ERAs during late pregnancy have 
been reported in the limited number of human case reports, further research is needed 
to evaluate the pharmacokinetics and safety of these drugs in pregnancy, preferably 
by performing third trimester toxicology studies in animals with a longer gestation, 
like non-human primates. This is relevant because many of the previous experimental 
studies have used extremely high dosages, sometimes reaching 300 mg/kg/day, while 
patients with PAH are being treated with a maximum of 250 mg per day, i.e. 100 times 
less in a patient with an average weight of 70 kg. In addition, something that can be 
done relatively easy at this moment is to investigate the trans-placental transfer of the 
two clinically available ERAs that are FDA-approved, making use of the ex vivo human 
dual-sided perfusion model with cotyledons from both uncomplicated and PE pregnan-
cies. Furthermore, the perfusion model might provide information on the passage (or 
lack thereof ) of ERAs bound to peptides preventing them from crossing the placenta. 
At a later stage, we suggest that proof of principles studies should be performed in pa-
tients with very early onset (< 24 weeks of gestation) severe PE, in whom termination of 
pregnancy is considered, because of the severity of the maternal and/or fetal condition. 
In this setting, outcome parameters would be maternal blood pressure, proteinuria, 
and the disappearance of HELLP symptoms. In patients who are untreated we would 
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start with ERA, while in patients who already use antihypertensive treatment we would 
continue this medication and add an ERA, guided by the effect on blood pressure. In 
cases where blood pressure drops too much we would stop or decrease the already used 
antihypertensive medication.
In conclusion, the findings of this review support the idea that ERA treatment for severe 
early onset PE might be an option if applied later in pregnancy, when organogenesis is 
completed to avoid teratogenic risks, with close monitoring of closure of the ductus 
arteriosus. However, third trimester toxicology studies are warranted to evaluate drug 
safety and it remains to be established whether ERA treatment is effective for alleviat-
ing maternal symptoms, allowing pregnancy prolongation without leading to adverse 
neonatal outcomes.
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figure s1. Flowchart of the systematic search in literature. A systematic search in fi ve diff erent databases 
was performed on 18 February 2019 and yielded 2031 articles. After de-duplication 1363 articles were left 
for screening. Based on title/abstract relevance 1246 articles were excluded and of the remaining 117 full 
text was screened. Finally, 18 articles describing 39 cases of ERA use during human pregnancy were found 
and included in this review.
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AbsTRAcT
Increasing evidence suggests a role for the endothelin (ET) system in preeclampsia (PE). 
Hence, blocking this system with endothelin receptor antagonists (ERAs) could be a 
therapeutic strategy. Yet, clinical studies are lacking due to possible teratogenic effects 
of ERAs. In this study we investigated the placental transfer of ERAs and their effect on 
ET-1-mediated vasoconstriction. Term placentas were dually perfused with the selective 
ET type A receptor (ETAR) antagonists sitaxentan and ambrisentan or the non-selective 
ETAR/ETBR antagonist macitentan and subsequently exposed to ET-1 in the fetal circula-
tion. ET-1 concentration-response curves after incubation with sitaxentan, ambrisentan, 
macitentan or the selective ETBR antagonist BQ-788 were also constructed in isolated 
chorionic plate arteries using wire-myography, and gene expression of the ET-system 
was quantified in healthy and early onset PE placentas. At steady state, the mean fetal-
to-maternal transfer ratios were 0.32±0.05 for sitaxentan, 0.21±0.02 for ambrisentan, 
and 0.05±0.01 for macitentan. Except for BQ-788, all ERAs lowered the response to ET-1, 
both in the perfused cotyledon and isolated chorionic plate arteries. Placental gene 
expression of ECE-1, ETAR and ETBR were comparable in healthy and PE placentas, while 
ET-1 expression was higher in PE. Our study is the first to show direct transfer of ERAs 
across the term human placenta. Furthermore, ETAR exclusively mediates ET-1-induced 
constriction in the fetoplacental vasculature. Given its limited transfer, macitentan could 
be considered as potential PE therapy. Extending knowledge on placental transfer to 





Preeclampsia (PE) is a severe placenta-related pregnancy complication, characterized by 
de novo hypertension after 20 weeks of gestation, accompanied by evidence of maternal 
organ damage (e.g. proteinuria, elevated liver enzymes, pulmonary - or cerebral edema) 
and/or fetal growth restriction.1 Besides increasing the risk of maternal and fetal morbid-
ity and mortality during pregnancy, PE is associated with maternal and offspring health 
problems in later life.2, 3 Over the last years, increased activity of the endothelin (ET) 
system has been recognized as a key factor in the pathogenesis of PE.4 ET is a family of 
three potent vasoconstrictors (i.e. ET-1, -2 and -3), with ET-1 being the most abundantly 
synthesized by endothelial cells and syncytiotrophoblasts of the placenta.5 Binding of 
ET-1 to the ET type A receptor (ETAR) or ET type B receptor (ETBR) on vascular smooth 
muscle cells leads to vasoconstriction and cell proliferation. In contrast, activation of 
ETBR on endothelial cells stimulates vasodilation through the release of nitric oxide 
and prostacyclin.6 It has been previously shown that ET-1 plasma levels are increased in 
women with PE compared to healthy pregnancy, and that ET-1 is an independent predic-
tor of proteinuria in PE.7, 8 Also, a decrease in ETBR expression in vascular endothelial cells 
has been found in women with PE.9 Similarly, PE animal models have shown a significant 
increase in the expression of the precursor peptide prepro-ET-1, likely leading to higher 
levels of ET-1, causing hypertension and renal dysfunction.10-12 Blocking the effect of 
ET-1 with endothelin receptor antagonists (ERAs) alleviated maternal PE symptoms and 
improved fetal growth in animal studies.13-16 However, developmental toxicity studies 
have also shown serious teratogenic effects, mainly craniofacial and cardiovascular 
malformations, in offspring of animals treated with ERAs during pregnancy, arguing 
against clinical trials in pregnant women.17-19 It should be noted that teratogenic effects 
might be species-specific – indeed, certain drugs (e.g. corticosteroids) are known to be 
teratogenic in mice and rats but safe in humans.20 Moreover, 39 cases of ERA use during 
pregnancy in women with pulmonary hypertension have been presented in the litera-
ture, and none of these reported teratogenic effects.21 This raises the possibility that ERA 
treatment might still be an option for severe PE if applied later in pregnancy, thereby 
avoiding potential teratogenic effects. Since knowledge is lacking regarding the use of 
ERAs in human pregnancy, the aim of this study was to investigate the placental transfer 
of different ERAs making use of an ex vivo placental perfusion model, and to evaluate 
the effect of ERAs on ET-1 mediated vasoconstriction in the fetoplacental vasculature, 
comparing both healthy and PE placentas.
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All supporting data are available within the article and in the Data Supplement.
Patients and setting
Placentas of women with uncomplicated singleton pregnancies who underwent an 
elective cesarean section, or women with severe early onset PE (diagnosis ≤ 34 weeks 
of gestation22) were collected immediately after delivery at the Erasmus Medical Center, 
Rotterdam, the Netherlands. Baseline characteristics were obtained from the digital 
medical files. The study was exempted from approval by the local institutional Medical 
Ethics Committee according to the Dutch Medical Research with Human Subjects Law 
(MEC-2016-418 and MEC-2017-418). All women who donated their placenta provided 
written informed consent for the use of their placenta and personal data regarding their 
pregnancy.
Perfusion experiments
The perfusion model used in the current study was previously described extensively by 
Hitzerd et al.23 Perfusion experiments were conducted in healthy placentas only, given 
the extreme difficulty to successfully perfuse a preterm (PE) placenta.23 In brief, maternal 
and fetal perfusion media consisted of Krebs-Henseleit buffer at 37ºC, supplemented 
with heparin (final concentration; 2500 IU/L) and aerated with 95% O2 - 5% CO2. The 
fetal circulation (closed-circuit; flow rate 6 mL/min) was established by cannulating the 
chorionic artery and corresponding vein of an intact cotyledon. Maternal circulation 
(closed-circuit; flow rate 12 mL/min) was created by placing four blunt cannulas in the 
intervillous space. At t=0, at a concentration of ~10x Cmax, either one of the selective 
ETAR antagonists sitaxentan (100 mg/L,24 a kind gift of dr. M. Iglarz, Actelion, Allschwill, 
Switzerland) or ambrisentan (10 mg/L,25 Sigma-Aldrich Chemie, Schnelldorf, Germany), 
or the non-selective antagonist macitentan (2 mg/L,26 a kind gift of dr. M. Iglarz) was 
added to the maternal circulation. Such high concentrations were chosen to prevent 
underestimation of transfer. To prove good overlap between maternal and fetal circu-
lations antipyrine (100 mg/L) was also added to the maternal buffer. FITC-dextran (40 
kDa, 36 mg/L) in the fetal circulation was used as a marker of integrity of the capillary 
bed. Samples of the maternal and fetal circulations were taken at eight set time points, 
and immediately stored at -80°C. After 180 min of perfusion, ET-1 (0.1-100 nmol/L) was 
added to the fetal circulation to construct a concentration-response curve (CRC). These 
concentrations are higher than the ET-1 concentrations observed in blood,7 in agree-
ment with the concept that ET-1 normally is synthesized locally, resulting in abluminal 
concentrations that are far above those in the circulation. An ET-1 CRC was also per-
formed in placentas that were perfused for the same duration without an ERA, to serve 
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as controls. Changes in pressure were measured by pressure transducers and recorded 
using acquisition software (Biopac, Goleta, CA, USA).
Quality control
An experiment was considered successful when the fetal-to-maternal (F/M) ratio of an-
tipyrine was >0.75 and the maternal-to-fetal (M/F) ratio of FITC-dextran <0.03 at t=180.
Analysis of antipyrine and fiTc-dextran
For measuring antipyrine concentration, samples were first deproteinized with perchlo-
ric acid 6%, and subsequently a mixture of 0.2 mg/mL NaNO2 and 0.6% H2SO4 was added 
in a 1:1 ratio to form nitroantipyrine. Absorption was measured at 350 nm using ultravio-
let–visible spectroscopy (Shimadzu UV-1800). For analysis of FITC-dextran, fluorescence 
was measured using a Multiwell Plate Reader (Victor X4 Perkin Elmer, excitation/emis-
sion 485/519 respectively).
lc-ms analysis of endothelin receptor antagonists
Ambrisentan, macitentan and sitaxentan concentrations were measured in the perfus-
ate by using UPLC-MS/MS. The method was validated in a linear range of 20.28 - 2028 
μg/L for ambrisentan, 4.052 - 405.2 μg/L for macitentan and 205.4 – 10270 μg/L for 
sitaxentan. The method was successfully validated according to FDA guidelines and is 
used in our pharmacy laboratory for research and patient analysis.
wire-myography experiments
Second order branches of chorionic plate arteries of both healthy and PE placentas 
were cut into segments of 2 mm and mounted in 6-mL organ baths (Danish Myograph 
Technology, Aarhus, Denmark), filled with Krebs-Henseleit buffer at 37°C and aerated 
with 95% O2 – 5% CO2. Tension was normalized to 90% of the estimated diameter at 100 
mmHg effective transmural pressure. Maximum contractile responses were determined 
using 100 mmol/L potassium chloride (KCl). After washout of the KCl, vessel segments 
were incubated with sitaxentan (200 µmol/L), macitentan (3 µmol/L), ambrisentan (10 
µmol/L) or the selective ETBR antagonist BQ-788 (10 nmol/L, Sigma-Aldrich Chemie, 
Schnelldorf, Germany). For sitaxentan, macitentan and ambrisentan the same concen-
trations were used as in the perfusion experiments (~10x Cmax) and the concentration 
of BQ-788 was based on previous experiments with this antagonist.27 Vessel segments 
without any inhibitor were used as control. After an incubation period of 30 minutes, 
CRCs to ET-1 (0.1-100 nmol/L) were constructed.
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Quantitative PcR (qPcR) Analysis
Gene expression levels of ET-1 (EDN1), ETAR, ETBR and endothelin converting enzyme-1 
(ECE-1) were measured with qPCR analysis. ECE-1 is an enzyme involved in converting 
the precursor ET-1 gene into biologically active ET-1.6 After delivery of the placenta, 
pieces of placental tissue were immediately dissected from both the decidual (‘mater-
nal’) and the amniotic (‘fetal’) side of the placenta, and were subsequently snap frozen 
in liquid nitrogen. As described previously by Hitzerd et al.,23 small tissue pieces were ho-
mogenized in RLT lysis buffer (Qiagen, Venlo, the Netherlands) with β-mercaptoethanol 
for RNA extraction. Total RNA was extracted (RNeasy Fibrous Tissue Mini Kit, Qiagen) 
after proteinase K treatment (Invitrogen, Breda, the Netherlands) for ten minutes at 
55°C. RNA was eluted in RNase free water and concentration and purity were assessed 
with a NanoDrop1000 Spectrophotometer (Thermo Fisher Scientific, Bleiswijk, the Neth-
erlands). Complimentary DNA (cDNA) was synthesized from 0.5 μg RNA template with 
the SensiFast cDNA Synthesis Kit (Bioline, London, UK) according to the manufacturer’s 
instructions. This cDNA was used for qPCR using the SYBR Green qPCR Kit (Bioline, Lon-
don, UK) and specific primer pairs on a CFX-96 light cycler (Bio-Rad, Hercules, CA, USA). 
The primer pairs used in this article are listed in Table S1. Target genes were normalized 
against the reference genes β-actin and Peptidylprolyl Isomerase A (PPIA) and relative 
gene expression was calculated by the ΔΔCt method. qPCR was performed according to 
the following conditions: initial denaturation at 95°C for eight min and 30 s, followed by 
40 cycles comprising 15 s at 95°C, and one min at 60°C.
statistical analysis
Data are presented as mean ± SEM for normally distributed data or median (interquartile 
range) in case of skewed distributions. Statistical analysis was performed with GraphPad 
Prism (version 5, La Jolla, CA, USA) and SPSS (version 21, SPSS Chicago, IL, USA) on 
Windows. To compare groups the Student’s t test or Mann-Whitney U test (in case of 
non-normally distributed data) were used. For the comparison of continuous variables 
between more than two groups, one-way ANOVA or Kruskall-Wallis test (in case of 
skewed distributions) was applied, with a Dunnet or Bonferroni correction for multiple 
testing. A P-value of <0.05 was considered to be statistically significant.
ResulTs
Placental transfer of endothelin receptor antagonists
Forty-three women were initially included in the study. Twenty-three out of 43 coty-
ledons met the quality control criteria and were included in the analysis, leading to a 
success percentage of 53%, which is comparable to previous research from our lab.23 
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Maternal characteristics as well as clinical characteristics of the placentas and offspring 
are shown in Table 1. There were no significant differences between groups. At t=180 
the mean F/M ratio for antipyrine was 0.92±0.01, indicating adequate overlap between 
fetal and maternal circulations (Figure S1). shows the placental transfer of sitaxentan, 
ambrisentan and macitentan. Only in the case of macitentan, the t=0 level was lower 
than its level thereafter, suggesting that the distribution across the maternal reservoir 
occurred somewhat slower than that of sitaxentan and ambrisentan. After 180 min of 
perfusion the F/M ratio for sitaxentan (n=5) was 0.32±0.05 (Figure 1A). At this steady 
state condition, only 33±4% of the total added sitaxentan concentration was recovered 
in the fetal and maternal circulations together. Adherence experiments (running the 
experiment without a placenta) showed only ~9% tube adherence, indicating that ~60% 
of the added sitaxentan had accumulated in the placental tissue. For ambrisentan (n=5), 
the F/M ratio was 0.21±0.02 and 80±6% of the starting concentration was retrieved 
after 180 min of perfusion (Figure 1B). No tubal adherence was observed. Only minimal 
amounts of macitentan (n=5) passed the placental barrier (F/M ratio 0.05±0.01), result-
ing in a fetal concentration of around 150 nmol/L (5%) after three hours of perfusion. 
Most of the added concentration (86±6%) was still detectable in the maternal and fetal 
circulations at t=180, therefore no tissue accumulation occurred (Figure 1C).
Since no albumin was used in the current setup, corrections for protein binding were 
applied by adjusting the F/M ratios following the method of Hill and Abramson (for 
the exact calculation see Supplemental Methods).28, 29 For this method pKa values of 
the drugs were subtracted from literature.30-32 No major changes were seen in the F/M 
ratios of sitaxentan, ambrisentan and macitentan (adjusted ratios 0.37, 0.25 and 0.06, 
respectively). The F/M ratios for all drugs are summarized in Table S2.
Placental vascular reactivity
After 180 min of perfusion, placentas were exposed to increasing concentrations of ET-1 
in the fetal circulation to evaluate the effect of maternally applied ERAs on the fetopla-
cental vasculature. There was no significant difference in baseline pressure at start of 
the ET-1 curve between controls and ERA-exposed placentas (Figure 2A). After adding 
the highest concentration of ET-1 (100 nmol/L) to the fetal side of control placentas, 
the pressure was increased to 181±16 mm Hg (Figure 2A and 2B). Placentas that had 
been exposed maternally to sitaxentan, ambrisentan and macitentan all showed attenu-
ated pressure increases to fetally applied ET-1 (pressures of 76±19, 88±32 and 120±15 
mm Hg, respectively), which were significant for sitaxentan (P=0.002) and ambrisentan 
(P=0.01), but not macitentan (P=0.09, Figure 2A and 2B).
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figure 1. Placental transfer of sitaxentan (A), ambrisentan (B) and macitentan (C). Measured concentrations 
in the maternal (closed circles) and fetal (open circles) circulations are expressed as µg/L, n=5 per group. 
Panel D shows the fetal-to-maternal (F/M) transfer ratios over time.
Table 1. Clinical characteristics of perfused placentas.
characteristic sitaxentan (n=5) Ambrisentan (n=5) macitentan (n=5) control (n=8)
Maternal age (y) 34 (33-37) 30 (25-37) 34 (28-35) 35 (32-36)
Parity 1 (1-2) 1 (0.5-1) 1 (1-3) 1 (1-2)
Western ethnicity (n) 2 2 3 4
Body mass index (kg/
m2)
26.0 (21.2-34.0) 28.0 (20.8-32.5) 21.8 (20.8-39.9) 29.4 (22.5-34.6)
Smoking (n) 0 0 0 1
Highest DBP (mm Hg) 80 (73-83) 75 (65-81) 80 (65-80) 78 (71-83)
Gestational age 
(weeks)
39 (39-40) 39 (39-39) 39 (39-39) 39 (38-39)
Fetal sex (M/F) 2/3 1/4 2/3 2/6
Birth weight (g) 3620 (3363-4078) 3500 (3258-4085) 3360 (3320-3828) 3428 (3153-3610)
Birth weight (centile) 63 (55-95) 68 (44-94) 52 (47-87) 59 (43-63)
Placental weight (g) 645 (597-790) 618 (543-747) 773 (616-827) 631 (610-689)
Data are presented as median (interquartile range). There were no significant differences between groups 




Chorionic plate arteries of 11 healthy and five PE placentas were included in these ex-
periments. The clinical characteristics of these placentas are shown in Table 2 and the 
results of these experiments are shown in Figure 3. At its highest concentration (100 
nmol/L), ET-1 elicited a constriction corresponding with 132±9% of KCl constriction 
in control segments of healthy placentas (Figure 3A). Vessel segments that had been 
pre-incubated with sitaxentan, ambrisentan and macitentan all displayed a significant 
decreased response to 100 nmol/L (response 1±1, 2±1 and 10±3% of KCl constriction, re-
spectively, P<0.0001 for all), whereas incubation with BQ-788 did not alter the response 
to 100 nmol/L ET-1 (130±14% of KCl constriction). Data on vessel segments that had 
been pre-incubated with different concentrations of macitentan are shown in Figure S2, 
and confirm the concentration-dependency of its blocking effect. Vessel segments of PE 
placentas displayed similar ET-1 responses as those of healthy placentas (Figure 3B). The 
effect of 100 nmol/L ET-1 in control segments was 112±38% of KCl constriction, compared 
to 1±1, 1±1 and 6±4% of KCl constriction for segments pre-incubated with sitaxentan, 
ambrisentan and macitentan, respectively (P<0.01 for all). There were no differences in 
the response to 100 nmol/L ET-1 between healthy and PE placentas (Figure 3C).
Gene expression
Gene expression of ET-1 (EDN1), ETAR and ETBR, but not ECE-1, was lower on the amniotic 
side of the placenta compared to the decidual side, both in healthy and PE placentas 
(Figure 4). In PE placentas, there was increased gene expression of ET-1 on both the 
decidual and amniotic side (P=0.02 and 0.06, respectively). No changes in the expression 


























































figure 2. Panel A shows the concentration response curves for fetally applied endothelin-1 (ET-1) in the 
perfused cotyledon without (control, squares) or with prior exposure of the maternal circulation to the 
endothelin receptor antagonists sitaxentan (circles), macitentan (triangles) or ambrisentan (diamonds). The 
effect achieved at 100 nmol/L ET-1 is shown in panel B. Responses are expressed as mean±SEM of n=5-8. 
*P<0.05, **P<0.01 vs. control (one-way ANOVA with Dunnett post-hoc evaluation).
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DiscussioN
This study is the first to show direct transfer of ERAs across the human placental bar-
rier. Importantly, the transfer of macitentan was limited (F/M ratio <0.1), while that of 
sitaxentan and ambrisentan was substantial although no accumulation occurred (F/M 
ratio <1.0). In line with this, only sitaxentan and ambrisentan (when applied maternally) 
significantly reduced the contractile effect of fetally applied ET-1 in the cotyledon setup. 
Yet, all antagonists, when applied at a concentration corresponding with 10 times Cmax 
to isolated chorionic plate arteries, were capable of fully blocking the contractile ef-
fect of ET-1. In contrast, the selective ETBR antagonist BQ-788 did not affect the ET-1 
response, arguing against a role for ETBR. No differences were observed in the vascular 
Table 2. Clinical characteristics of placentas used for wire-myography experiments.
characteristic healthy (n=11) Pe (n=5)
Maternal age (y) 32 (28-34) 29 (27-32)
Parity 1 (1-3) 0 (0-0.5)*
Western ethnicity (n) 6 4
Body mass index (kg/m2) 25.7 (22.3-30.5) 24.9 (19.5-25.7)
Smoking (n) 0 0
Highest DBP (mm Hg) 80 (75-80) 103 (98-111)*
Gestational age (weeks) 39 (39-40) 30 (28-31)*
Fetal sex (M/F) 5/6 3/2
Birth weight (g) 3410 (3200-3645) 920 (708-1281)*
Birth weight (centile) 52 (43-68) 1 (0.3-2.3)*
Placental weight (g) 654 (610-769) 285 (243-395)*
Data are presented as median (interquartile range). *P<0.05, Mann-Whitney U test. DBP = diastolic blood 
pressure; F = female; M = male; PE = preeclampsia.












































































figure 3. Vascular responses of isolated chorionic plate arteries of healthy (A) and preeclamptic (B) placen-
tas to endothelin-1 (ET-1) in the absence (control, squares) or presence of sitaxentan (circles), macitentan 
(triangles), ambrisentan (diamonds) or BQ-788 (cross marks). Panel C shows the response to 100 nmol/L 
ET-1 of healthy (closed bars) compared to preeclamptic (open bars) placentas. Responses are expressed 




response to ET-1 between healthy and PE placentas. Gene expression of ET-1 and its 
receptors was lower on the amniotic side of the placenta compared to the decidual side. 
Furthermore, PE placentas showed an increased expression of ET-1, while no changes in 
the expression of ETAR, ETBR and ECE-1 were found.
A significant role for the ET-system has been implicated in the pathogenesis of PE, 
contributing to hypertension, endothelial- and renal dysfunction with proteinuria.7, 33 
Aside from increased circulating ET-1 levels in preeclamptic women, placental ET-1 lev-
els are similarly elevated, which may account for the increased placental vascular resis-
tance in vivo.8 Thus, administration of ERAs may prove beneficial through alleviation of 
maternal symptoms and by improving vascular resistance in the placenta. Interestingly, 
we and others found no difference in ET-1 induced vasoconstriction between chorionic 
plate arteries of healthy and PE placentas, indicating that there is no altered response 
to ET-1 during PE. Moreover, while administration of an ERA significantly attenuated 
ET-1 induced vasoconstriction, this effect was not different between healthy or PE pla-
centas. Taken together, these data, obtained in two different models (the perfusion 








































































figure 4. Gene expression of endothelin-1 (A), endothelin-converting enzyme-1 (B), endothelin-receptor 
type A (C) and endothelin-receptor type B (D) in healthy and preeclamptic placentas (n=12 per group). 
Expression was measured on both the decidual side (black bars) and amniotic side (white bars) of the pla-
centa. Data are expressed as fold change of control samples from the decidual side. *P<0.05 (unpaired or 
paired Student’s t-test where appropriate).
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setup, involving larger second-order arteries) imply that elevated ET-1 levels, but not 
an enhanced response, accounts for the increased placental vascular resistance during 
PE. Indeed, we observed elevated expression of the ET-1 gene in PE placentas, while 
ETAR and ETBR expression did not differ between healthy and PE placentas. In a previous 
study by Benoit et al. blockade of ETAR, but not ETBR reduced vasoconstriction in healthy 
placentas when they were exposed to extracts from PE placentas.34 In the current study, 
we observed similar results regarding exposure to ET-1, indicating that ET-1-induced 
vasoconstriction in the fetoplacental vasculature is exclusively mediated by ETAR. It 
should be mentioned however, that we were not able to extend these studies towards 
uterine spiral arteries, since we did not obtain myometrial biopsies.
Given the observed fetotoxicity of ERAs in developmental toxicity studies in animals, 
no clinical trials in pregnant women have been performed with these drugs, and 
therefore knowledge regarding the placental transfer of ERAs in humans is virtually 
non-existent. However, the placenta is the most species-specific organ, making direct 
translation of the results of animal studies to humans challenging.35 As treatment for 
PE is generally started in the second or third trimester, i.e. when fetal organogenesis 
has already been completed, one should not disregard ERAs as potential treatment for 
PE. Moreover, sporadic cases of pregnant women with pulmonary arterial hypertension 
(PAH) using ERAs in the second or third trimester did not report an increased incidence of 
fetal birth defects.21 Importantly, it should be noted that sitaxentan has been withdrawn 
from therapeutic use in 2010 due to drug-induced hepatotoxicity, while ambrisentan 
and macitentan are both registered for the treatment of PAH.
A striking finding of our study is the limited transfer observed of the non-selective 
antagonist macitentan. Whereas all three ERAs used in this study have low molecular 
weights (<600 g/mol) and lipophilic properties, which in general would favor placental 
transfer,36 macitentan is characterized by sustained receptor binding and enhanced 
tissue penetration.37 However, this does not seem to explain the limited transfer, since 
86% of the starting concentration was recovered at the end of an experiment in the fetal 
and maternal circulations together. Although the absence or presence of albumin in the 
perfusion system should not affect the F/M ratio at steady state,38 to better predict in 
vivo fetal exposure to ERAs we also corrected the results of the current study for protein 
binding. Yet, this did not alter the outcome of the study, nor did lowering the fetal pH 
to 6.9.
Despite its almost absent placental transfer, the fetal vascular bed of the macitentan-
perfused placentas did display a (non-significant) decrease in contractile response 
to ET-1 of approximately 34%. Here it should be noted that we applied a maternal 
macitentan concentration of 3 µmol/L, resulting in a fetal concentration of around 150 
nmol/L (5%) after three hours of perfusion. Wire-myography experiments with chorionic 
plate arteries in which different concentrations of macitentan were used, revealed that 
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such a reduction would indeed be expected at 150 nmol/L (Figure S2). The approved 
macitentan dosage for PAH treatment is 10 mg per day,39 and with this dosage the Cmax 
in plasma of (non-pregnant) Caucasian women is 234 ng/mL, or, at a MW of 588, 0.4 
µmol/L.26 If indeed 5% of this concentration would reach the fetus (~20 nmol/L), it can-
not be excluded that a modest degree of blockade occurs in the fetus. Blocking the 
ET-system in the fetus could lead to undesirable effects, since ET-1 plays an important 
role in the maintenance of high vascular resistance crucial for fetal lung development.40 
The ETAR is abundantly expressed in fetal lungs during pre- and postnatal periods, and 
lung maturation is not completed at the end of third trimester.41 On the other hand, ETAR 
blockade could prove beneficial, since elevated serum ET-1 levels are observed in babies 
that are born from PE pregnancies.42 Moreover, one of the standard treatments for neo-
nates with pulmonary hypertension is the non-selective ERA bosentan.43, 44 Although 
no long-term follow-up studies have been performed, short-term follow-up showed no 
adverse effects on lung- and brain development in these children.43 Another point of 
concern could be patency of the ductus arteriosus after birth. However, the evidence 
regarding the effect of ERAs on closure of the ductus is conflicting. Although it has been 
shown that oxygen-triggered ET-1 release regulates closure of the ductus through bind-
ing to ETAR on vascular smooth muscle cells,45 ETAR blockade does not seem to prevent 
the ductus from closing.46, 47
PeRsPecTiVes
Given its key role in the pathogenesis of PE, targeting the ET-system would be an in-
teresting approach in the treatment of this severe placenta-related disease. This study 
was the first to evaluate transfer of ERAs across the human placenta. Since macitentan 
only displayed very limited placental transfer, and is already registered for treatment of 
PAH, it could be a promising drug to further investigate for PE treatment. Expanding this 
knowledge to early onset PE placentas is needed to further evaluate whether it can be 
safely applied in pregnancy. Furthermore, third-trimester toxicology studies in animals 
with a longer gestation than rodents are warranted. Subsequently, as described previ-
ously,21 we would suggest a proof of principle study in women with severe early onset 
PE (< 24 weeks of gestation), when medically indicated termination of pregnancy is 
considered because of disease severity, to evaluate the effect on maternal PE symptoms 
and neonatal outcome.
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Albumin was not added to the experimental system, since it is very difficult to mimic 
exact physiological concentrations. Although the F/M ratio of the free drug concentra-
tion at steady state should not be affected by the presence or absence of albumin,1, 2 the 
obtained F/M ratios were adjusted for protein binding to estimate the fetal exposure as 






% unboundF 1+10pKa – pH(M) CLFM + CLf
In this formula the differences in protein binding between both circulations are taken 
into account, as the % unboundF and the % unboundM represent the free drug concentra-
tions in the maternal and fetal circulations, respectively. pKa is the acid-base dissociation 
constant of the drug, and pH(F) and pH(M) are the pH values of fetal (7.35) and maternal 
(7.40) blood, respectively. The last part of the equation stands for drug clearance (MF = 
maternal-to-fetal, FM = fetal-to-maternal and f = fetus). In the closed perfusion setup, 
CLMF/CLFM can be taken as the F/M ratio at steady state. The assumption was made that 
clearance by the fetus was negligible. Because ERAs are strictly contraindicated, there 
is no available data regarding the % protein binding in plasma of pregnant women 
and their fetus. However, it is known that in non-pregnant adults all three ERAs used in 
the current study bind for ~99% to albumin. With this information, protein binding in 
maternal and fetal plasma could be estimated using the method of Hill and Abramson:1
% unbound = 100 -
100 x (B/F)
(B/F) + 1
B/F is the ratio between bound (B) and free (F) drug concentrations. This can be cal-
culated for the maternal and fetal circulations, using the known B/F of non-pregnant 
adults and the plasma protein ratios for albumin (fetal:non-pregnant adult ratio is 0.866 
and the maternal:non-pregnant adult ratio is 0.733.1
(B/F)F or M = (B/F) non-pregnant x (Plasma albumin ratio)F or M
All three ERAs have a B/F of 99 in non-pregnant adults. From this we calculated the B/F 
in the fetal (85.7) and maternal (72.6) circulations, leading to unbound fractions of 1.2% 
and 1.4%, respectively. The pKa of macitentan is 6.2, of ambrisentan 3.5 and of sitaxentan 
5.0,4-6 leading to corrected F/M ratios of 0.06, 0.25 and 0.37, respectively.
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figure s2. Blocking effect of different macitentan concentrations in chorionic plate arteries. Concentra-
tion-response curves to endothelin (ET)-1 are shown in the absence (control) or presence of different maci-
tentan concentrations (A). Panel B shows the blocking effect of those different concentrations expressed as 
% of maximum contraction to 100 nmol/L ET-1 in control segments.
Table s1. qPCR Primer Sequences.





Table s2. F/M ratios according to different drugs.




Fetal-to-maternal (F/M) ratios are shown for sitaxentan, ambrisentan and macitentan. Adjusted F/M ratio 
indicates correction for protein binding using the method of Hill and Abramson.








































figure s1. Antipyrine transfer. Panel A shows the mean maternal (closed circles) and fetal (open circles) 
concentrations of antipyrine, proving good overlap between both circulations. Panel B shows the mean 
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AbsTRAcT
Objective: To explore the correlation between in vivo placental volumetric parameters 
in the first trimester of pregnancy and ex vivo parameters of fetoplacental vascular 
function after delivery. Methods: In ten singleton physiological pregnancies, placental 
volume (PV) and uteroplacental vascular volume (uPVV) were measured offline in three-
dimensional ultrasound volumes at 7, 9 and 11 weeks gestational age (GA) using Virtual 
Organ AnaLysis and Virtual Reality. Directly postpartum, term placentas were ex vivo 
dually perfused and pressure in the fetoplacental vasculature was measured to calculate 
baseline pressure (pressure after a washout period), pressure increase (pressure after 
a stepwise fetal flow rate increase of 1 mL/min up to 6 mL/min) and flow-mediated 
vasodilation (FMVD; reduction in inflow hydrostatic pressure on the fetal side at 6mL/
min flow rate). Correlations between in vivo and ex vivo parameters were assessed by 
Spearman’s correlation coefficients (R). Results: Throughout the first trimester, PV was 
negatively correlated with pressure increase (Rgrowth=-0.84) and, at 11 weeks GA, also 
positively correlated with FMVD (R=0.89). At 7 weeks GA, uPVV and uPVV/PV ratio were 
negatively correlated with pressure increase (R=-0.58 and R=-0.81, respectively) and 
positively correlated with FMVD (R=0.62 and R=0.90, respectively). Discussion: Mainly 
in the early first trimester, larger placental volumetric parameters are associated with 
lower pressure and more FMVD in the fetoplacental vasculature after delivery. This may 
suggest that larger and/or more vascularized placentas in early pregnancy have better 




Placenta-related pregnancy complications, such as preeclampsia (PE) and fetal growth 
restriction (FGR), are highly prevalent and not only affect fetal development and 
pregnancy outcome, but also future maternal and offspring health.1-3 Most of these 
pregnancy complications originate already in the first trimester of pregnancy.4 Within 
this time window, development of the placental bed takes place, which is characterized 
by remodelling of the uterine spiral arteries, thereby creating a low-resistance circula-
tion. Adequate remodelling is crucial to placental development, subsequently affecting 
embryonic and fetal health.5, 6 After the placental vascular network has been formed in 
early pregnancy, capillary growth continues until delivery, mediated by various growth 
factors. From mid-gestation onwards, there is an exponential growth in vascular volume 
of fetoplacental vessels to accommodate the needs of the growing fetus.7
Non-invasive assessment of in vivo placental development remains challenging, since 
the value of available markers of placental function and development is limited. Most 
commonly, placental function is assessed by the use of derivatives of the placental 
circulation. For example, abnormal uterine artery Doppler waveforms have been related 
to pregnancy complications, such as pregnancy-induced hypertension and PE.8, 9 An 
innovative method to determine placental development resulted from the introduction 
of Virtual Organ Computer-aided AnaLysis (VOCAL), which enables the assessment of 
three-dimensional (3D) placental volume measurements and uteroplacental vasculari-
sation indices (i.e. vascularisation indices, flow indices and vascularisation-flow indices). 
These parameters have all been associated with adverse outcomes, such as miscarriage, 
PE and FGR.10-12 A newly developed technique is Virtual Reality (VR) which can be com-
bined with measurements of 3D power Doppler ultrasound volumes and visualizes the 
placental circulation from early pregnancy onwards, in three dimensions with depth 
perception. As previously demonstrated by Reijnders et al. this technique is feasible and 
reliable for use in the first trimester of pregnancy to measure placental parameters, that 
reflect placental volume and uteroplacental vascularisation of the uterine/maternal side 
(i.e. the placental bed).13
Ex vivo assessment of the fetoplacental vasculature can be performed using dual-
sided placental perfusion, an experimental model to study fetal vascular reactivity of 
a single cotyledon directly after birth. Unlike most other vascular systems, the fetopla-
cental vasculature is not innervated. Local vascular tone and fetal cardiac output are 
the main determinants of blood flow through these vessels, regulated by circulating 
and locally produced hormones and vasoactive compounds.14 Therefore, flow-mediated 
pressure changes in the ex vivo dual-sided perfused cotyledon are a measure of vascular 
resistance in the placenta. Jones et al. have already shown that there is a significant 
correlation between vascular resistance measured in vivo (i.e. umbilical artery Doppler 
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velocimetry at term) and ex vivo placental perfusion.15 However, no study has yet as-
sessed the relation between in vivo parameters of early placental vascular development 
and ex vivo placental vascular perfusion.
Since early non-invasive assessment of placental development is challenging and 
it is unknown whether available markers actually represent placental function later in 
pregnancy, the aim of this study was to explore whether correlations exist between in 
vivo ultrasound parameters of first-trimester placental (vascular) development and ex 
vivo parameters of fetoplacental vascular reactivity at delivery. Not only will this provide 
better insight in the pathophysiology of placental disorders, it could also demonstrate 
the need for earlier evaluation of the placental circulation.
meThoDs
This explorative study was conducted within the Virtual placenta study, embedded in 
the Rotterdam Periconception Cohort (Predict Study), which is an ongoing prospec-
tive cohort study performed at the Department of Obstetrics and Gynecology of the 
Erasmus MC, University Medical Center in Rotterdam, The Netherlands.16 Women who 
participated in the Predict study before 10 weeks gestational age (GA), were also invited 
to participate in the Virtual Placenta study that was carried out between January 2017 
and March 2018. Pregnancies conceived either spontaneously or through assisted re-
production techniques (ART) were eligible. The study protocol has been approved by 
the Erasmus MC Institutional Review Board (MEC 2015-494). All participating women 
and their partners signed written informed consent at enrolment, also on behalf of their 
unborn child. Women were asked for consent to use their placenta for research purposes 
after delivery. Women with multiple pregnancies, (gestational) diabetes, viral infections 
(e.g. HIV) or placental anomalies were not eligible for inclusion in this subset.
study Parameters
Maternal characteristics were obtained from self-reported questionnaires filled out 
upon enrolment. First-trimester body-mass index (BMI) and blood pressure were also 
measured at intake. After delivery, participating women again filled out a questionnaire 
on pregnancy and birth outcomes. The retrieved information was checked with data 
from medical records and delivery reports where available.
ultrasound
Participants underwent serial 3D ultrasound examinations at 7, 9 and 11 weeks GA to ob-
tain volumes encompassing the whole embryo and placenta. Ultrasound examinations 
were performed by experienced sonographers only, using a Voluson E8 or E10 system 
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(GE Medical Systems, Zipf, Austria). In the first trimester, 3D ultrasound examinations 
were performed using a transvaginal 6-12 MHz transducer. Vasculature of the complete 
placenta and embryo was imaged using Power Doppler (PD) US with standardized set-
ting (PD gain ‘-8.0’, pulse repetition frequency (PRF) ‘0.6 kHz’, wall motion filter (WMF) 
‘low1’, quality ‘high’). To minimize artefacts and measurement errors by movement, 
participants were asked to hold their breath for approximately 30 seconds during image 
acquisition. All ultrasound examinations were performed according to international 
guidelines on safe use of Doppler ultrasound in the first trimester of pregnancy (ALARA-
principle) and, as such, total scanning time was kept as low as possible with a maximal 
duration of 30 minutes and a maximal thermal index of 1.3.13, 17-19
offline 3D measurements
Placental volume (PV) measurements were performed with offline specialized VO-
CAL software (4D View, GE Medical System) according to standardized methods, to 
reconstruct the trophoblast (Reus et al., 2013). Uteroplacental vascular volume (uPVV) 
was measured using a VR desktop system (Figure 1). VR enables visualization of a 3D 
volume as a true hologram, which allows for depth perception and thus more optimal 
assessment of the uteroplacental vascularization. The VR desktop is a validated system 
composed of a personal computer using the V-Scope volume rendering application, a 
two-dimensional (2D) monitor which displays the user interface, a 3D monitor to display 
the volume, a tracking system allowing for interaction of the observer with the 3D 
volume, a pair of stereoscopic glasses to enable depth perception and a six-degrees of 
freedom mouse for 3D volume manipulation.20 By thresholding the 8-bit (range 0-255) 
Doppler magnitude data, semi-automatic volume measurements of the uPVV were 
obtained. To enable the most optimal visualization of the uteroplacental vasculature, 
the lower-Doppler threshold level was set at a value of 100, which means that semi-
automatic calculations only color and count by voxels with a Doppler value of 100 or 
higher. First, embryonic structures were removed from the segmentation. Then, the 
difference in echogenicity between the myometrium and placenta was used to erase 
the vessels up to the myometrial-placental border, thereby leaving the maternal vascu-
larization of the uteroplacental bed for volume assessment. Currently it is not possible to 
distinct between the maternal blood space and embryonic vasculature within the uPVV. 
A more detailed description and validation of the methods for uPVV measurements has 
previously been published.13 After VOCAL and VR measurements, uPVV was divided by 
PV to calculate a placental vascular volume ratio (uPVV/PV ratio). Due to limited image 
quality or study inclusion after 7 weeks GA, measurements of PV and uPVV could not be 
performed for all included pregnancies and/or study visits.
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Placental perfusion
The perfusion model used in our study has been previously described in detail by Hitzerd 
et al.21 In short, term placentas were collected immediately after delivery and fetal circula-
tion was established by cannulating a corresponding chorionic artery and vein of an intact 
cotyledon. Fetal flow rate was started at 1 mL/min. When cannulation was successful, the 
cotyledon was cut from the placenta and placed inside the perfusion chamber. Maternal 
circulation (constant flow rate of 12 mL/min) was created by placing four blunt cannulas 
in the intervillous space. Venous outflow was collected in a reservoir underneath the 
cotyledon and run back to the maternal reservoir. Perfusion media consisted of Krebs-
Henseleit buffer, supplemented with heparin (5000 IU, 0.5 mg/L) and aerated with 95% 
O2 – 5% CO2. A placental washout period of approximately 30 minutes was performed 
before starting an experiment. Changes in pressure on the fetal side of the placenta were 
measured by pressure transducers and recorded throughout the experiment using acqui-
sition software (Biopac, Goleta, CA USA). When a stable baseline pressure was reached 
after the washout period, the fetal flow rate was increased stepwise with 1 mL/min, until 
a flow rate of 6 mL/min was reached. After each step a new steady state in pressure was 
awaited before continuing with the next step (Figure 2). The parameters baseline pres-
sure, total pressure increase and flow-mediated vasodilation (FMVD) were used for analy-
sis. Total pressure increase was defined as the difference between baseline at pressure at 
start of the experiment and the new steady state at a flow rate of 6 mL/min. As previously 
described by Jones et al., FMVD is the percentage of reduction in hydrostatic pressure 
on the fetal side as a result of increased flow rate, measured at a flow rate of 6 mL/min.15
figure 1. Visualization of a three-dimensional power Doppler utero-placental vascular volume in Virtual 
Reality. On the left; complete three-dimensional power Doppler vascular volume at 9 weeks of gestation. 
On the right; Using grey values of the utero-placental tissue, a virtual brush allows to erase vascular vox-
els up to the myometrial-placental tissue interface margin, leaving uteroplacental vascular volume (uPVV) 
to be measured by threshold-based segmentation. Lower inserts; two-dimensional power Doppler image 
with complete vasculature in color delineated by dashed white line (left), placental vascularization delin-




Because of skewed distributions of most parameters, data are presented as medians 
(interquartile range). To identify correlations between in vivo and ex vivo measurements, 
Spearman’s rank correlation coefficients (R-values) were used and correlations were 
plotted in scatterplots. To further evaluate these correlations, linear mixed models were 
used to calculate individual slopes for each participant to establish placental growth 
trajectories throughout the first trimester (at 7, 9 and 11 weeks GA). In these models, 
uPVV, PV and the uPVV/PV ratio were transformed using a cubic root. The individual 
slopes were then also correlated with ex vivo parameters using Spearman’s correlation 
coefficients. All analyses were performed using SPSS software (version 21.0; SPSS Inc., 
Chicago, IL, USA) and RStudio Statistics (version 3.5.0, 2018). Correlations >0.5 were 
considered relevant and P-values <0.05 were considered statistically significant.
ResulTs
baseline characteristics
In this explorative study, twelve women were included, of whom ten placentas were suc-
cessfully perfused. Baseline characteristics of these ten women are provided in Table 1. 
Women had a median age of 31.9 years (29.7-37.1), 40% were nulliparous and 90% conceived 
spontaneously. None of the women smoked or used alcohol during pregnancy. In 60% of the 
women, the mode of delivery was an elective caesarean section (two nulliparous – and four 
multiparous women), all because a of breech position and/or previous caesarean section. Two 
women delivered spontaneously and another two women underwent an emergency cae-
sarean because of failure to progress. Median birth weight was 3365 grams (2835-3425) and 
70% of the offspring was male. None of the pregnancies were complicated by PE or any other 
pregnancy complication. All infants were born at term (i.e. >37 weeks GA), and one infant was 
small-for-gestational-age (birth weight below the 10th percentile).22 Median placental weight 
was 395 grams (322-451), and of two placentas, weight was below the 10th percentile.










figure 2. Stepwise increase in fetal flow rate leading to increase in pressure (representative).
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Table 1. Baseline characteristics (n=10).
characteristic
Maternal













BMI, first-trimester (measured) 22.8 (21.7-32.5)
Periconceptional folic acid supplement use 10 (100%)
Median first trimester RR (intake)
Systolic 108.0 (99.0-110.0)
Diastolic 65.0 (60.0-70.0)
Periconceptional smoking 1 (10%)
Periconceptional alcohol use 0 (0%)
At delivery
Gestational age at delivery 38+5 (37+4-39+1)
Mode of delivery
Vaginal 2 (20%)
Elective caesarean 6 (60%)
Emergency caesarean 2 (20%)
Placental weight 395 (322-451)
Placental weight <p10 at birth 2 (20%)
Histology: distal villous hypoplasia 1 (10%)
Neonatal









For the ten included pregnancies, six women had multiple measurements available for 
PV and eight women had multiple measurements available for uPVV. Three women had 
measurements available at all weeks for PV, four women had available measurements 
at all weeks for uPVV. A total of five measurements of PV and uPVV were available at 7 
weeks GA, eight measurements were available of PV and nine of uPVV at 9 weeks GA, 
and five measurements were available of PV and seven of uPVV at 11 weeks GA. Median 
values for in vivo placental measurements per week GA are displayed in Table 2 and 
increased from a median of 3.26 cm3 (0.96-6.40) at 7 weeks GA to 13.36 cm3 (6.27-30.08) 
at 11 weeks GA for uPVV, a median of 20.15 cm3 (12.95-23.90) at 7 weeks GA to 92.76 cm3 
(69.18-125.36) at 11 weeks GA for PV, and a median of 0.16 (0.08-0.23) at 7 weeks GA to 
0.17 (0.10-0.35) at 11 weeks GA for the uPVV/PV ratio.
Placental perfusion
Median gestational age at delivery was 38+5 (37+4-39+1) weeks. Median values for ex vivo 
placental measurements are displayed in Table 3. Median baseline pressure at the start-
ing flow rate of 1 mL/min was 21 mmHg (19-25) mmHg, which increased to 32.5 mmHg 
(23.8-36.0) at 6 mL/min, leading to a total pressure increase of 10.5 mmHg (3.0-13.0) 
(Figure 3a and 3b). Median FMVD at 6 mL/min was 50% (50-100) (Figure 3c).
Table 2. Median and ranges of measurable in-vivo placental volumetric parameters per week GA.
7 weeks GA (n=5) 9 weeks GA (n=9) 11 weeks GA (n=7)
Median IQR Median IQR Median IQR
PV (cm3) 20.15 12.95 - 23.90 44.69 25.57 - 57.25 92.76 69.18 - 125.36
uPVV (cm3) 3.26 0.96 - 6.40 8.80 3.97 - 10.61 13.36 6.27 - 30.08
uPVV/PV ratio 0.16 0.08 - 0.23 0.16 0.14 - 0.33 0.17 0.10 - 0.35
uPVV = uteroplacental vascular volume (in cm3); PV = placental volume (in cm3); uPVV/PV ratio = ratio be-
tween uPVV and PV; IQR = interquartile range.
Table 3. Median and ranges of ex-vivo placental measurements at term.
n=10 median iQR
Pressure at baseline 21.0 19.0 - 25.0
Total pressure increase (mmHg) 10.5 3.0 - 13.0
End pressure (mmHg) 32.5 23.8 - 36.0
FMVD at 6 mL/min 50.0 50.0 - 100.0
FMVD = flow-mediated vasodilation (% pressure reduction from peak to new steady state); IQR = interquar-
tile range.
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correlations
Correlations between in vivo and ex vivo measurements are depicted in Table 4 and Figure 
4. PV was negatively correlated with pressure increase at 7 weeks GA (R=-0.53), 9 weeks 
GA (R=0.74) and 11 weeks GA (R=-0.98). At 11 weeks GA, PV was positively correlated 
with baseline pressure (R=0.62) and FMVD (R=0.89). uPVV was negatively correlated with 
pressure increase (R=-0.58) and positively correlated with FMVD (R=0.62) at 7 weeks GA. 
No correlations between uPVV and ex vivo parameters were observed at 9 and 11 weeks 
GA. The uPVV/PV ratio was negatively correlated with pressure increase (R=-0.81) and 
positively correlated with FMVD (R=0.90) at 7 weeks GA. At 11 weeks GA, a negative 
correlation was observed between the uPVV/PV ratio and FMVD (R=-0.67), although this 
correlation was not statistically significant. When studying the correlations between in 
vivo placental growth throughout the first trimester (i.e. slopes of placental parameters) 
and cross-sectional ex vivo placental parameters, a significantly negative correlation 
was observed between first-trimester PV growth and FMVD (Rgrowth=-0.84) and between 
uPVV/PV ratio and FMVD (Rgrowth=-0.90). Also, relevant positive correlations, although 
not statistically significant, were observed between PV growth and FMVD (Rgrowth=0.50) 
and between uPVV/PV ratio growth and pressure increase (Rgrowth=0.51).
























































figure 3. Ex vivo placental perfusion parameters. 
Panel a shows the steady state fetoplacental 
pressure that was measured after each increase 
of flow rate. Pressure increase was highest after 
the first increase of flow rate from 1 to 2 mL/min 
(panel b). Panel c shows the flow-mediated va-
sodilation (FMVD) per flow rate. Data (n=10) are 
shown as median (interquartile range).
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figure 4. Scatterplots depicting correlations between in vivo and ex vivo placental parameters. This figure 
shows the correlations of the ex vivo parameters measured postpartum and PV (panel a), uPVV (panel b) 
and the uPVV/PV ratio (panel c) at 7 weeks GA (black circles), 9 weeks GA (orange circles) and 11 weeks GA 
(blue circles). FMVD = flow-mediated vasodilation (% reduction in pressure from peak to new steady state); 
PI = pressure increase; PV = placental volume (in cm3); uPVV = uteroplacental vascular volume (in cm3); 
uPVV/PV ratio = ratio between uPVV and PV.
Table 4. Correlations between in-vivo and ex-vivo placental parameters per week GA.
Placental parameter R7weeks R9weeks R11weeks Rgrowth
PV - pressure at baseline -0.05 -0.05 0.62 0.25
- total pressure increase -0.53 -0.74* -0.98* -0.84*
- FMVD at 6mL/min 0.05 -0.04 0.89* 0.50
uPVV - pressure at baseline 0.15 -0.40 0.42 0.03
- total pressure increase -0.58 0.14 0.22 -0.25
- FMVD at 6mL/min 0.62 -0.25 -0.21 0.15
uPVV/PV ratio - pressure at baseline -0.24 -0.01 0.05 -0.15
- total pressure increase -0.81 0.12 0.36 0.51
- FMVD at 6mL/min 0.90* 0.21 -0.67 -0.90*
R= Spearman’s correlation coefficient. Relevant correlations in bold. *Significant at level <0.05.
FMVD = flow-mediated vasodilation (% pressure reduction from peak to new steady state); uPVV = utero-
placental vascular volume (in cm3); PV = placental volume (in cm3); uPVV/PV ratio = ratio between uPVV and 
PV; R = correlation coefficient.
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DiscussioN
The results of this study suggest that, mainly in the early first trimester, larger placental 
volumetric parameters, measured by 3D ultrasound and VR technique, are associated 
with lower pressure and more FMVD in the fetoplacental vasculature after delivery. Cor-
relations between in vivo placental growth throughout the first trimester and ex vivo 
placental parameters were negative for the growth of PV and pressure increase (R=-
0.84), but positive for FMVD (R=0.50) although not statistically significant. In contrast, 
a negative correlation existed between the growth of first-trimester uPVV/PV ratio and 
FMVD (R= -0.90).
To our knowledge, the current study is the first to investigate associations between in 
vivo first-trimester ultrasound parameters of the maternal uteroplacental circulation and 
third-trimester ex vivo perfusion parameters of the fetoplacental circulation. Previously, 
it has been shown by Jones et al. that at term there is a positive correlation between in 
vivo umbilical artery Doppler velocimetry and ex vivo fetoplacental vascular resistance 
in placentas from uncomplicated pregnancies.15 However, one should keep in mind that 
umbilical artery Doppler velocimetry and ex vivo vascular resistance both represent 
the fetal side of the placenta, while our placental parameters reflect the volume and 
vascularization of the uterine/maternal side (i.e. the uteroplacental bed). In line with the 
results of Jones et al., we found a negative correlation between pressure increase at ex 
vivo perfusion and PV (throughout the first trimester) and uPVV (at 7 weeks GA only). 
Furthermore, this corresponds with the positive correlation that was observed between 
PV, uPVV and FMVD. These findings suggest a greater ability of larger placentas to adjust 
to higher pressure by vasodilation, due to a greater compensatory capacity in the form 
of vasodilation. This is contrasted by the finding that the growth trajectory of uPVV/PV 
ratio was positively correlated with pressure increase and negatively with FMVD, which 
suggests that placentas with more vascular development (i.e. more increase of uPVV 
compared to PV throughout the first trimester) demonstrate higher pressure and less 
vasodilation in response to flow. Since PV and uPVV only reflect the maternal part of 
the placental circulation, a possible explanation for this correlation could be that less 
vascularized placentas in the first trimester have been exposed to higher pressure in 
utero and therefore show more pressure increase and less vasodilation ex vivo.
A larger PV at 11 weeks GA was associated with higher baseline pressure in this group 
of uncomplicated pregnancies. In line with this, previous research by our group showed 
that baseline pressure during ex vivo perfusion in placentas of pregnancies complicated 
by early onset PE was significantly lower compared to healthy placentas.21 These placen-
tas were significantly smaller, exposed to higher blood pressure in vivo, and displayed 
altered vascular responsiveness. However, the direct response to flow rate increase was 
not studied. Interestingly, Jones et al. did not find the same positive correlation between 
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in vivo umbilical artery Doppler velocimetry and ex vivo fetoplacental vascular resistance 
in placentas of pregnancies complicated by FGR as in healthy placentas.15 Since smaller 
first-trimester placental volume is associated with the occurrence of FGR and PE,23 it 
would be interesting to study whether the correlations seen in the current study also 
exist in placentas of pregnancies complicated by placental insufficiency (e.g. FGR or PE). 
Only one patient in the current study delivered a small-for-gestational-age infant, there-
fore it was not possible to show a clear correlation with fetal growth, however values 
of this case were not outliers. Comparing histology of the included placentas did not 
provide additional explanations for our results (data not shown). Histological analysis 
was performed according to the Amsterdam criteria24 and included maternal stromal-
vascular lesions, fetal stromal vascular lesions, infectious inflammatory lesions, immune/
idiopathic inflammatory lesions, massive perivillous fibrin(oid) deposition, abnormal 
placental shape or umbilical insertion site, morbidly adherent placentas (accreta), 
meconium-associated changes and increased circulating nucleated red blood cells.
The differences in findings across the increasing gestational ages could be attributed 
to the unplugging of the spiral arteries around 9 weeks gestation. In early gestation, cy-
totrophoblast plugs occlude the spiral arteries, preventing perfusion of the intervillous 
space to safeguard a low-oxygen environment,25 which is needed for vasculogenesis and 
cytotrophoblast proliferation.26 Later in the first trimester, extravillous cytotrophoblast 
cells invade around the spiral arteries, initiating their remodelling and unplugging.27 
This leads to a low-resistance circulation with an increased perfusion capacity and 
reduced blood flow velocity into the intervillous space.28, 29 We hypothesize that these 
vascular modifications impact PV and uPVV measurements and, especially after 9 weeks 
GA, could result in less pressure increase and more FMVD after delivery for larger PV and 
uPVV in the late first trimester. We did not demonstrate such an impact for uPVV in this 
study, but we did observe a negative correlation between PV and pressure increase and 
a positive correlation between PV and FMVD, in particular after 9 weeks GA.
This study is strengthened by the longitudinal data collection, creating a unique data 
set combining patient characteristics with in vivo and ex vivo measurements of the 
placenta. On the other hand, there is a large time gap between our measurements by 
first-trimester ultrasound and perfusion postpartum. Alterations in placental develop-
ment during second- and third trimesters could have impacted our results, since capil-
lary growth continues until delivery to accommodate the growing fetus, resulting in 
an exponential increase in volume of placental vessels in the third trimester.7 Still, it is 
known that failure of the maternal spiral arteries to properly remodel in early pregnancy 
is already associated with higher fetoplacental vascular resistance later in pregnancy.15, 30 
Despite ongoing alterations, the foundation for placental vascular development is es-
tablished in the first trimester, and this knowledge supports the correlations found in 
this study. Further, it remains uncertain whether mode of delivery could have affected 
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vascular resistance. Most placentas in our study were obtained after elective caesarean 
section (70%) and have not been subjected to labour. Only two placentas were delivered 
vaginally and one after emergency caesarean section. There is much debate in literature 
whether mode of delivery affects placental perfusion experiments. On the one hand it 
has been demonstrated that placentas after vaginal delivery show increased oxidative 
stress and inflammatory cytokines on both gene- and protein levels.31 On the other 
hand, multiple studies showed no difference in placental barrier function during ex 
vivo perfusion for delivery mode.32, 33 Lastly, identified correlations should be cautiously 
interpreted due to the small sample size of the study, which also hampered correction 
for multiple testing. Furthermore, such small sample size could lead to bias. However, 
values of patients with characteristics that stood out from the rest (e.g. IVF pregnancy, 
periconceptional smoking, spontaneous delivery), were not outliers. Also, male/female 
differences could introduce bias. Unfortunately only 3 female neonates were included in 
this study which made verification of bias impossible, although they were not outliers. 
A larger sample size would have probably strengthened the identified correlations, but 
since this was an explorative study and ex vivo placental perfusion is a difficult, expand-
ing the group size within a reasonable time frame was not feasible.
In conclusion, we showed that in vivo larger first-trimester PV and uPVV are associated 
with less pressure increase and higher FMVD of the ex vivo fetoplacental vasculature at 
term, suggesting that enhanced adaptive mechanisms after delivery relate to a more 
optimal development of the placenta early in pregnancy. First-trimester evaluation of 
placental volume and vascularization could therefore be of value to predict placental 
function in later pregnancy, thereby providing future opportunities for early preven-
tion as well as treatment of placenta-related pregnancy complications. As a next step 
towards this, future research should focus on validation of these measurements in the 
general population and in placentas from complicated pregnancies (FGR and/or PE).
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The placenta is the most important organ in pregnancy, connecting the fetus to the 
mother. Placenta-related pregnancy complications can affect the health of mother and 
child, both during pregnancy and in later life. Optimal pregnancy outcome for both 
mother and child thus requires close collaboration between obstetrical and neonatal 
care givers. The research described in this thesis is the result of the idea to establish a 
placenta lab and connects these departments.
PlAceNTA ReseARch
The importance of studying the placenta is driven by the fact that approximately 10% 
of pregnancies is complicated by placenta-related disorders.1 Furthermore, up to 85% 
of women will be prescribed medication at one point during pregnancy, that possibly 
crosses the placental barrier and thereby exposes the fetus to exogenous substances.2 
The importance has recently been emphasized even further by the outcome of the 
STRIDER study. In this large international consortium of randomized controlled trials, the 
effect of sildenafil versus placebo on pregnancy outcome in severe fetal growth restric-
tion (FGR) was evaluated.3 Due to an overall lack of beneficial effects and increased neo-
natal morbidity in one of the cohorts, the study was halted prematurely.4-6 Clinical trials 
were started after sildenafil had shown promising results in animal studies, although 
knowledge on the use of this drug in pregnancy was lacking. For example, there was no 
pharmacokinetic model developed for pregnant women, nor were there studies avail-
able on the transfer of sildenafil across the human placenta. Now it seems that placental 
transfer of sildenafil could be higher, and the beneficial effects less evident in preterm 
preeclamptic placentas (chapter 3). This could at least partially explain the futility and 
neonatal toxicity. Therefore, when considering drugs for the treatment of pregnancy 
complications, its placental transfer and effect should be investigated first, preferably 
per trimester of gestation.
The only way to study placental transfer of novel drugs in humans without exposing 
the mother, and thus potentially the fetus, to the risk of toxicity, is the ex vivo placental 
perfusion model. It has not only been proven to be a reliable method to estimate fetal 
drug exposure, but it can also be used for studying transfer and release of hormones, 
amino acids, electrolytes and viruses.7 Since a whole cotyledon is perfused, structural 
integrity and cell-cell organization are maintained, making it the closest resemblance 
of the in vivo situation. Furthermore, it is possible to measure transfer over time and 
tissue accumulation can be assessed. Although it has been shown that this model can 
accurately predict in vivo placental transfer at steady state at term,7 there are some 
limitations. As discussed in chapter 3, perfusion of preterm placentas remains very 
challenging, and determining transfer in the first trimester of pregnancy is not possible. 
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Second, since this is a very specialized technique with intricate equipment, there are 
many inter-laboratory differences. To optimize future placental perfusion studies, proto-
cols need to be standardized between laboratories.
TReATmeNT of PReeclAmPsiA
Currently, the only effective treatment of preeclampsia (PE) is termination of pregnancy, 
often leading to severe preterm birth of the baby. Different antihypertensive drugs, e.g. 
methyldopa and calcium antagonists, have been tested in randomized controlled trials. 
However, they only temporarily stabilize the maternal symptoms of PE, and do not im-
prove hard clinical outcomes such as mortality.8-10 Targeting the generalized endothelial 
dysfunction seems a promising strategy in developing new treatment options for this 
disease (chapter 2).
As discussed in chapter 5, (over)activation of the endothelin (ET) system has emerged 
as an important factor in the pathophysiology of PE. Plasma levels of ET-1 are signifi-
cantly increased in women with PE,11 contributing to the development of hypertension 
and proteinuria.12, 13 These findings led to preclinical studies with endothelin receptor 
antagonists (ERAs) and indeed, in PE animal models, blockade of the ET type A receptor 
(ETAR) attenuated hypertension and proteinuria, and prevented FGR.14-16 Unfortunately, 
developmental toxicity studies showed severe teratogenic effects of both selective 
ETAR and dual ETAR/ETBR blockade, mainly craniofacial and cardiovascular malforma-
tions, arguing against the start of clinical trials.17, 18 However, the placenta is the most 
species-specific organ, making translation of results from animal studies to humans 
complicated.19 Furthermore, in most animal studies ERAs were given before the end of 
the Carnegie stages (i.e. 23 stages of the morphological development of the vertebrate 
embryo). In contrast, in women with PE these drugs could be given after the comple-
tion of embryogenesis. The fact that evaluation of human cases of ERA exposure during 
pregnancy did not show an increased incidence of fetal congenital malformations 
(chapter 5), opens the door for the possibility of treating severe PE with ERAs. Future 
research should focus on evaluation of pharmacokinetics and safety during pregnancy, 
first by performing second/third trimester toxicology studies in animals with a longer 
gestation, for example non-human primates, and with clinically relevant dosages. In 
chapter 6 we showed that only a very small fraction of macitentan passes the placental 
barrier, favoring this dual ERA for further research. Another option to prevent ERAs from 
passing the placenta, would be to bind them to peptides that do not cross the placental 
barrier. At a later stage, we would suggest a proof of principle study in women with 
severe early onset PE (<24 weeks of gestation), when medically indicated termination of 
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pregnancy is considered because of disease severity, to evaluate the effect on maternal 
PE symptoms and neonatal outcome.
Another suggested therapeutic intervention is the non-selective phosphodiesterase 
(PDE) inhibitor pentoxifylline (PTX), because of its supposed anti-inflammatory proper-
ties as well as the ability to improve endothelial function.20 It has been shown that PTX 
reduces inflammation in placental explants and that it has a beneficial effect on the 
fetoplacental circulation in vivo.21, 22 In chapter 4 we showed that PTX induces vasodi-
lation in placental vasculature, especially in that of preeclamptic placentas. As a next 
step, we would like to investigate its placental transfer, both in healthy and PE placentas. 
Next we suggest to expand knowledge on the anti-inflammatory effects of PTX in the 
PE placenta, using placental explants and/or trophoblast cell culture. Furthermore, a 
pharmacokinetic model of PTX in pregnant women should be made before starting a 
clinical trial. No teratogenic effects of PTX are described in animal studies, and currently 
in Poland pregnant women are already treated with PTX for imminent preterm labor.21 
Blood samples of these women (both maternal plasma and umbilical cord) in combina-
tion with the transfer data from our placental perfusion experiments could be used to 
make such a model.
Although PDE5 inhibition with sildenafil to restore the decreased activity of the NO 
pathway was not effective in PE, this does not necessarily mean that targeting this 
pathway is the wrong approach. It could be that stimulation of NO on other levels 
does improve endothelial function. Clinical studies using compounds that (in)directly 
increase NO concentrations did reduce hypertension, but did not change maternal or 
fetal outcome.23-25 However, stimulating the NO pathway in an NO-independent manner 
with soluble guanylate cyclase stimulators or activators, has been shown to improve 
endothelial function in PE tissue, and to inhibit placental production of soluble FMS-like 
tyrosine kinase-1 (sFlt-1).26 sFlt-1 is produced in villous trophoblast cells and binds with 
high affinity to vascular endothelial growth factor (VEGF) and placental growth factor 
(PlGF), preventing them from promoting angiogenesis and maintaining vascular endo-
thelial function.27, 28 It has been shown that sFlt-1 infusion in pregnant animals induces a 
PE-like syndrome.29, 30 Indeed, plasma levels of sFlt-1 are elevated in women with PE, and 
these levels are positively correlated with ET-1 levels.11, 31, 32 Furthermore, PE placentas 
have an increased gene expression of sFlt-1.29 Decreasing sFlt-1 levels (e.g. through 
extracorporeal removal using dextrane sulphate apheresis) has resulted in significant 
improvement of PE symptoms.33 Therefore, targeting the excessive production of sFlt-1 
could be beneficial in PE treatment. Future placental perfusion studies and clinical trials 
remain to confirm safety and efficacy of these drugs.
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eARly iDeNTificATioN of PlAceNTAl iNsufficieNcy
One of the complicating factors of successful PE treatment is the fact that early de-
tection of placental insufficiency remains difficult. In the current clinical setting the 
standard method for evaluation of the placenta is ultrasound biometry in combination 
with Doppler parameters.34, 35 However, although ultrasound examination provides 
accurate information on the location, size and anatomy of the placenta, it has limited 
value for the assessment of placental function. Only when placenta-related complica-
tions have been already established, placenta function is suspected to be abnormal on 
ultrasound.36 Placental insufficiency is characterized by impaired trophoblast invasion 
and aberrant remodeling of the spiral arteries, causing increased vascular resistance and 
placental hypoperfusion.37, 38 Indeed, this can result in increased pulsatility indices (PI) 
of the maternal uterine arteries and fetal umbilical artery, and a decrease in PI of the 
fetal medial cerebral artery.34, 39 However, measurements of the uteroplacental circula-
tion assess blood flow and are thus an indirect estimate of placental function. Moreover, 
the predictive value of uteroplacental circulation assessment for fetal outcome in an 
unselected population is low.35
Novel parameters for the early identification of patients at risk for developing pla-
cental-related pregnancy complications are placental volumetric parameters, measured 
offline in three-dimensional ultrasound volumes from the first trimester.40 As described 
in chapter 7, mainly early in the first trimester, larger placental volumetric parameters 
are associated with lower pressure and more flow-mediated vasodilation in the feto-
placental vasculature of healthy placentas after delivery. This may suggest that larger 
and/or more vascularized placentas have better adaptive mechanisms and possibly lead 
to better pregnancy outcomes. Therefore, routine first-trimester evaluation of placental 
volumetric parameters could help to predict placental function in later pregnancy, 
thereby providing opportunities for early detection of placenta-related pregnancy com-
plications. Future research should focus on repeating these measurements in placentas 
from complicated pregnancies (FGR and/or PE).
Another promising, non-invasive technique for a more direct assessment of placental 
function is Magnetic Resonance Imaging (MRI). MRI with magnetic fields up to 3 Tesla 
has been safely used in pregnancy for over 30 years.41, 42 MRI of the placenta was primarily 
used for the assessment of an abnormally invasive placenta,43 and in recent years it has 
been increasingly applied to evaluate fetal structural anomalies, especially at advanced 
gestational age or in obese women.44 Experience with functional MRI (fMRI) has shown 
promising insight into the fetal brain and placental function in vivo.45, 46 Placental fMRI 
allows assessment of functional tissue aspects, and could be used to examine placental 
functions related to vascularization, oxygenation, and metabolism.47 Blood Oxygen 
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Level-Dependent (BOLD) MRI is an fMRI technique that measures changes in tissue 
oxygenation during hyperoxia or hypoxia, using hemoglobin (Hb) as an endogenous 
contrast agent. It is mainly used in clinical neuroimaging, linking brain anatomy and 
cognitive function.48, 49 The BOLD effect is based on the fact that paramagnetic properties 
of Hb and deoxyhemoglobin (dHb) are different. The paramagnetic properties of dHb af-
fect the spin of neighboring protons, thereby creating magnetic field in-homogeneities, 
which decrease T2-T2* weighted signal intensity. Thus, reduced tissue oxygenation 
leads to a decreased BOLD signal. During hyperoxia, there is a decrease in dHb, and 
an increase in BOLD signal is expected.50, 51 This process has been previously proven in 
animal placentas and fetal organs.52-55 In normal pregnancies, creating a state of ma-
ternal hyperoxia will give an increase in BOLD signal intensity in the placenta and fetal 
organs.51, 55-57 It is thought that in pregnancies complicated by placental insufficiency 
there will be less of an increase.56, 58 As a first step towards using fMRI as a diagnostic tool 
to identify high risk pregnancies we have started a feasibility study for performing BOLD 
MRI in the Erasmus MC. Women with uncomplicated singleton pregnancies between 
28 and 34 weeks of gestation are eligible for inclusion. Placenta function is assessed 
using the BOLD technique. When this is successful, a next step would be to repeat these 
measurements in women with placental insufficiency.
TowARDs PeRsoNAlizeD meDiciNe
More and more, medicine is moving towards individualized treatment instead of pop-
ulation-based care. Evidence is accumulating that often different entities exist within 
one disease. Unlike previously thought, with the classical diagnosis of hypertension and 
proteinuria, we now recognize that PE is a spectrum disorder that can involve many 
organ systems, with a widely varying clinical manifestation. For example, it is now the 
general assumption that early onset PE (manifestation before 34 weeks of gestation) 
and late onset PE (manifestation from 34 weeks of gestation onwards) have different 
pathophysiological mechanisms, as clear histopathological differences have been 
shown.59, 60 Late onset PE seems more of a maternal, rather than a placental syndrome. 
That there is a difference between these two sub-classifications is also apparent in our 
vascular research. We found that, although both early – and late onset PE placentas have 
a lower baseline tension in the perfusion model (Figure 1A), they do not display the 
same decreased responsiveness of the NO pathway (Figure 1B). These differences need 
to be taken into account in further research, as well as other sub-classifications such as 
PE with and without FGR, or FGR alone.
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As described in this thesis many pathways are involved in the pathogenesis of PE. 
Possibly, it could differ per patient - even within a subgroup - which alterations are most 
dominant, and would therefore require different diagnostic and/or therapeutic ap-
proaches. For example, in one patient the rise in ET-1 could be more prominent, and in 
another the inflammatory imbalance. Something that could help to better understand 
these different parts of the spectrum would be extensive phenotyping of the placenta. 
However, in-depth fundamental knowledge regarding human placental development 
in health and disease is still lacking. Novel techniques to study this, such as single-cell 
RNA sequencing and organoids, are currently still in its infancy, but could provide more 
answers in the future. To establish this, there is a need for expert centers, specialized in 
both placental research and clinical care for women and their fetuses/neonates that are 






































figure 1. Differences in vascular response between early onset - and late onset preeclampsia. Panel A 
shows the baseline pressure of healthy, early onset preeclamptic (EoPE) and late onset preeclamptic (LoPE) 
placentas in the perfusion model. Panel B depicts the pressure decrease (%) in response to the NO-donor 
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Preeclampsia (PE) is a common but potentially severe placenta-related complication 
of pregnancy, that accounts for a substantial part of perinatal and maternal morbidity 
and mortality worldwide. To date, no cure is available for PE, except for termination of 
pregnancy, often leading to preterm birth.
Many pathophysiological pathways have been proposed, such as oxidative stress, 
immunological imbalance, and environmental and genetic factors, all contributing to in-
adequate development of the placenta. Instead of the low-resistance circulation that is 
seen in healthy placentas, PE is characterized by increased placental vascular resistance 
and hypoperfusion, leading to generalized endothelial dysfunction and endovascular 
inflammation. In chapter 1 we presented (historical) background on PE and explained 
the experimental model that was used in this thesis.
In chapter 2, the most important vascular reactivity pathways of the placenta were 
summarized, which are the nitric oxide (NO) pathway and its NO-dependent vasodila-
tors, vascular endothelial growth factor and the endothelin (ET) system, the renin-angio-
tensin system, prostaglandins, serotonin and tryptophan, and calcitonin gene-related 
peptide. Many of these pathways show alterations in PE, that are a consequence of, or 
could have attributed to the pathogenesis of this disease. Targeting these disturbances 
could be a promising strategy in developing novel treatments for PE.
chapter 3 focused on the NO pathway. One of the novel therapeutic strategies that 
had emerged over the last years is the phosphodiesterase (PDE)5 inhibitor sildenafil. 
Sildenafil enhances systemic vasodilation through the NO pathway, and because of 
its promising effects in PE animal studies, a large randomized controlled clinical trial 
was started (the STRIDER study). Unfortunately, this trial was halted due to futility to 
show beneficial effects and increased neonatal morbidity. Beforehand, not much was 
known about the transfer and effect of sildenafil in the human placenta, especially in 
the case of PE, as studied in this chapter. We found that although sildenafil improved 
NO-mediated vasodilation in isolated chorionic plate arteries of healthy placentas, this 
was not the case in arteries of PE placentas. The lack of this NO-potentiation by sildenafil 
in PE placentas, and the fact that there was no PDE5 upregulation on gene – or protein 
level in PE, made us question sildenafil as a suited therapy for this disease. Furthermore, 
placental transfer of sildenafil was highest in the PE placentas, which could (partially) 
explain the increased neonatal morbidity as seen in the STRIDER study.
In chapter 4 we described the effect of another potential therapeutic for PE, the non-
selective PDE inhibitor pentoxifylline on porcine coronary arteries and human chorionic 
plate arteries. We found that its vasodilator effect is mainly cGMP-mediated, and that it 
is more pronounced in vasculature of preeclamptic placentas.
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In chapters 5 & 6 we focused on targeting the ET system. Increased activity of the ET 
system plays a role in the pathogenesis of PE, and blocking this system with endothelin 
receptor antagonists (ERAs) would be a logical step. However, although ERAs indeed 
attenuated hypertension and proteinuria in PE animal studies, they also caused severe 
teratogenic effects on offspring (mainly craniofacial malformations) in developmental 
toxicity studies. Therefore, no clinical trials have been performed with these drugs. In 
chapter 5 we discussed the involvement of the ET system in normal pregnancy, the 
pathophysiology of PE, and embryogenesis, to evaluate if possibly a therapeutic window 
exists in which ERAs could be safely administered during human pregnancy. Through a 
systematic review of literature we found 39 reported cases of women who were exposed 
to ERAs during pregnancy. All these women were treated with ERAs because of its regis-
tered indication (pulmonary arterial hypertension) and there was no increased incidence 
of congenital malformations. Although in most cases exposure was of short duration 
and the rate of elective termination of pregnancy was high (31%), this supported the 
theory that ERA treatment could be safe, when started after organogenesis is completed 
to avoid teratogenic risks. To further study this possibility, we investigated the placental 
transfer and effects of three ERAs (sitaxentan, ambrisentan and macitentan) in chapter 
6. We found that sitaxentan and ambrisentan both substantially passed the placental 
barrier, however the transfer of macitentan was very limited. All three blockers were 
capable of blocking the vasoconstrictive effect of ET-1 in the chorionic plate arteries, 
which seems to be solely mediated by the ET type A receptor. Furthermore, we con-
firmed that gene expression of ET-1 is increased in PE placentas, but that there is no 
difference in receptor expression.
In chapter 7 we explored the correlation between placental volumetric parameters, 
measured by ultrasound in the first trimester of pregnancy, and parameters of fetopla-
cental vascular function, measured using placental perfusion after delivery. We found 
that, mainly early in the first trimester, larger placental volumetric parameters are associ-
ated with better vascular function (lower pressure and more vasodilation in response to 
flow increase) at placental perfusion. This suggests that larger and/or more vascularized 
placentas in early pregnancy have better adaptive mechanisms, which could possibly 
lead to better pregnancy outcomes.
Finally, in chapter 8 we discussed the clinical implications and addressed the strengths 
and limitations of the studies in this thesis. Furthermore, we have elaborated on what 




Pre-eclampsie (PE) is een veelvoorkomende, maar potentieel ernstige, placenta-gere-
lateerde zwangerschapscomplicatie, die wereldwijd verantwoordelijk is voor een sub-
stantieel deel van de perinatale en maternale morbiditeit en mortaliteit. Tot op heden is 
er geen adequate behandeling voor PE, behalve beëindiging van de zwangerschap, wat 
vaak leidt tot vroeggeboorte.
Er zijn vele oorzakelijke factoren die bijdragen aan het ontstaan van PE, zoals oxida-
tieve stress, immunologische onbalans, omgevingsfactoren en genetische factoren. 
Al deze factoren samen leiden tot een inadequate ontwikkeling van de placenta. In 
plaats van de lage weerstandscirculatie die normaliter ontstaat in gezonde placenta’s, 
wordt PE juist gekenmerkt door verhoogde vaatweerstand en verminderde perfusie, 
hetgeen leidt tot generaliseerde endotheel dysfunctie en endovasculaire ontsteking. In 
hoofdstuk 1 presenteerden we de (historische) achtergrond van PE en hebben we het 
experimentele model besproken dat is gebruikt voor een groot deel van het onderzoek 
in dit proefschrift.
In hoofdstuk 2 zijn de belangrijkste factoren die betrokken zijn bij de vasculaire 
reactiviteit van de placenta samengevat, namelijk stikstof en stikstof-afhankelijke vaat-
verwijders, ‘vascular endothelial growth factor’ en het endotheline (ET)-systeem, het 
renine-angiotensine-systeem, prostaglandines, serotonine en tryptofaan en ‘calcitonin 
gene-related peptide’. Veel van deze factoren vertonen veranderingen bij PE, als gevolg 
van, of die juist kunnen hebben bijgedragen aan het ontstaan van deze ziekte. Het 
proberen te herstellen van de verstoringen in deze factoren zou een veelbelovende 
strategie kunnen zijn in de ontwikkeling van nieuwe behandelmogelijkheden voor PE.
In hoofdstuk 3 lag de focus op stikstof. Een van de nieuwe behandelstrategieën die 
de laatste jaren in opkomst was, is behandelen met de fosfodiësterase (PDE)5 remmer 
sildenafil. Sildenafil stimuleert de systemische vaatverwijding door stikstof en vanwege 
veelbelovende effecten in dierstudies was een grote gerandomiseerde klinische studie 
gestart (de STRIDER studie). Helaas is deze studie voortijdig gestaakt, omdat er geen 
gunstige effecten werden gezien en zelfs een toename van neonatale complicaties 
in één van de cohorten. Voorafgaand aan deze studie was er weinig bekend over de 
effecten van sildenafil op de placenta en de passage van moeder naar kind, vooral in 
het geval van PE, zoals we in dit hoofdstuk hebben bestudeerd. In onze studie vonden 
we dat sildenafil de vaatverwijding niet stimuleert in bloedvaten van PE placenta’s, in 
tegenstelling tot in vaten van gezonde placenta’s. Dit in combinatie met het gebrek 
aan PDE5 opregulatie op gen- of eiwitniveau, suggereert dat sildenafil wellicht geen 
geschikte behandeling is voor PE. Bovendien was de placentapassage van sildenafil het 
hoogste in de PE placenta’s, wat deels een verklaring zou kunnen zijn voor de toename 
aan neonatale complicaties in de STRIDER studie.
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hoofdstuk 4 beschrijft de effecten van de non-selectieve PDE-remmer pentoxifylline 
op coronairvaten van varkens en humane placentavaten. We hebben in dit hoofdstuk 
aangetoond dat de vaatverwijding die wordt veroorzaakt door pentoxifylline met name 
cGMP-gemedieerd is, en versterkt is in vaten van PE placenta’s.
In hoofdstuk 5 & 6 hebben we ons gericht op het ET-systeem. Verhoogde activiteit 
van het ET-systeem speelt een rol in het ontstaan van PE, dus behandeling middels 
blokkade van dit systeem met endotheline receptorantagonisten (ERA’s) zou een 
logische stap zijn. Echter, hoewel ERA’s inderdaad de symptomen van PE verbeterden 
in dierstudies, gingen ze ook gepaard met ernstige aangeboren afwijkingen bij het 
nageslacht (voornamelijk afwijkingen aan de botten van het gezicht). Vanwege deze 
teratogene effecten zijn er geen klinische studies uitgevoerd met deze medicijnen. 
Om te evalueren of er tijdens humane zwangerschappen een window bestaat waarin 
ERA’s veilig gegeven kunnen worden, werd in hoofdstuk 5 de rol van het ET-systeem 
in normale zwangerschappen, in het ontstaan van PE en in de ontwikkeling van het 
embryo bediscussieerd. Door middel van een systematisch review van de literatuur 
vonden we 39 gerapporteerde casussen van vrouwen die zijn blootgesteld aan ERA’s 
tijdens de zwangerschap. Al deze vrouwen werden behandeld met ERA’s vanwege pul-
monale arteriële hypertensie, waarvoor deze medicijnen ook geregistreerd zijn. Er werd 
geen verhoogde incidentie gezien van aangeboren afwijkingen. Hoewel er in de meeste 
casussen slechts kortdurig blootstelling was aan ERA’s en er een hoog percentage (31%) 
van de zwangerschappen werd afgebroken op medische indicatie, ondersteunt het ge-
brek aan aangeboren afwijkingen de theorie dat behandeling met ERA’s veilig kan zijn 
wanneer ze gegeven worden nadat de foetale organen zijn aangelegd. Om dit verder te 
onderzoeken hebben we in hoofdstuk 6 de placentaire passage en effecten van drie 
ERA’s (sitaxentan, ambrisentan en macitentan) onderzocht. We vonden dat substantiële 
hoeveelheden van sitaxentan en ambrisentan de placenta barrière passeren, maar dat 
de passage van macitentan zeer beperkt is. Alle drie de ERA’s konden het effect van ET-1 
nagenoeg compleet blokkeren in placentavaten, wat volledig afhankelijk lijkt van de ET 
type A receptor. Ook hebben we bevestigd dat de genexpressie van ET-1 verhoogd is in 
weefsel van PE placenta’s, maar vonden we geen verschil in receptorexpressie.
hoofdstuk 7 exploreerde de correlatie tussen volume parameters van de placenta, 
gemeten middels echografie in het eerste trimester van de zwangerschap, en placen-
taire vaatfunctie, gemeten met placenta perfusie na de geboorte. Het blijkt dat grotere 
placenta (vasculaire) volumes, met name vroeg in het eerste trimester, geassocieerd zijn 
met betere vaatfunctie (lagere druk en meer vaatverwijding in reactie op verhoging 
van de stroomsnelheid) bij placenta perfusie. Dit suggereert dat grotere en/of meer 
gevasculariseerde placenta’s mogelijk betere aanpassingsmechanismes hebben, wat 
zou kunnen leiden tot een betere zwangerschapsuitkomst.
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Tenslotte hebben we in hoofdstuk 8 de klinische implicaties van dit proefschrift 
bediscussieerd, evenals de sterke en zwakke punten van de beschreven studies. We heb-
ben besproken wat het onderzoek in dit proefschrift heeft toegevoegd aan de huidige 
kennis en hebben suggesties gedaan voor toekomstig onderzoek.
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